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Abstract	Leukaemia	is	11th	most	common	cancer	worldwide,	associated	with	poor	prognosis.	The	10	years’	survival	for	leukaemia	is	between	44%	-	47%.	One	of	the	main	reasons	for	 this	 is	 the	 disease	 being	 diagnosed	 in	 late	 stages.	Most	 of	 leukaemia	 screening	techniques	are	invasive	or	give	radiation.	It	is	therefore	obvious	to	improve	prognosis	and	 refine	 diagnostic	 techniques	 for	 early	 detection,	 and	 better	management	 of	 its	therapeutic	response.	Spectroscopic	and	spectrometric	techniques	are	widely	used	by	a	 huge	 group	 of	 scientists;	 as	 biochemical	 analysis	 of	 the	 disease,	 may	 provide	biochemical	signatures	to	be	used	in	diagnostics	and	management	of	the	disease.	 In	this	 work,	 the	 feasibility	 of	 measuring	 both	 qualitatively	 and	 quantitatively	 VOCs	released	by	PBMC,	 leukaemia	cells	and	BM	cells	 in	vitro	has	been	shown.	There	are	clear	 differences	 in	 the	 VOCs	 profile	 even	 among	 different	 leukaemia	 cells	 lines	 as	well	 as	 from	 leukaemia	 cells	 exposed	 to	 drugs,	 PBMCs	 and	 bone	 marrow.	 These	differences	 in	 the	VOCs	 release	 could	 be	 exploited	 towards	 a	 clinical	 application	 of	SIFT-MS	in	the	diagnosis	and	therapeutic	response	of	the	disease.	Direct	sampling	is	the	 most	 convenient	 method	 of	 sampling,	 which	 could	 avoid	 loss	 of	 the	 many	important	 VOCs	 by	 diffusion	 and/or	 absorption.	 Since	 it	 is	 not	 very	 easy	 to	 obtain	direct	 breath,	 appropriate	 storage	 of	 exhaled	 breath	 and	 transportation	 are	 very	important	 issues	 to	 be	 considered.	My	 study	 proved	 that	 stability	 over	 time	might	vary	 for	 different	 VOCs,	 especially	 those	 present	 in	 smaller	 concentrations.	 The	addition	of	 Imatinib	or	Nilotinib	 to	K562	cell	clones	 induces	changes	 in	cell	biology	and	cellular	structure	which	translates	into	changes	in	the	S-FTIR	spectra	and	Raman	Spectra	of	the	cells.	There	are	remarkable	differences	in	the	biochemical	composition	of	cells	 incubated	at	different	drug	concentrations	and	at	different	 levels	of	oxygen.	Further	studies	are	needed	to	confirm	these	changes	in	the	spectra.	
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Chapter	1																												
Introduction	
	
1.1:	Leukaemia	(Bone	Marrow	Cancer)		Medical	 science	 has	 advanced	 a	 great	 deal	 in	 last	 few	 decades,	 especially	 in	 the	diagnosis	 and	 management	 of	 cancer.	 However,	 in	 spite	 of	 these	 developments,	cancer	is	still	the	leading	cause	of	death	worldwide.	The	latest	statistics	available	are	from	2012,	when	about	14.1	million	new	cases	of	cancer	were	reported	worldwide,	with	8.2	million	cancer-related	deaths	accounting	for	22,000	deaths	each	day.	In	the	same	year,	around	163,300	cancer	cases	were	diagnosed	among	children	aged	0-14	years	 worldwide	 with	 around	 80,000	 cancer-related	 deaths.	 It	 is	 expected	 that	 by	2030,	the	global	burden	of	cancer	will	grow	to	21.7	million	with	expected	deaths	of	13	x	106	[Cancer	Research	UK].	Mortality	trends	over	the	last	decades	have	decreased	for	 12	 out	 of	 20	 cancer	 types	 in	 males	 and	 11	 out	 of	 20	 cancer	 types	 in	 females.	Examples	are	lung,	bowel,	breast,	and	prostate	cancer,	and	leukaemia,	for	which	the	decrease	in	mortality	over	the	last	decades	in	the	UK	is	due	to	the	advances	in	cancer	screening	 programmes	 and	 awareness	 for	 cancer	 as	 disease,	 coupled	 with	 higher	standards	of	cancer	care	[Cancer	Research	UK].	Early	detection	of	the	disease	is	one	of	the	main	aspects	in	increasing	cancer	survival	rates.	However,	many	of	the	cancer	screening	 techniques	 (imaging,	 blood	 tests,	…)	 are	 invasive	or	 give	 radiation.	Thus,	these	 screening	 processes	 are	 important	 but	 might	 be	 associated	 to	 risks.	 On	 the	other	hand,	some	of	these	screening	techniques	might	not	always	be	able	to	identify	cancer	 in	 early	 stages,	 i.e.	 before	 patients	 present	 with	 symptoms.	 It	 is	 therefore	obvious	that	further	developments	are	needed.	
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The	human	body	produces	blood	cells	inside	the	bone	marrow,	the	soft	inner	portion	of	the	bones.	The	bone	is	made	up	of	compact	bone,	spongy	bone,	and	bone	marrow	(soft	fatty/spongy	tissue	inside	bone	cavity).	Compact	bone	makes	up	the	outer	layer	of	 the	 bone.	 Spongy	 bone	 is	 found	 mostly	 at	 the	 ends	 of	 bones	 and	 contains	 red	marrow.	Bone	marrow	 is	 found	 in	 the	center	of	most	bones	containing	many	blood	vessels.	There	are	two	types	of	bone	marrow:	red	and	yellow.	Red	marrow	contains	blood	 stem	 cells	 that	 can	 become	 red	 blood	 cells,	 white	 blood	 cells,	 or	 platelets	[Queensburry 2001].	 Yellow	 marrow	 consists	 of	 mostly	 fat	 cells	 and	 few	 primitive	blood	cells.	The	human	body	needs	 these	blood	cells	 to	perform	different	 functions	such	as	oxygen	transport	(e.g.	red	blood	cells),	fight	infections	and	immune	response	(e.g.	white	blood	cells)	and	stop	bleeding	(e.g.	platelets)	amongst	other.	The	human	body	 is	 producing	 new	 blood	 cells	 constantly.	 Every	 day,	 billions	 of	 the	 red	 blood	cells,	white	blood	cells,	and	platelets	are	produced	in	the	bone	marrow,	which	replace	the	dead	cells	 (dead	due	 to	 illness	or	normal	processes).	The	process	of	new	blood	cells	production	is	called	haematopoiesis.	A	group	of	master	cells	(stem	cells)	inside	the	 bone	 marrow	 is	 responsible	 for	 the	 production	 of	 the	 blood	 cells,	 having	 the	ability	 to	 produce	 all	 sorts	 of	 blood	 cells.	 These	 stem	 cells	 divide	 into	 one	 of	three	major	 types	 of	mature	 blood	 cells,	 red	 blood	 cells	 (erythrocytes),	white	 blood	 cells	(leukocytes)	 and	 platelets.	 These	 white	 blood	 cells	 are	 further	 divided	 into	 three	major	 types	 of	 white	 blood	 cells	 e.g.	 granulocytes,	 lymphocytes,	 and	 monocytes	(Figure	1).		Granulocytes	and	monocytes	are	collectively	called	myeloid	cells.	These	myeloid	cells	play	a	vital	role	 in	 innate	immunity,	as	upon	pathogen	attack	these	cells	are	rapidly	recruited	 into	 local	 tissues	 via	 various	 receptors	 and	 become	 activated	 for	
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phagocytosis	as	well	 as	 secreting	 inflammatory	cytokines.	Any	genetic	alteration	or	mutations	 in	 these	 cells	 may	 cause	 an	 abnormal	 increase	 in	 mature/immature	myeloid	 or	 blast	 cells	 that	 could	 result	 in	 chronic	 or	 acute	myelogenous	 leukaemia	[Kawamoto	2004].															These	blood	cells	are	not	just	produced	in	the	blood	stream	but	in	their	specific	blood	producing	organs,	 specifically	marrow	of	 certain	bones.	 In	a	human	body,	all	of	 the	red	blood	 cells,	most	 of	 the	white	blood	 cells	 and	 all	 the	platelets	 are	produced	by	bone	marrow.	However	 other	 lymphatic	 tissues	 as	well	 as	 thymus,	 spleen,	 and	 the	lymph	nodes	produce	 lymphocytes.	Two	 types	of	 these	 lymphocytes,	T	 and	B	 cells,	are	 produced	 in	 lymph	 nodes	 and	 spleen.	 B	 type	 cells	 are	 responsible	 for	 the	production	of	antibodies	and	attacking	invading	bacteria,	viruses	or	any	toxin,	while	
Figure	1:	Normal	production	of	blood	cells:	[www.ghr.nlm.nih.gov (online)].	
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T	 type	 of	 cells	 destroys	 infected	 cells	 or	 cancerous	 cells.	 Any	 abnormality	 in	 these	cells	may	cause	abnormal	production	of	these	B	and	T	type	of	cells	and	cause	acute	or	chronic	leukaemia.			Leukaemia	 is	 an	 abnormal	 proliferation	 of	 haematopoietic	 stem	 cells	 in	 the	 bone	marrow,	 which	 leads	 to	 a	 high	 number	 of	 immature	 white	 cells	 in	 blood	 [Cancer	Research	UK].	White	blood	cells	are	the	most	important	part	of	our	immune	system,	which	help	our	body	to	fight	infections.	During	abnormal	production	of	white	blood	cells,	 it	 becomes	 harder	 for	 the	 body	 to	 get	 rid	 of	 infections.	 Furthermore,	 these	abnormal	 or	 immature	 cells	 may	 also	 build	 up	 in	 different	 parts	 of	 our	 lymphatic	system	 and	 in	 the	 spleen1	and	 overcrowd	 the	 bone	 marrow,	 making	 it	 harder	 to	produce	normal	cells.	This	also	translates	into	a	lower	normal	blood	cell	count.	Low	number	of	normal	blood	cells	or	higher	number	of	abnormal	white	blood	cells	is	the	one	of	the	first	signs	of	leukaemia.			There	are	several	types	of	leukaemia.	When	leukaemia	is	diagnosed	by	doctors,	 it	 is	very	important	to	know	exactly	what	type	of	leukaemia	doctors	are	dealing	with,	as	the	 treatment	 will	 vary	 for	 each	 type	 of	 leukaemia.	 There	 are	 four	major	 types	 of	leukaemia.			
1.1.1:	Acute	Lymphoblastic	Leukaemia	Acute	 lymphoblastic	 leukaemia	 (ALL)	 is	 a	 disorder	 of	 lymphoid	 progenitor	 cells	occurring	in	children	as	well	as	in	adults.	It	arises	from	T	type	or	B	type	lymphocytes,	
                                                1	The	spleen	is	a	vital	abdominal	organ	responsible	for	the	storage	and	getting	rid	of	non-healthy	blood	cells.		
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also	 called	 lymphoblasts.	 Genetic	 abnormality	 or	 abnormalities	 in	 a	 single	lymphocyte	 or	 lymphoblast	 may	 trigger	 disordered	 cell	 proliferation,	 abnormal	survival	 and	 lethal	 accumulation	 of	 immature	 cells.	 Acute	 (sudden	 onset)	lymphoblastic	leukaemia	is	a	rapid	progression	form	of	leukaemia	with	high	number	of	 white	 blood	 cells	 (lymphocytes,	 lymphoblast)	 unable	 to	 properly	 fight	 infection	[Pui	2008;	Quensenberr	1995].	It	is	the	most	commonly	occurring	type	of	leukaemia	with	 almost	 25%	 of	 all	 cases,	 and	 is	 more	 common	 in	 males	 than	 in	 females	[Quensenberry	1995].		
1.1.2:	Acute	Myelogenous	Leukaemia	Acute	 myelogenous	 or	 myeloid	 leukaemia	 (AML)	 is	 a	 rapidly	 progressing	heterogeneous	 clonal	 disorder	 of	 progenitor	 cells	 leading	 to	 an	 abundance	 of	immature	blood	forming	cells	in	the	blood	stream	and	bone	marrow,	which	decreases	the	 production	 of	 normal	 blood	 cells.	 These	 cells	 become	 immune	 cells	 at	differentiation.	 These	 immature	 cells	 are	 named	 blast	 cells,	 which	 fill	 the	 bone	marrow	and	spill	into	the	main	blood	stream	[Newson	2011].	AML	may	occur	in	adult	and	 children,	 but	more	 commonly	 in	 adults.	 It	 is	 also	 abbreviated	 as	 ANLL	 (Acute	nonlymphocytic	leukaemia)			
1.1.3:	Chronic	Lymphocytic	Leukaemia	Chronic	 lymphocytic	 leukaemia	 (CLL)	 is	 a	 monoclonal	 disorder	 characterized	 by	functionally	 incompetent	 lymphocytes	 and	 is	 the	 most	 common	 form	 of	 adult	leukaemia	 in	 the	western	world	 [Dohne	2000].	 It	 causes	 the	slow	 increase	of	white	blood	 cells	 called	 B	 cells.	 These	 abnormal	 cells	 crowd	 other	 type	 of	 cells	 in	 bone	
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marrow,	which	 thwarts	 the	production	of	 red	blood	 cells,	 normal	white	blood	 cells	and	 platelets.	 These	 cancerous	 cells	 spread	 in	 the	 blood	 stream,	 infiltrating	 lymph	nodes	 or	 other	 organs	 such	 as	 the	 liver	 or	 spleen	 [Newson	 2011].	 Chronic	lymphocytic	 leukaemia	 is	 the	 second	most	 common	 type	of	 leukaemia	 occurring	 in	adults	and	rarely	occurring	in	children.		
1.1.4:	Chronic	Myelogenous	Leukaemia	Chronic	myelogenous	or	myeloid	leukaemia	(CML)	is	a	very	slow	developing	disease.	It	is	a	white	blood	cell	disorder	in	which	abnormal	proliferation	of	granulocytic	cells	increases	but	they	remain	immature.	With	time,	these	granulocytes	accumulate	in	the	spleen	causing	its	enlargement.	These	granulocytes	also	overcrowd	the	bone	marrow	preventing	the	production	of	normal	white	blood	cells,	red	blood	cells,	and	platelets	[Quintas-Cardama 2006].	CML	typically	affects	middle-aged	individuals.	This	disease	is	very	uncommon	in	youngsters.	CML	is	among	those	few	cancers	known	to	be	caused	by	 a	 single	 specific	 genetic	mutation	 [Newson	 2011].	 This	mutation	 takes	 place	 on	Philadelphia	 chromosome	 (chromosome	 22).	 A	 reciprocal	 swap	 of	 the	 location	between	the	pieces	of	chromosome	9	and	22	happens.	Chromosome	9	contains	gene	c-ABL	and	22	contain	BCR.	So,	the	newly	formed	gene	as	a	result	of	this	translocation	is	called	the	BCR-ABL	(appendix	3)	gene	that	starts	producing	mutated	protein,	which	in	turn	converts	the	marrow	stem	cells	from	normal	to	leukemic	[Kimball	1999].			
1.2:	Leukaemia	Incidence	The	 incidence	 of	 leukaemia	 in	 the	 world	 is	 about	 1	 per	 100,000	 of	 all	 cancers	diagnosed	per	year	 [Cartwright	1992; Bhayat 2009].	According	 to	 the	 latest	 statistics	
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available	from	2012,	about	352,000	cases	were	diagnosed	with	leukaemia	worldwide	[Cancer	Research	UK].	It	is	the	11th	most	common	cancer	in	the	world	accounting	for	2.5%	 of	 all	 cancers	 [Cancer	 Stats	 Incidence	 2009-UK]	 and	 accounts	 for	more	 than	8,000	new	cases	diagnosed	every	year	[Cancer	Research	UK],	with	a	higher	incidence	in	the	older	population.	However,	4.5	%	of	cases	are	diagnosed	in	children	aged	10	or	younger	 [Davies	2014].	As	childhood	malignancy,	 it	 accounts	 for	around	31%	of	all	cancer	 diagnosed	 in	 children	 under	 the	 age	 of	 15	 [Cancer	 Stats	 childhood	 cancer	Great	 Britain	 &	 UK	 2010].	 While	 the	 5-year	 survival	 for	 all	 types	 of	 leukaemia	 is	greater	 than	 65%,	 the	 survival	 is	 worse	 with	 increased	 age	 at	 diagnosis	 [Davies	2014].	The	incidence	of	leukaemia	is	higher	in	men	than	in	women	with	a	ratio	of	7:5.									
	
	
 
	
	
Figure	 2:	 Schematic	 image	 of	 the	 main	 steps	 in	 the	 diagnosis	 of	 leukaemia.	[www.nlm.nih.gov	(online)].	
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1.3:	Diagnosis	of	Leukaemia		The	symptoms	for	leukaemia	such	as	fever,	nausea,	sleeplessness,	and	flu	can	easily	go	 unnoticed	 for	 years.	 They	 are	 also	 likely	 to	 be	 associated	 with	 other	 diseases.	Figure	2	shows	the	main	steps	involved	in	the	diagnosis	of	leukaemia.	
	
1.3.1:	Anamnesis	First,	doctors	have	to	obtain	the	patient’s	complete	medical	history	in	order	to	have	a	detailed	medical	review	of	his/her	general	health,	family’s	medical	conditions	and	of	any	symptoms	and	signs	2that	could	be	associated	with	leukaemia	[Fayed	2006].		
1.3.2:	Physical	Examination	During	 the	physical	 examination,	doctors	may	examine	 the	body	 looking	 for	 lumps,	bleeding	areas,	and	sources	of	infection	amongst	other	[Fayed	2006].		
1.3.3:	Blood	Test	A	full	blood	count	(FBC)	which	includes	number	of	red,	and	white	cells	and	platelets	amongst	other,	and	blood	smears	can	help	to	detect	leukaemia.	When	blood	samples	are	 observed	under	microscope,	 changes	 in	 cells’	morphology	 and	numbers	 can	 be	identified	[Fayed	2006].		
	
	
                                                2	A	symptom	is	any	subjective	evidence	of	disease,	while	a	sign	is	any	objective	evidence	of	disease.		
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1.3.4:	Biopsy		Bone	marrow	 biopsy	 and	 aspiration	 are	 done	 at	 the	 same	 time.	 Biopsy	 entails	 the	removal	of	soft	tissues	present	inside	the	bone	marrow	and	aspiration	is	the	sampling	of	 just	 liquid	 present	 inside	 the	 bone	 marrow	 [Fayed	 2006].	 	 In	 the	 case	 of	 bone	marrow	 biopsy,	 a	 large	 bore	 needle	 is	 inserted	 in	 the	 hipbone	 or	 occasionally	 the	breastbone	or	any	other	 large	bone,	 and	samples	of	 the	bone	marrow	are	obtained	(Figure	 3).	 Aspiration	 is	 carried	 out	 using	 a	 smaller	 needle	 to	 take	 the	 sample.	 A	pathologist	 then	 examines	 the	 sample	 to	 assess	 the	 presence	 of	 leukaemia	 cells.	Lymph	 node	 biopsy	 can	 also	 be	 performed	when	 there	 is	 nodal	 infiltration	 [Fayed	2006;	Cancer	Health	Centre	(Online);	Bain	2001].		
	
Figure	3:	Schematic	image	of	Bone	Marrow	Biopsy.	[www.nlm.nih.gov	(online)].	
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1.3.5:	Lumbar	puncture		
Lumbar	 Puncture	 (LP),	 known	 also	 as	 spinal	 tap,	 is	 carried	 out	 in	 order	 to	 assess	central	 nervous	 system	 involvement	 [Robert	 2008;	 Pearson	 2012].	 A	 needle	 is	inserted	into	the	subarachnoid	space	in	the	lower	back	(lumbar	area)	into	the	spine.	The	 subarachnoid	 space	 is	 the	 canal	 within	 the	 spinal	 column	 that	 contains	cerebrospinal	fluid	(CSF).	CSF	is	a	transparent	fluid	acting	as	a	protecting	cover	of	the	brain	and	the	spinal	cord.	This	fluid	 is	constantly	produced	in	the	choroid	plexus	of	the	 brain.	 CSF	 is	 spun	down	and	 analysed	 for	 the	presence	 of	malignant/abnormal	cells	in	the	sample	[Pearson	2012].		
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	4:	Schematic	image	of	Lumbar	Puncture	[Cancer	Research	UK	(online)]			
 
1.3.6:	Immunophenotyping	
Immunophenotyping	 refers	 to	 the	 technique	 of	 characterizing	 and	 identifying	different	 molecules	 and	 biomarkers	 present	 in	 the	 inner	 or	 outer	 side	 of	 the	 cell	
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surface	 [Maeda	 1993;	 Campana	 2000].	 Specifically,	 this	 technique	 refers	 to	 the	labelling	 of	 white	 blood	 cells	 (WBC)	 with	 antibodies	 linked	 to	 surface	 antigens3.	Leukaemia	has	got	characteristic	groupings,	which	allow	immunophenotyping	to	help	in	the	diagnosis	and	characterization	of	cancerous	cells	in	the	blood	or	from	biopsies.	This	technique	also	gives	indication	of	the	aggressiveness	of	the	disease	and	can	help	in	choosing	the	right	treatment	[Maeda	1993;	Campana	2000].	
	
1.3.7:	Cytogenetic	or	Chromosome	Analysis	
Cytogenetic	analysis	involves	the	study	of	chromosome/genes	at	cell	level.	In	the	case	of	leukaemia,	studies	of	chromosomes	have	significant	impact	in	the	diagnosis.	Most	of	 the	 time,	 chromosomal	 abnormalities	 are	 involved	 in	 the	 pathogenesis	 of	leukaemia.	 In	 many	 cases,	 molecular	 studies	 of	 chromosomal	 aberrations	 have	identified	 specific	 genes	 implicated	 in	 the	 progression	 of	 leukaemia	 [Cross	 1986;	
Dohner 2000; Mrozek.	 2004].	 Cytogenic	 analysis	 is	 the	 most	 important	 diagnostic	technique	 in	 determining	 prognosis	 in	 some	 types	 of	 leukaemia	 especially	 AML,	 as	the	majority	of	patients	with	this	type	of	leukaemia	have	shown	to	have	chromosomal	aberrations.	This	technique	has	also	helped	to	clone	many	genes,	opening	a	new	era	of	 disease	 diagnosis	 and	 treatment	 [Mrozek	 2004].	 Along	 with	 conventional	techniques	 to	 perform	 cytogenetic	 tests,	 reverse	 transcriptase	 polymerase	 chain	reaction	(RT-PCR)	[Slack	1998;	Coco	1999],	fluorescence	in	situ	hybridization	(FISH),	and	 immunostaining	 with	 particular	 antibodies	 are	 more	 recently	 developed	
                                                3	An	antigen	is	any	substance	that	causes	an	immune	system	to	produce	antibodies	against	it.		
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techniques	used	 for	genetic	analysis.	These	 techniques	have	changed	 the	diagnostic	approach,	making	diagnosis	more	reliable	and	precise	[Maeda	1993;	Fayed	2006].		
	
1.4:	Imaging	Techniques	Used	to	Diagnose	Leukaemia	
	
1.4.1:	 X-Ray,	 Ultrasound,	 Computed	 Tomography	 (CT)	 Scan,	
Magnetic	Resonance	Imaging	(MRI)	Chest	X	Rays	(CXR)	are	used	in	the	diagnosis	of	leukaemia	to	assess	the	lungs	and,	to	less	 extent,	 lymph	nodes	 in	 the	 chest.	However,	 the	 sensitivity	 is	 very	 limited.	 In	 a	study	 of	 leukaemia	 patients	 having	 chest	 symptoms,	 CXR	 were	 inadequate	 in	establishing	an	etiological	diagnosis	[Godet	2012].	Ultrasound	can	be	used	to	look	for	masses	or	abnormally	large	lymph	nodes.	It	can	detect	leukaemia	cell	masses	inside	the	body	 in	 liver,	kidneys	or	 spleen	amongst	other.	CT	scan	 is	a	 specialized	 type	of	diagnostic	imaging	technique	producing	cross	sectional	detailed	images	of	the	body.	It	 is	 used	 in	 leukaemia	 for	 diagnostic	 purposes	 and	 to	 assess	 tumour	 response	 to	treatment.	Magnetic	 Resonance	 Imaging	 (MRI)	 uses	 radio	waves	 along	with	 strong	magnets	to	acquire	the	image	of	targets	 inside	the	body.	MRI	is	able	to	characterize	soft	 tissues	 better	 than	 CT	 Scan	 aiding	 to	 the	 diagnosis	 of	 leukaemia	 [Dimopoulos	2009].	
	
1.5:	Treatment	of	Leukaemia	Recently,	 significant	 developments	 have	 taken	place	 in	 the	 treatment	 of	 leukaemia,	which	 have	 led	 to	 increased	 survival	 rates	 for	 this	 disease.	 Leukaemia	 has	 many	
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treatment	options	including	watchful	waiting,	targeted	therapy4,	biological	therapy,5	radiation	therapy	and	stem	cell	transplantation,	but	the	main	treatment	at	present	is	chemotherapy.	Combinations	of	 these	treatments	are	also	used	depending	upon	the	case	and	age	of	the	patient.	There	are	few	factors	that	play	a	vital	role	in	deciding	the	treatment	 choice	 such	 as	 type	 of	 leukaemia,	 age	 of	 the	 patient,	 and	 stage	 of	 the	disease	 (Appendix	 2).	 Cytotoxic	 drugs	 used	 in	 the	 treatment	 of	 leukemia	 include	doxorubicin,	 methotrexate,	 cytarabine,	 etoposide	 and	 cisplatin	 amongst	 other	[Friesen	1999].			 	 					
	
Figure	5:	Chemical	structure	of	Imatinib	and	Nilotinib.		Imatinib	(figure	5)	is	an	anti-leukemic	selective	tyrosine	kinase	inhibitor	with	specific	activity	 for	ABL,	 Platelet	 derived	 growth	 factor	 receptor,	 c-kit,	 and	Albeson-related	gene	[Druker	2003].	It	was	first	used	clinically	in	1998	for	the	treatment	of	CML.	It	is	
                                                4	Targeted	therapy	is	cancer	treatment	that	uses	drugs	to	more	precisely	identify	and	attack	cancer	cells.		5	Biological	therapy	is	treatment	that	acts	on	processes	in	cells	i.e.	stopping	cancer	cells	from	dividing,	encourage	immune	system	to	attack	cancer	cells		
Imatinib Nilotinib 
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an	 orally	 bioavailability	 mesylate	 salt,	 a	 multi-target	 inhibitor	 of	 v-Abl,	 c-Kit	 and	PDGFR	 with	 IC50	 of	 0.6	 μM,	 0.1	 μM	 and	 0.1	 μM	 in	 cell-free	 or	 cell-based	 assays,	respectively.		Imatinib	 (Glivec®)	 is	 a	 frequently	 used	 drug	 for	 some	 types	 of	 Leukemia	 i.e.	 CML,	Philadelphia	 Chromosome	 positive	 (Ph+ALL),	 chronic	 eosinophilic	 Leukemia,	 and	blood	disorders	myelodysplastic	and	myeloproliferative	conditions,	and	as	hallmark	of	target	therapies	for	many	malignant	diseases	i.e.	gastro-intestinal	stromal	tumors	(GISTs),	 and	 dermatofibrosarcoma	 protuberans	 (DFSP).	 However,	 one	 of	 the	 main	problems	 is	 the	 development	 of	 resistance	 which	 often	 cannot	 be	 overcome	 even	with	higher	doses	of	Imatinib.		Nilotinib	(figure	5)	is	a	second-generation	inhibitor	of	BCR-ABL	tyrosine	kinase	used	as	an	alternative	to	Imatinib	when	cells	become	resistant.	The	drug	is	a	derivative	of	Imatinib,	with	similar	structure	to	Imatinib	but	is	more	potent,	and	therefore,	able	to	overcome	 mutations	 that	 can	 cause	 Imatinib	 resistance.	 Nilotinib	 inhibits	 the	autophosphorylation,	 at	 IC50	 values	 as	 indicated,	 20-60	 nM	 for	 Bcr-Abl,	 69	 nM	 for	PDGFR	and	210	nM	for	c-Kit.	Cells	that	did	not	express	the	BCR-ABL	were	resistant	to	Nilotinib	 below	2	 μM.	Nilotinib	was	 active	 against	many	mutant	 forms	 of	BCR-ABL	that	 proved	 resistant	 against	 Imatinib	 and	 few	 mutants	 were	 less	 sensitive	 to	Nilotinib	with	 IC50	values	of	150	 -	390	nM,	while	T351I	was	 resistant	up	 to	below	10,000	 nM.	 Using	 the	 same	 cell	 lines	 Nilotinib	 inhibited	 viability	 and	 proliferation	with	 IC50	 values	 ranging	 from	 8	 to	 24	 nM	 [Scientific	 discussion.	 Online	 at	http://www.ema.europa.eu].		Since	IC	50	values	for	this	drug	vary	vastly	within	each	cell	line,	preliminary	experiments	showed	that	most	cells	were	alive	when	incubated	
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for	 five	 days	with	 10	µM	 Imatinib	 and	 no	 cells	 survive	 in	 the	 presence	 of	 500	µM	Nilotinib.		Nilotinib	 and	 Imatinib	 (figure	 5)	 (drugs	 used	 in	 this	 work)	 are	 kinase	 inhibitors	mainly	 used	 for	 leukaemia	 treatment.	 These	 are	 selective	 inhibitors	 of	 BCR-ABL	tyrosine	kinase	giving	a	high	response	rate.	These	inhibit	other	kinases	as	well	as	c-kit,	 ARG,	 and	 platelet-derived	 growth	 factor	 [Quintas-Cardama	 2006]	 by	 hindering	their	 interaction	 with	 ATP	 thereby	 inhibiting	 their	 ability	 to	 phosphorylate	 and	activate	downstream	proteins.	These	are	mainly	used	for	chronic	myeloid	leukaemia	[Peggs	2003].	It	is	estimated	that	10-40%	of	patients	using	Imatinib	for	leukaemia	get	resistance	to	this	drug,	so	there	is	an	immediate	need	of	alternative	treatments.													
Figure	 6:	 Schematic	 representation	 of	 the	 mechanism	 of	 action	 of	 Imatinib	 [	Zaharieva	2013]		
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The	mechanism	of	action	of	 Imatinib	 is	depicted	 in	Figure	6.	 It	 attaches	 to	 the	ATP	binding	 site	 of	 BCR-ABL	 tyrosine	 kinase,	 thus	 stopping	 the	 transfer	 of	 phosphate	groups	to	other	proteins,	which	blocks	downstream	signalling	resulting	in	cell	death	[Zaharieva	2013].			It	 is	well	known	that	cancer	cells	can	become	resistant	to	cytotoxic	drugs	through	a	process	called	multi	drug	resistance	[Krishna	2006].	Leukemia	cells	become	resistant	to	 Imatinib.	 Therefore,	 researchers	 at	 Novartis	 Pharmaceuticals	 designed	 novel	inhibitors	with	effective	results	against	Imatinib	resistant	mutants	of	BCR-ABL,	which	was	based	upon	the	crystal	structure	of	the	Imatinib-ABL	complex	[Schindler	2000].	Their	 hypothesis	 about	 alternative	 binding	 groups	 led	 them	 to	 the	 development	 of	AMN107	 Nilotinib.	 It	 is	 a	 high	 affinity	 amino	 pyrimidine-based	 ATP	 competitive	inhibitor,	which	decreases	 the	proliferation	and	viability	of	wild	 type	BCR-ABL	and	Imatinib	 resistant	 BCR_ABL	 mutant	 expressing	 cells	 by	 inhibiting	 BCR_ABL	 auto	phosphorylation.	Nilotinib	has	proven	superior	potency	to	Imatinib	in	a	wide	range	of	CML	derived	cells	lines	in-vitro	[Golemovic	2005].	
	
1.5.1:	Limitations	with	Diagnosis	and	Treatment	The	use	of	chemotherapy	or	combination	chemotherapy	at	high	doses	for	leukaemia	patients	before	transplantation	kills	the	leukemic	cells	and	stem	cells	as	well,	placing	patients	 at	 high	 risk	 of	 infection.	 Transplanted	 stem	 cells	 need	 time	 (24	 hours)	 to	reach	 to	 the	bone	marrow	and	 then	start	dividing	and	multiply	 in	order	 to	develop	new	immune	cells,	which	can	fight	infectious	diseases.	Infection	may	develop	due	to	the	time	delay	in	the	renewal	of	the	immune	system	with	white	blood	cells.		
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	One	of	the	problems	in	the	management	of	leukaemia	and	solid	tumours	is	assessing	whether	the	disease	will	be	sensitive	or	not	to	a	chemotherapy	drug	or	combination	of	 drugs.	 FACS	 (Fluorescence-activated	 cell	 sorting	 analysis)	 or	 PCR	 determines	minimal	 residual	 disease	 to	 check	 the	 patient’s	 response	 to	 the	 treatment.	 Due	 to	discomfort,	 high	 costs,	 need	 of	 skilled	manpower,	 and	 risk	 involving	 bone	marrow	sampling,	 these	 measurements	 cannot	 be	 done	 on	 a	 daily	 basis	 throughout	 the	treatment	period.	Thus,	a	method	to	assess	tumour	cell	sensitivity	to	chemotherapy	is	still	 needed.	 Similarly,	 new	 drug	 development	 requires	 different	 tests	 to	 assess	tumour	 cell	 sensitivity	 to	 new	 drugs.	 There	 are	 several	 chemotherapy	sensitivity/resistance	 assays	 such	 as	 gene	 expression	 profiling,	 in	 vitro	 clonogenic	and	proliferation	 assays,	molecular	 assays,	 and	 in	vivo	 tumour	 growth	 and	 survival	assays	amongst	other	[Chang	2003;	Robert	2004;	Blumenthal	2007;	Cree	2009].	It	is	not	clear	yet	whether	these	assays	can	improve	the	outcome	of	patients	with	cancer	[Samson	2004;	Schrag	2004]	and,	so	far,	 the	clinical	application	has	proved	difficult	[Cree	2009].	Therefore,	further	techniques	are	needed	to	improve	the	management	of	leukaemia.		
1.5.2:	Companion	Diagnostics	Companion	diagnostics	 are	 assays	 intended	 to	help	physicians	 to	 select	 or	monitor	therapy,	and	facilitate	precision	medicine	by	selecting	the	correct	drug	for	the	right	patient	at	the	precise	dose.	Companion	diagnostic	tests	are	needed	to	assess	whether	a	 new	 drug	will	work	 against	 a	 specific	 genetic	 or	 biological	 target,	 but	 not	 for	 all	patients	 with	 a	 certain	 cancer	 or	 disease.	 These	 tests	 are	 used	 to	 categorise	 who	would	benefit	from	certain	treatment	or	combination	of	treatments	and	sometimes	to	
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establish	whether	 a	 patient	would	 not	 benefit,	 or	 could	 be	 harmed	 by	 the	 use	 of	 a	certain	 treatment.	 Companion	 diagnostics	 are	 a	 key	 part	 of	 personalized	medicine	and	 will	 likely	 continue	 to	 rapidly	 increase	 in	 number	 and	 application	 to	 disease	areas	 [Agarwal	 2015,	 Olsen	 2013].	 Despite	 of	 the	 promising	 results	 of	 companion	diagnostics,	 there	 are	 also	 complications	 i.e.	 developing	 a	 successful	 companion	diagnostic	with	 its	 complementary	 drug	 is	 complex,	 disintegrated	 and	with	 several	challenges.	 The	 components	 involved	 in	 companion	diagnosis	 development	 require	specific	expertise	which	are	not	really	found	within	a	single	organization,	puts	several	challenges	ahead	in	their	development.	The	key	challenges	can	be	categorised	in	four	broad	categories	[Moore	2012].	Strategic	business	challenges,	Regulatory	challenges,	Financial	challenges,	Logistical	challenges.			
1.5.2.1:	 Currently	 used	 companion	 diagnostic	 techniques,	 their	
advantages	and	disadvantages.		
	
1.5.2.1.1:	IHC	(immunohistochemistry)	This	process	 is	 easy	and	 routinely	performed,	very	 suitable	 for	 small	 tumours.	 It	 is	quick,	 cost	 effective	 and	 does	 not	 require	 a	 highly-qualified	 person	 to	 perform	[Gremel	2013].	It	is	easy	to	preserve	the	information	gained	through	this	technique.	However,	IHC	is	semi-quantitative	and	requires	skilled	staff	for	the	interpretation	of	results.	 Since	 it	 requires	 sample	 preparation,	 it	 could	 vary	 in	 fixation	 procedure,	staining	protocol,	and	antibody	selection	[Gremel	2013].	
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1.5.2.1.2:	Quantitative	real-time	PCR	(qRT-PCR)	Quantitative	 real	 time	 PCR	 is	 very	 important	 technique	 used	 for	 companion	diagnostics	 and	has	 got	 large	dynamic	 range.	Qrt-PCR	 is	 also	 associated	with	 some	disadvantages	as	 there	 is	no	histological	 information	retained	during	the	procedure	[Gremel	2013].	Contamination	of	test	results	by	stromal/normal	tissue	is	possible.	It	has	 got	 increased	 time,	 cost	 and	 technological	 requirements.	 qRT-PCR	 results	may	also	vary	depending	on	tissue	quality	and	RNA	extraction/processing	[Gremel	2013].	
	
1.6:	New	Techniques	to	Be	Explored		There	 is	 still	 a	 vacuum	 for	 the	 development	 of	 new	 techniques	 to	 improve	 the	treatment	and	management	of	all	cancers	so	further	work	is	needed	to	establish	new	approaches.	 During	 my	 PhD,	 I	 have	 worked	 on	 several	 techniques	 to	 improve	 the	diagnosis	 and	management	 of	 leukaemia	 i.e.	 Synchrotron	 based	 Fourier	 Transform	Infrared	(FTIR)	Spectroscopy,	Raman	Spectroscopy	and	 the	Selected	 Ion	Flow	Tube	Mass	Spectroscopy	(SIFT-MS).	These	are	discussed	below.		
1.6.1:	Vibrational	Spectroscopy	In	 recent	 years,	 an	 immense	 field	 of	 studies	 has	 shed	 light	 (using	 spectroscopic	technique)	on	 the	medical	and	biomedical	 fields.	The	 first	application	of	vibrational	spectroscopy	 took	 place	 in	 1850	 [Paul	 2006].	 Thanks	 to	 the	 developments	 in	technology,	 vibrational	 spectroscopy	 has	 become	 very	 important	 in	 the	 field	 of	biomedical	science	in	recent	years.		
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When	light	interacts	with	matter,	it	may	be	absorbed	or	scattered	or	may	not	interact	with	 the	matter	 at	 all.	 Stretching	 and	 bending	 are	 the	 two	main	 oscillations	 of	 the	atoms,	which	correspond	 to	vibrational	modes.	Stretching	 involves	asymmetric	and	symmetric	 motion	 while	 bending	 motions	 are	 scissoring,	 wagging,	 rocking,	 and	twisting	(Figure	7).													
	
	
Figure	7:	Different	vibrational	modes	of	a	molecule.		Spectroscopic	 techniques	 are	 used	 to	 detect	 the	 loss	 or	 gain	 of	 energy	 through	vibrational	 motion	 in	 molecules,	 which	 could	 be	 of	 infrared	 absorption	 or	 Raman	scattering.	 The	 detection	 of	 loss	 of	 energy	 of	 radiation	 is	 called	 absorption	spectroscopy.	 Vibrational	 spectroscopy	 uses	 an	 infrared	 (FTIR	 spectroscopy)	 or	 a	laser	(Raman	spectroscopy)	beam	to	study	the	biochemical	composition	and	physical	structures	of	cells	and	tissues	amongst	other,	with	the	help	of	their	spectral	patterns	(fingerprinting).	When	an	infrared	or	a	laser	beam	passes	through	the	sample,	some	
		
21	
of	the	radiation	is	absorbed	by	the	sample	while	some	will	go	through.	This	difference	in	 light	 emitting	 from	 the	 sample	 can	 be	 recorded	 by	 specialised	 detectors	 that	produce	 a	 spectrum	 based	 on	 the	 biochemical	 composition	 of	 the	 sample	 [Miller	1992;	Jagannatha	2002].	Infrared	and	Raman	spectroscopy	are	techniques	presently	used	to	detect	and	recognise	disease	and	improve	its	management.	In	fact,	vibrational	spectroscopy	can	detect	changes	in	structural	composition	of	a	molecule	from	normal	to	 cancerous	 state,	 [Jackson	 1998]	 which	 could	 be	 applied	 in	 early	 diagnosis	 of	malignancy.	 This	 technique	 does	 open	 new	 horizons	 in	 the	 field	 of	 biomedical	sciences	because	of	its	non-invasive	nature		
1.6.2:	Infrared	Spectroscopy	Infrared	radiation	is	one	part	of	the	electromagnetic	spectrum.	Infrared	Spectroscopy	is	a	well-known,	non-destructive	technique,	which	can	identify	vibrational	motions	of	molecules	 describing	 its	 structure.	 Chemical	 functional	 groups	 of	 a	 sample	 can	 be	detected	 when	 it	 is	 placed	 in	 the	 path	 of	 an	 infrared	 beam	 in	 a	 non-destructive	manner.			In	 the	case	of	 infrared	spectroscopy,	a	 range	of	 frequencies	 is	directed	 towards	 the	sample	and	absorption	occurs.	The	loss	of	this	frequency	of	radiation	from	the	beam	due	to	the	absorption	is	detected	and	measured.	Infrared	spectroscopy	can	be	used	to	analyse	gases,	liquids,	and	solids.	Perkin	Elmer	in	1944	offered	the	first	ever-infrared		spectrometer	 at	 commercial	 level.	 It	 produced	 a	 computer	 controlled	 IR	spectrometer	in	1976	[Miller	1992].	
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1.6.3:	Fourier	Transform	Infrared	Spectroscopy		Fourier	 transform	 infrared	 spectroscopy	has	become	a	powerful	 tool	 to	 fingerprint	the	chemical	composition	at	molecular	level	because	of	its	ability	to	provide	detailed	biochemical	 information.	The	development	of	 the	Michelson	 Interferometer	 (Figure	8)	 in	 1880	 allowed	 the	 study	 of	 samples	 with	 FTIR	 spectroscopy	 using	 several	wavelengths	simultaneously	(figure	8).		
	
Figure	8:	Michelson	Interferometer.		The	 basic	 set	 up	 of	 FTIR	 Spectroscopy	 consists	 of	 a	 broadband	 radiation	 source,	interferometer,	a	sample	chamber/microscope	and	a	detector.	FTIR	Spectroscopy	has	been	 used	 in	 cancer	 diagnosis	 with	 encouraging	 results	 [Bhargava	 2007;	 Kendall	2009;	Bellisola	2012;	Petibois	2010]	and	to	study	the	effects	of	chemotherapy	agents	
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on	cancer	 cells	 [Liu	2001;	Zhou	2001;	Gasparri	2003;	Sulé-Suso	2005;	Draux	2009;	Bellisola	2010].	The	development	of	mathematical	and	statistical	methods	has	helped	in	the	analysis	and	management	of	large	amounts	of	spectral	data.												
	
Figure	9:	A	typical	IR	spectrum	of	a	cell.		
	A	 typical	 infrared	 spectrum	 of	 a	 biological	 sample	 can	 be	 divided	 into	 two	 main	portions,	 one	 includes	 protein,	 lipid,	 and	 H2O	 and	 the	 second	 one	 contains	information	 about	 protein,	 lipid,	 nucleic	 acid	 and	 carbohydrate	 (Figure	 9).	 This	technique	 can	 provide	 very	 valuable	 composite	 information	 about	 the	 lipids.	 The	vibrations	in	lipids	are	due	to	the	CH2	stretching	which	appears	in	the	region	of	3100	to	2800	cm-1	(Figure	9),	CH2	asymmetric	mode	at	2920	cm-1	(Figure	9)	and	symmetric	at	2851	cm-1.	Methylene	and	methyl	groups	appear	in	the	region	of	1500-1350	cm-1	(Figure	 9)	 and	 CH2	 bending	 occurs	 at	 1470	 cm-1	 (Figure	 9).	 Proteins	 are	 a	 basic	functional	unit	of	the	cell,	with	each	cell	having	its	distinct	functional	protein.	Infrared	
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spectra	 of	 proteins	 show	 their	 characteristic	 amide	 I	 group	 (C=O	 stretching)	 in	 the	1600-1700	cm-1	region.	The	amide	II	band	is	due	to	N-H	bending	and	C-N	stretching	which	occurs	in	infrared	spectra	at	the	region	around	1150	cm-1	to	1450	cm-1	(Figure	9).	The	amide	III	band	arises	from	coupling	of	C-N	stretching	and	N-H	bending	giving	rise	to	bands	in	the	1230-1300	cm-1	region.	One	of	the	most	important	infrared	bands	of	 proteins	 is	 the	 amide	 I,	 very	 useful	 for	 the	 analysis	 of	 secondary	 structures	 of	proteins	(Figure	9).		
	
1.6.4:	Synchrotron	FTIR	Spectroscopy	There	 is	 increasing	 interest	 in	 infrared	 microscopy	 with	 the	 development	 of	Synchrotron	radiation	sources,	a	source	of	 infrared	radiation	produced	by	electrons	travelling	at	high	speed	in	vacuum	whose	path	is	controlled	by	magnets	(Figure	10)	[Yarwood.	1984,	Elleaume.	2002].		
	
	
Figure	 10:	 Schematic	 presentation	 of	 a	 Synchrotron.	 Magnetic	 field	 accelerates	electrons	by	curving	its	path,	as	a	result	synchrotron	radiation	is	produced.	
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It	 has	 very	 high	 brilliance	 and	 much	 smaller	 spot	 size	 when	 compared	 to	conventional	 sources,	 allowing	 the	 study	 of	 biological	 samples	 at	 both	 cellular	 and	subcellular	 levels	 extending	 from	 x-ray	 to	 infrared	 frequency	 [reviewed	 in:	 Dumas	2007].	It	provides	an	intense	light	source	of	up	to	1000x	brighter	than	a	globar	source	improving	 the	 detection	 of	 molecular	 information	 at	 the	 subcellular	 level	 with	excellent	spectral	quality.	
	
1.6.5:	Raman	Spectroscopy	When	light	interacts	with	matter,	it	is	possible	for	the	photons	that	make	up	the	light	to	 interact	 with	 the	 molecules	 and	 scatter	 as	 a	 resulting	 light.	 These	 scattering	photons	can	be	observed	with	the	help	of	detectors	at	particular	angle	to	the	incident	light.	Scattering	is	a	widely-used	technique.												 		Figure 11: Energy-level	diagram	showing	the	states	involved	in	Raman	signal.	
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One	every	day	illustration	of	scattering	is	the	blue	colour	of	the	sky	due	to	the	higher	energy	blue	light	scattering	from	molecules	in	the	atmosphere	than	lower	energy	red	light.	 Raman	 spectroscopy	 is	 the	 main	 technique	 used	 to	 measure	 scattering	 to	identify	 molecules.	 Figure	 11	 is	 a	 simple	 illustration	 of	 the	 different	 energy	 levels	involved	in	Raman	signal.	 	Raman	spectroscopy	uses	a	single	frequency	of	radiation	directed	 to	 the	 sample	 and	 the	 radiation	 scattered	 from	 the	molecules	 is	 recorded	and	measured.		Raman	spectroscopy	can	be	used	to	detect	changes	at	molecular	level	both	 in	 vivo	 and	 in	 vitro	 and	 compare	 diseased	 versus	 normal	 tissues	 (figure	 12).	There	 are	 three	 main	 components	 in	 Raman	 spectrometer,	 the	 laser,	 the	spectrometer	and	the	sampling	interface.													
	
Figure	12:	Representative	Raman	spectrum	of	a	cell	[Downes	2010].		
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The	 advantage	 of	 both	 FTIR	 and	 Raman	 spectroscopies	 is	 providing	 chemical	information	 both	 at	 cellular	 and	 sub-cellular	 level	 without	 the	 need	 of	 stains	 and	labels	 or	 external	 agents.	 The	 differing	 underlying	 mechanisms	 give	 rise	 to	 a	complementarity	 of	 the	 two	 techniques,	 such	 that	 vibrations	 of	 asymmetric,	 polar	bonds	 tend	 to	 be	 strong	 in	 IR	 spectra,	whereas	Raman	 is	 particularly	 suitable	 as	 a	probe	of	symmetric,	nonpolar	groups.	A	further	implication	of	the	differing	physical	origins	of	the	techniques	is	that,	whereas	IR	monitors	the	absorption	of	IR	radiation,	Raman	 scattering	 can	 be	 employed	 in	 the	 UV,	 visible	 or	 near-IR	 regions	 of	 the	spectrum.	 Raman	 scattering	 thus	 offers	 intrinsically	 higher	 spatial	 resolution	 for	mapping	 or	 profiling,	 the	 limit	 of	 resolution	 being	 (classically)	 determined	 by	 the	wavelength	(<1	µm	for	Raman,	~5-10	µm	for	IR)	(Byrne	2014).			All	 the	 diseases	 present	 with	 chemical	 and/or	 structural	 changes	 that	 can	 be	identified	with	vibrational	 spectroscopy	and	compared	 to	normal	 conditions.	These	changes	 in	 spectra	 can	 be	 used	 as	 spectral	 markers	 of	 a	 specific	 disease.	 These	techniques	have	been	used	in	a	variety	of	different	fields	of	biology,	i.e.	single	human	normal	 and	 leukemic	 cell	 analysis	 [Benedetti 1988], biomedical	 application	 in	diagnosis	[Krafft	2006],	chemical	imaging	using	Synchrotron	IR	[Miller	2006],	clinical	diagnostics	 [Dubois	 2004],	 metabolic	 fingerprinting	 [Ellis	 2006]	 and	 biochemical	analysis	of	cells	[Swain	2007]		In	 this	 thesis,	 I	have	worked	with	both	Synchrotron-FTIR	and	Raman	Spectroscopy	for	 the	 treatment	and	management	of	 leukaemia	using	 two	different	 leukaemia	cell	lines,	 Jurkat	 and	 K562.	 The	 resistance	 to	 the	 drug	 is	 a	 challenging	 issue	 in	 cancer	treatment	and	management.	One	of	 the	aims	of	 this	work	was	 to	establish	whether	
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FTIR	 and	 Raman	 spectroscopies	 could	 be	 used	 to	 identify	 the	 resistance	 and/or	sensitivity	of	leukaemia	cells	prior	to	treatment.		
	
1.7:	Release	of	Volatile	Compounds	from	Leukaemia	
Phillips	et	al.	 (1994)	 stated	 there	are	3,481	different	 compounds	 in	human	exhaled	breath	which	have	been	observed	at	different	concentrations	ranging	from	parts	per	billion	 by	 volume	 (ppbv)	 to	 parts	 per	 trillion	 by	 volume	 (pptv),	 which	 vary	 from	person	to	person.	Among	this	number	of	volatile	organic	compounds	(VOCs),	only	a	small	 number	 of	 VOCs	 are	 common	 among	 all	 people.	 These	 include	 isoprene,	acetone,	ethanol,	and	methanol	amongst	other.	Along	with	these,	exhaled	breath	also	contains	 NO,	 H2	 NH3,	 and	 CO2.	 	 Some	 of	 these	 compounds	 show	 negative	 alveolar	gradient6,	 as	 they	 are	 in	 higher	 concentrations	 in	 inhaled	 air	 rather	 than	 exhaled	breath.	 About	 1,753	 compounds	were	 observed	 showing	 positive	 alveolar	 gradient	(higher	concentration	exhaled	breath	than	inhaled	air)	[Phillips	1994;	Phillips	1999].		Over	 the	 last	 few	 years,	 there	 has	 been	 an	 increased	 interest	 in	 the	 study	 of	 VOCs	released	 by	 cancer	 cells.	 Several	 techniques	 such	 as	 Gas	 Chromatography	 Mass	Spectrometry	 (GC-MS),	 Proton	Transfer	Reaction	Mass	 Spectrometry	 (PTR-MS),	 ion	mobility	spectrometry	(IMS),	and	Selected	Ion	Flow	Tube	Mass	Spectrometry	(SIFT-MS)	have	been	used	in	the	study	of	VOCs	released	by	cancer	cells	[Amann	2005].	All	above-mentioned	techniques	have	their	own	advantages	and	shortcomings.			
                                                6	The	Alveolar	arterial	gradient	(A-a	gradient)	is	a	measure	of	the	difference	between	the	alveolar	concentration	(A)	of	oxygen	and	the	arterial	(a)	concentration	of	oxygen.		
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Alveolar	 gradient	 SIFT-MS,	 used	 in	 this	 work,	 detects	 accurately	 and	 in	 real	 time	several	 compounds	 simultaneously	 down	 to	 concentrations	 of	 parts-per-billion	 by	volume	(ppbv).	More	importantly,	it	obviates	sample	preparation	that	could	not	only	alter	the	sample	but	take	up	valuable	time	[Smith	2005;	Španĕl	2011].	Several	groups	have	applied	 the	SIFT-MS	technique	to	study	the	release	of	volatiles	by	cancer	cells	[Sulé-Suso	2009]	aimed	mainly	at	developing	applications	of	this	sensitive	technique	for	cancer	diagnosis.		
Table	I:	Current	Breath	Analysis	Techniques.			
	
Analytical	
Technique	
	
Mode	of	operation	
	
Detection	
Limit	
	
Sensitivity	
	
Specificity	
	
SIFT-MS	
	
PTR-MS	
	
IMS	
	
GCMS	
	Direct/Real-time	[Smith	2005]			Direct/Real	Time	[Lindinger	1998;	Kushch	2008]			Real	time	[Ulanowska	2008]			Pre-Concentration	[Ligor	2008;	Fuchs	2010]	
	ppbv		pptv		ppbv		pptv-ppbv	
	High		High		Medium		Very	high	
	High		Medium/High		Medium		Very	high		
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In	breath	analysis,	lung	pathophysiology	and	lung	diseases	have	been	widely	studied	to	 achieve	 an	 early	 diagnosis	 of	 lung	 cancer	 [Di	 Natale	 2003;	 Mazzone	 2008;	Bajtarevic	 2009;	 Sponring 2009].	 However,	 this	 methodology	 could	 be	 extended	 to	other	medical	applications	such	as	the	study	of	blood	diseases	thanks	to	the	exchange	of	volatiles	through	the	blood-gas	interface	in	lung	alveoli	[Sapoval	2002].	It	has	been	estimated	that	the	mean	number	of	alveoli	in	a	healthy	lung	is	around	480	x	106	[Ochs	2004]	 providing	 a	 surface	 area	 of	 around	 70	 m2	 [Notter	 2000].	 Thus,	 it	 could	 be	hypothesised	that	the	presence	of	a	high	number	of	leukaemia	cells	in	patients’	blood	and/or	in	the	bone	marrow	could	lead	VOCs	profiles	in	breath	different	from	those	of	healthy	people.	To	better	 characterise	 the	VOCs	 released	by	 leukaemia	 cells,	 I	 have	carried	out	 the	present	study	comparing	VOCs	released	by	2	 leukaemia	cell	 lines	 to	healthy	peripheral	blood	mononuclear	cells.	
	
1.7.1:	Selected	Ion	Flow	Tube	Mass	Spectrometry	(SIFT-MS)	SIFT-MS	 is	 an	 innovative	 investigative	method.	 The	 history	 of	 this	 technique	 starts	with	the	development	of	Selected	Ion	Flow	Tube	in	1976	by	Dr	David	Smith,	[Španēl	2001]	the	concept	of	which	was	to	study	the	ion	molecule	reactions	in	the	gas	phase	at	 thermal	 energies.	 This	 instrument	 has	 made	 great	 progress	 in	 the	 field	 of	 gas	analysis	with	 the	help	 of	 a	 quantitative	Mass	 Spectrometer.	 SIFT-MS	 is	 based	upon	the	principle	of	chemical	ionization	(CI),	which	uses	specifically	chosen	reagent	ions	H3O+,	NO+,	and	O2+	(which	do	not	react	readily	with	major	molecules	present	 in	the	air	but	most	of	the	trace	gases	and	vapors	of	medical	 interest)	along	with	flow	tube	technology	and	quantitative	mass	spectrometry.	It	works	on	real-time	quantification	of	 several	 trace	 gases	 simultaneously	 in	 air	 and	 breath.	 Absolute	 concentrations	 of	
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trace	 gases	 in	 single	 breath	 exhalation/headspace	 can	 be	 determined	 by	 SIFT-MS	down	 to	ppb	 levels,	 obviating	 sample	modification.	 SIFT-MS	utilizes	 the	 reaction	of	mass	selected	precursor	 ions	with	sample	 ions	 that	are	 introduced	 into	a	 flow	tube	via	 a	 helium	 gas	 carrier.	 The	 subsequent	 product	 ions	 are	 then	 studied	 by	 a	downstream	 mass	 spectrometer	 (Figure	 13).	 Mass	 selected	 precursor	 ions	 are	created	using	a	microwave	resonator;	commonly	selected	ions	are	H3O+,	NO+	and	O2+	ions,	 for	 the	 simple	 reason	 that	 they	 do	 not	 react	 readily	 with	 the	 common	constituents	of	air	[Španěl	2011;	Michalčíková 2014].	
	
	
Figure	13:	Typical	Schematic	diagram	of	a	SIFT-MS	machine	being	used	in	this	study	[Smith	2011].		
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	A	downstream	mass	spectrometer	is	then	used	to	select	the	correct	ions	generated	by	the	 microwave	 generator.	 A	 series	 of	 pumps	 and	 sampling	 orifices	 are	 used	 to	maintain	 the	 correct	 pressure	 and	 to	 focus	 the	 ions	 along	 the	 SIFT-MS.	 The	downstream	mass	spectrometer	operates	at	around	5-10	Torr,	 the	proceeding	 flow	tube	operates	at	0.5	Torr	 in	order	 to	achieve	articulate	gas	reactions.	Venturi	 inlets	are	 used	 to	 sustain	 such	 changes	 in	 pressure	 but	maintain	 a	 focussed	 flow	of	 ions.	Once	a	stream	of	defined	precursor	ions	has	been	established	the	sample	of	interest	is	then	 injected	 into	 the	 flow	 tube	 through	 a	 helium	 carrier	 gas;	 the	 gas	 again	 being	specific	 for	this	purpose,	due	to	 its	 inert	nature	at	a	pressure	of	around	1	Torr.	The	introduced	 ion	 species	 from	 the	 sample	 of	 interest	 then	 reacts	with	 the	 precursor	ions	(preselected	by	the	upstream	quadrupole)	as	they	travel	across	the	flow	tube	at	high	 speed	 (Španěl	 2011).	 Product	 ions	 and	 precursor	 ions	 travel	 through	 a	 final	sampling	 orifice	 where	 they	 are	 met	 by	 the	 downstream	 quadrupole.	 An	 electron	multiplier	 then	 amplifies	 the	 signal	 given	 from	 the	 final	 quadrupole.	 An	 on-line	computer	is	then	able	to	calculate	the	relative	concentration	of	trace	compounds	from	the	reaction	of	product	 ions	and	sample	gas	(Smith	2005;	Španěl	2011).	These	data	are	 analyzed	 in	 real	 time	with	 the	 help	 of	 chemical	 information	 recorded	 in	 SIFT’s	extensive	compound	library	giving	instant,	accurate	quantification	of	all	compounds	in	the	samples.		The	primary	advantage	of	SIFT-MS,	 in	 contrast	with	GC-MS,	 is	 that	 the	 compounds’	concentrations	in	the	sample	can	be	measured	in	real	time	(seconds)	while	in	case	of	GC-MS	the	speed	of	measurement	is	limited	by	the	retention	time.		
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In	 this	 thesis,	 I	 have	 also	 worked	 on	 the	 analysis	 of	 VOCs	 released	 from	 both	Leukemia	 cell	 lines,	 the	 difference	 in	 the	 VOCs’	 profile	 of	 different	 clones	 from	 the	same	 cell	 line,	 differences	 in	 the	 VOCs’	 profile	 after	 drug	 administration	 and	difference	in	the	release	of	VOCs	in	hypoxic	and	normoxic	conditions.		
	
1.8:	AIMS	of	the	Study	In	order	to	improve	the	early	diagnosis	and	management	of	leukaemia,	further	work	is	 needed	 to	develop	 and	apply	 in	 the	 clinical	 practice	 techniques	 that	provide	 fast	and	 robust	 results.	While	 I	 acknowledge	 that	 further	work	 is	 needed	 to	 take	 these	techniques	into	a	hospital	set	up,	the	work	carried	out	here	shows	promise	for	both	techniques	as	helping	aids	to	clinicians	managing	patients	with	leukaemia.		 1. To	 assess	 whether	 vibrational	 spectroscopy	 and	 SIFT-MS	 could	 have	 the	potential,	that	could	be	used	in	clinical	practice.		2. To	characterize	 the	best	methodology	 for	 these	 techniques	 to	 translate	 their	best	use	into	clinics.		
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Chapter:	2																							 
General	Material	and	Methods 
	
2.1:	Cell	Culture		The	cells	used	in	this	study	were:		Jurkat	(kind	gift	of	Dr	Bellisola,	University	of	Verona),	an	Acute	T	Cell	Leukaemia	cell	line,	established	from	the	peripheral	blood	of	a	14-year-old	male	by	Schneider	et	al.	(1977).		K562	(kind	gift	of	Dr	Bellisola)	is	a	Chronic	Myelogenous	Leukaemia	cell	line.	This	cell	line	 is	 derived	 from	 a	 53-year-old	 female	 with	 chronic	 myelogenous	 leukaemia	(CML).	 K562	 is	 used	widely	 as	 a	 highly	 sensitive	 in	vitro	 target	 for	many	 different	drug	assays	[Pietarinen	2015].			Fresh	Human	Peripheral	Blood	Mononuclear	cells	 (PBMC)	bought	 from	ZenBio,	 Inc.	(UK).	 A	 blood	 cell	 with	 one	 nucleus	 is	 called	 a	 peripheral	 blood	mononuclear	 cell	(PBMC).	 PBMC	 are	 very	 important	 part	 of	 the	 blood	 system	 containing	 cells	 of	 the	immune	system,	a	natural	defence	system	against	infections.	PBMC	contain	all	types	of	 leukocytes	 including	 T	 type,	 B	 Type,	 natural	 killer	 cells,	 monocytes,	 basophils,	neutrophils,	 and	eosinophil	 cells.	These	 cells	were	extracted	 from	whole	blood	of	 a	healthy	person.	I	used	these	cells	as	control	against	leukaemia	cell	lines.			
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Human	 bone	 marrow	 aspirates	 (BMA)	 from	 the	 iliac	 crest	 of	 3	 different	 healthy	donors	were	purchased	from	Lonza,	USA.			Both	 leukaemia	 cell	 lines	 (Jurkat,	 K562)	 were	 maintained	 in	 RPMI	 1640	supplemented	 with	 10%	 Foetal	 Bovine	 Serum	 (FBS),	 1%	 L-Glutamine,	 1%	 Hepes	Buffer,	 and	 1%	 Antibiotic/antimycotic.	 Growth	 conditions	 were	 maintained	 within	culture	flasks	(Sarstedt,	UK)	at	37°C	and	5%	CO2.	Media	was	changed	every	3-4	days.	Cells	were	passaged	before	reaching	confluence.	These	cells	grow	in	suspension.			Fresh	PBMC	were	 thawed	and	cultured	 in	RPMI	1640	supplemented	with	30%	FBS	1%	 L-Glutamine,	 1%	 Hepes	 Buffer,	 and	 1%	 Antibiotic/antimycotic.	 Growth	conditions	were	maintained	within	culture	flasks	(Sarstedt,	UK)	at	37°C	and	5%	CO2.	These	cells	grow	in	suspension.		Whole	bone	marrow	samples	were	seeded	at	a	density	of	7.5	x	106	cells	in	20	mL	of	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	supplemented	with	5	ml	Hepes	buffer,	5%	FBS,	1%	L-glutamine	and	1%	NEAA	on	10	ng/ml	fibronectine-coated	T-75	tissue	culture	flasks	(Sigma,	UK).	Samples	were	incubated	at	37	°C	and	5%	CO2.	
	
2.1.1:	Cell	Viability	Cell	viability	was	determined	with	the	Trypan	Blue	exclusion	method.	20	µL	of	0.4%	Trypan	Blue	solution	(Sigma	Aldrich,	UK)	were	added	to	20	µL	of	cell	suspension	and	mixed	gently.	A	haemocytometer	was	then	loaded	with	the	stained	suspension.	Live	and	 dead	 cells	 were	 counted	 under	 the	 microscope	 (non-stained	 cells	 were	
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considered	as	live	cells,	those	cells	that	take	up	the	Trypan	blue	stain,	are	considered	as	non-viable).		
2.1.2:	Cell	Cloning	K562	cell	 line	was	used	to	obtain	 leukaemia	cell	clones	[Chu	2009;	Rutter 2014].	For	this	purpose,	cells	were	collected	from	the	culture	flasks	and	centrifuged	at	950	rpm	for	3	minutes.	Supernatant	was	then	discarded	and	the	cell	pellet	was	dislodged	and	resuspended	 in	 fresh	 complete	 medium.	 After	 adding	 the	 medium,	 the	 cells	 were	counted	 using	 the	 trypan	 blue	 exclusion	 assay.	 Cells	 then	 were	 seeded	 in	 flat-bottomed	96	well	plates	at	a	concentration	of	0.5	cells/well	in	200	μL/well	complete	media	(for	example	and	for	simplicity,	for	100	wells,	50	cells	were	placed	in	20	mL	of	medium	and	distributed	evenly	in	these	100	wells.	Diluted	such	that	the	probability	is	0.5	cells/well).	 	The	plates	were	wrapped	in	foil	to	avoid	dehydration,	incubated	at	37°C	and	5%	CO2.	Media	was	changed	after	one-week	culture	by	spinning	the	plates	at	1200	rpm	for	7	minutes.	Following	this,	100	μL	of	media	were	removed	and	100μL	of	fresh	complete	media	were	added.	Plates	were	further	incubated	at	37°C	and	5%	CO2	for	one	week	to	allow	the	clones	to	develop.	Clones	were	inspected	regularly	so	those	wells	with	more	than	 1	 clone	 could	 be	 discarded.	 Figure	 14	 is	 a	 representative	 example	 of	 four	different	 clones	 1,	 2,	 3	 and	 4	 used	 during	 the	 experiment,	 while,	 figure	 15	 is	 the	example	of	 clones,	which	were	discarded.	The	number	of	 clones	obtained	with	 this	experimental	set	up	was	more	than	15	clones	per	each	96	well	plate	(Figure	14).				
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Figure	14:	Representative	examples	of	 four	K562	Clones	 (clone	1,	 clone	2,	 clone	3,	and	cone	4)	(Pictures	taken	at	7th	day	of	Seeding).			
 
 
 
 
 
 
	
Figure	15:	Representative	example	of	K562	clones	in	single	well,	those	clones	were	discarded.			
100	µm 100	µm
200	µm 200	µm
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2.2:	Imatinib		The	doses	of	Imatinib	used	in	the	present	work	were	50	µM	and	100	µM.	Since	IC	50	values	 for	 this	 drug	 varies	 vastly	 with	 in	 each	 cell	 line,	 preliminary	 experiments	showed	that	most	cells	were	alive	when	incubated	for	five	days	with	10	µM	Imatinib	and	no	cells	survive	in	the	presence	of	500	µM	Imatinib.		Imatinib	mesylate	was	a	kind	gift	of	Novartis	(Switzerland).	The	drug	was	provided	in	powder	 form	(58	mg).	The	powder	was	reconstituted	with	distilled	water	 to	a	 final	concentration	of	10	mM	according	to	the	provider’s	instructions	and	stored	at	-20	°C.		
	
2.3:	Nilotinib		The	doses	of	Nilotinib	used	in	the	present	work	were	50	µM	and	100	µM.	Since	IC	50	values	for	this	drug	varies	vastly	with	in	each	type	of	cell	line	same	as	Imatinib,	preliminary	work	proved	that	ratio	of	live	over	dead	cells	was	high	when	incubated	for	five	days	with	10	µM	Nilotinib	and	low	in	the	presence	of	500	µM	Nilotinib.	
	Nilotinib	was	 also	 a	 kind	 gift	 of	 Novartis	 (Switzerland).	 The	 drug	was	 provided	 in	powder	 form	 (100	 gm).	 The	 powder	 was	 reconstituted	 with	 DMSO	 to	 a	 final	concentration	of	10	mM	according	to	the	provider’s	instructions	and	stored	at	-20	°C.			
2.4:	Disulfiram	Inhibition			Disulfiram	(tetraethylthioperoxydicarbonic	diamide)	(DSF),	known	as	Antabuse,	has	been	 used	 in	 the	 treatment	 of	 alcoholism	 since	 1948,	 as	 an	 alcohol	 aversion	 agent	[Bell	1949].	DSF	given	to	patients	with	alcohol	consumption	results	 in	acetaldehyde	
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accumulation	[Bell	1949],	due	to	disulfiram	ethanol	reaction	[Maracto	2011].	It	is	an	Acetaldehyde	 dehydrogenase	 (ALDH)	 inhibitor,	 which	 primarily	 inhibits	 ALDH	 by	covalently	modifying	sulfhydryl	group,	 leading	to	high	blood	levels	of	Acetaldehyde.	DSF	 also	 inhibits	 other	 copper-dependent	 enzymes,	 such	 as	 carboxyl	 esterase	 and	cholinesterase	 [Zemaitis	 1976],	 due	 to	which	DSF	 is	 thought	 to	 induce	 proteasome	inhibition	 and	 subsequently	 cancer	 cell	 apoptosis	 [Wang	 2011].	 Lin	 et	 al.	 (2011)	observed	also	inhibition	by	disulfiram	of	prostate	cancer	cell	growth	along	with	DNA-DE-methylation	 [Lin	 2011].	 Currently,	 clinical	 trials	 are	 on-going	 to	 testify	 DSF’s	ability	to	inhibit	cancer	growth	[Lin	2011].					It	has	been	suggested	that	acetaldehyde	produced	by	microorganisms	present	in	the	mouth	and	throat	may	affect	analysis	of	acetaldehyde	[Jones	1995].	In	vitro	inhibition	of	ALDH	by	DSF	was	studied	during	this	work	to	confirm	the	release	or	consumption	of	Acetaldehyde	by	Leukaemia	cells.			DSF	(SIGMA-ALDRICH)	was	provided	 in	powder	 form	(300	mg).	 It	was	dissolved	 in	DMSO	to	a	final	concentration	of	20	mM,	and	was	stored	at	-20	°C.	DMSO	was	selected	to	 be	 the	 common	 solvent	 for	 the	 inhibition	 experiment,	 as	 it	 has	 relatively	 low	vapour	 pressure	 so	 it	 was	 not	 expected	 to	 interfere	 significantly	 with	 headspace	analyses	 [Chippendale	 2012].	 Disulfiram inhibits ALDH-II at IC50 = 10 nM more 
potently than ALDH-I’s IC 50 >20 µM [Keung 1993]. Kim 2013, reported an inverse 
correlation between the percentage of cells expressing ALDH and IC
 
values for disulfiram. 
Notably, the IC
 
of disulfiram for hTERT-HPNE cells by far exceeded those of Mia PaCa-2 
and CFPAC-1 cells, indicating that a sufficiently wide therapeutic window can be secured 
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[Kim 2013]. As	DSF	was	already	reported	being	used	by	Thomas,	W.	E.	C.	2012,	at	20	µM,	I	used	two	concentrations,	20	µM	and	40	µM.			
2.5:	Selected	Ion	Flow	Tube	Mass	Spectrometry		Volatile	 organic	 compounds	 (VOCs)	 from	 the	 headspace	 of	 cell	 cultures	 were	measured	using	an	analytical	technique,	Selected	Ion	Flow	Tube	Mass	Spectrometry	Profile	3	instrument,	from	Instrument	Science,	UK	(Figure	16).	Selected	reagent	ions	are	produced	by	water	and	air	by	a	microwave	discharge	ion	source	and	categorized	with	 the	 help	 of	 a	 mass	 quadrupole.	 During	 my	 study,	 I	 used	 H3O+	 and	 NO+	 as	precursor	 ions.	 The	 humid	 headspace	 of	 the	 cell	 cultures	 was	 acquired	 through	 a	heated	 sampling	 line,	 a	 hypodermic	 needle	 puncturing	 the	 septum	 of	 the	 culture	bottles	 connecting	 the	 headspace	 directly	 into	 the	 inlet	 port	 of	 the	 Profile	 3	instrument.	 During	 headspace	 sampling,	 the	 cell	 culture	 bottles	 were	 maintained	within	a	water	bath	at	37°C.												
Figure	16:	Profile	3	SIFT-MS	instrument	at	ISTM,	Keele	University,	UK.	
		
41	
SIFT-MS	kinetic	 library	provides	a	list	of	the	compounds	present	in	the	sample.	The	instrument	 was	 used	 either	 in	multi-ion	monitoring	mode	 (MIM),	 to	 study	 chosen	VOCs,	or	on	Full	Scan	mode	(FSM),	to	study	possible	species	in	the	range	between	10	-180	m/z.			
2.5.1:	Sample	Preparation	for	SIFT-MS	The	SIFT-MS	studies	of	parental	cells	were	carried	out	as	follows.	Cells	were	cultured	in	culture	flasks	(Sarstedt,	UK)	at	37°C	and	5%	CO2	for	5	days.	Media	was	changed	on	the	3rd	day,	and	cells	were	incubated	further	2	days.	After	this	incubation	period,	cells	were	collected	and	counted	using	the	trypan	blue	exclusion	method	after	centrifuging	at	950	rpm	for	3	minutes.	The	cells	were	then	seeded	at	10,	20	or	40	x	106	cells/bottle	in	 150	 ml	 glass	 bottles.	 These	 bottles	 were	 incubated	 under	 standard	 conditions	described	above	for	2	hours	with	the	lids	slightly	loose.	After	this	incubation	period,	the	bottles	were	air	purged	with	dry	air	for	1	minute,	the	lids	were	then	closed	tightly	and	 further	 sealed	 using	 parafilm.	 The	 bottles	 were	 then	 incubated	 at	 37°C	 for	 a	further	16	hours.			In	order	to	compare	the	VOCs	released	by	clonal	populations	to	the	parental	cell	line,	I	 acquired	 the	 clones	as	previously	described.	The	 selected	 clones	after	 two	weeks’	incubation	were	then	transferred	to	24	well	plates.	After	one-week	incubation	in	24	well	plates	at	37°C	and	5%	CO2,	cells	were	transferred	to	T25	 flasks	(Sarstedt,	UK).	These	flasks	were	further	incubated	for	one	week;	media	was	changed	on	the	3rd	day.	Following	one-week	incubation,	the	clonal	cells	were	collected	and	counted	using	the	trypan	 blue	 exclusion	 assay.	 Cells	 were	 seeded	 at	 10	 x	 106	 cells/bottle	 in	 150	mL	glass	 bottles.	 This	 cell	 concentration	was	 used	 in	 order	 to	 keep	 to	 a	minimum	 the	
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number	 of	 passages	 needed	 to	 get	 a	 number	 of	 cells	 high	 enough	 to	 run	 these	experiments.	 It	 is	widely	accepted	that	the	higher	the	number	of	passages	the	more	different	 the	 cells	 are	 from	 the	 original	 one	 [Masters	 2007].	 The	 bottles	 were	incubated	at	37°C	and	5%	CO2	for	two	hours	with	the	 lids	 loosely	closed.	Following	this	incubation	time,	the	bottles	were	air	purged	with	dry	air,	lids	tightly	closed	and	further	 sealed	 with	 parafilm,	 and	 incubated	 overnight	 for	 16	 hours.	 SIFT-MS	experiments	were	carried	out	following	this	incubation	period.												 	
	
 
	
	
Figure	17:	Schematic	stepwise	presentation	of	SIFT-MS	set	up	and	sampling.		In	order	to	assess	the	possible	differences	in	the	VOCs	released	by	cells	following	the	incubation	 with	 drugs,	 the	 following	 experiments	 were	 carried	 out:	 cells	 were	
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collected	and	counted	using	the	trypan	blue	exclusion	assay	after	centrifuging	at	950	rpm	for	3	minutes.	Following	counting,	cells	were	seeded	in	150	mL	glass	bottles	at	a	concentration	of	10	x	106	cells/bottle.	These	bottles	were	then	incubated	for	2	hours	with	their	lids	loosely	closed.	Following	this	incubation	period,	Imatinib	or	Nilotinib	was	added	at	a	concentration	of	50	µM,	or	100μM.	The	bottles	were	air	purged	with	dry	 air	 for	 1	 minute;	 lids	 tightly	 closed	 and	 further	 sealed	 with	 parafilm,	 and	incubated	overnight	 for	16	hours.	 SIFT-MS	experiments	were	 carried	out	 following	this	incubation	period.			To	determine	that	acetaldehyde	release	is	not	coming	from	the	metabolic	activity	of	the	ethanol,	the	ALDH	inhibition	test	was	performed	as	follows:	cells	were	collected	and	counted	using	the	trypan	blue	exclusion	assay	after	centrifuging	at	950	rpm	for	3	minutes.	 Following	 this,	 cells	 were	 seeded	 in	 150	 mL	 glass	 bottles	 at	 the	 desired	concentrations.	These	bottles	were	then	incubated	for	2	hours	with	their	lids	loosely	closed.	Following	 this	 incubation	period,	DSF	was	added	at	 the	 concentration	of	20	µM,	or	40	μM.	The	bottles	were	air	purged	with	dry	air	for	1	minute;	lids	were	tightly	closed	 and	 further	 sealed	with	 parafilm,	 and	 cells	were	 incubated	 overnight	 for	 16	hours.	SIFT-MS	experiments	were	carried	out	following	this	incubation	period.	Cells	were	recounted	after	the	SIFT-MS	experiment	to	confirm	cell	survival.			In	 order	 to	 translate	 SIFT-MS	 into	 clinics,	 the	breath	 sampling	method	needs	 to	be	well	characterised.	At	present,	three	main	sampling	techniques	are	used	by	different	groups,	 i.e.,	 direct	 breath,	 bottles,	 and	 Nalophan	 bags.	 In	 order	 to	 obtain	 breath	samples,	healthy	controls	were	asked	not	to	eat	or	drink	anything	apart	from	water	in	the	morning	prior	 to	giving	a	breath	 sample.	They	were	not	allowed	 to	brush	 their	
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teeth	 as	 some	 VOCs	 from	 the	 toothpaste	 could	 interfere	with	 VOCs’	measurement.	Patients	 were	 allowed	 to	 take	 their	 medication	 if	 indicated.	 Samples	 were	 taken	before	9.00	AM.			Exhaling	directly	into	the	machine	allowed	to	obtain	direct	breath.				For	bag	samples,	Nalophan	tube	sheeting	was	cut	into	30	cm	length	and	a	3	cm	poly-tubing	length	was	inserted	into	one	end,	fixing	it	into	place	with	a	cable	tie	and	sealed	with	parafilm.	The	other	end	of	 the	sheet	was	sealed	using	a	cable	tie	and	parafilm.	Individuals	were	asked	to	exhale	3	times	into	the	bag.	A	syringe	was	used	to	seal	the	end	 tube	 of	 the	 sampling	 bag	 after	 the	 breath	was	 collected.	 Parafilm	was	 used	 to	further	seal	it.			Bottle	sampling	was	done	by	asking	the	individuals	to	fill	the	glass	bottles	of	150	ml	volume	with	 the	 help	 of	 10cm	 straw,	 inserted	 8	 cm	 into	 the	 bottles.	 These	 bottles	were	 sealed	 after	 the	 breath	 was	 exhaled	 into	 them	with	 a	 tightly	 closed	 cap	 and	parafilm.	The	caps	contain	a	septum	through	which	SIFT-MS	sampling	with	a	needle	is	carried	out.			Bag	 and	 Bottles	 were	 sampled	 at	 different	 incubation	 time	 points,	 1,	 3,	 6,	 and	 24	hours.	 Incubation	 was	 carried	 out	 at	 room	 temperature	 to	 assess	 how	 delays	 in	breath	sampling	could	affect	the	VOCs	profile.			As	 described	 in	 first	 chapter	 in	 1.7.1,	 SIFT-MS	 can	 run	 in	 2	 different	modes	 using	three	different	precursors.	Direct	breath	was	sampled	just	in	MIM	mode;	as	full	scan	
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mode	requires	longer	duration	to	acquire	the	data	making	it	impossible	for	a	patient	to	exhale	enough	breath	in	one	go.	On	the	other	hand,	bags	and	bottles	samples	were	run	 in	 both	modes,	MIM	mode	 using	 both	H3O+	 and	NO+	 precursors,	 and	 Full	 Scan	mode.		
2.5.2:	Data	Processing		Humidity	 in	 each	 sample	 might	 vary	 due	 to	 environmental	 reasons	 and/or	physiological	 characteristics	of	 the	 individual	 giving	a	breath	 sample.	The	humidity	can	affect	the	quantification	of	VOCs,	especially	when	using	H3O+.	To	compensate	for	changes	in	humidity,	a	6%	water	correction	method	(already	being	used	by	different	groups	 in	 the	 field)	was	 used.	 Each	 individual	VOC	measured	was	 corrected	 to	 6%	water	level	using	the	flow	rate	adjustment	built	in	the	SIFT-MS	software.	The	kinetic	library	then	quantifies	VOCs	on	this	percentage	of	water	[Smith 2011]. 
 
2.5.3:	Data	Analysis	The	data	obtained	using	the	SIFT-MS	is	presented	in	ASCII.	Using	SIFT-MS	software,	it	was	 transferred	 into	 Excel.	 Principal	 Component	 Analysis	 was	 carried	 out	 using.	Unscrambler	software	(Camo,	Oslo,	Norway)	and	visualised	using	Graph	Pad	Prism	6.	
 
2.6: Aldefluor Assay	AldefluorTM	kit	was	purchased	from	STEMCELL	TechnologiesTM	Cambridge,	UK.	Flow 
cytometry (CYTOMICS FC 500 Beckman Coulter) was used to carry out the Aldefluor assay	to	assess ALDH activity in cells.  
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Aldefluor	assay	has	been	used	for	the	identification,	evaluation	and	isolation	of	stem	and	progenitor	 cells	 expressing	 high	 levels	 of	ALDH	 [Zhang	2014].	 AldefluorTM	 is	 a	reagent	 kit	 used	 in	 the	 identification	 of	 cells	 that	 express	 high	 levels	 of	 ALDH	Activated	 AldefluorTM	 reagent,	 BODIPY-aminoacetaldehyde	 (BAAA)	 is	 a	 fluorescent	substrate	for	ALDH	that	easily	penetrates	cells.	 If	ALDH	enzyme	is	present,	BAAA	is	converted	 into	BODIPY-aminoacetate	 (BAA)	 that	 is	 retained	 by	 the	 cell.	 This	ALDH	activity	 is	 measured	 by	 flow	 cytometry	 (figure	 18).	 The	 amount	 of	 fluorescent	reaction	produced	is	directly	proportional	to	the	ALDH	activity	in	the	cell.	AldefluorTM	kit	 reagents	 were	 prepared	 and	 stored	 according	 to	 the	 provider’s	 instructions.	Aldefluor	assay	was	conducted	by	 following	 the	 instructions	 from	 the	kit	providers	using	in-house	flow cytometry (Figure 18). 
 
 
 
 
 
 
 
 
 
 
	
	
Figure	18:	Image	of	the	flow	cytometer	(CYTOMICS	FC	500	Beckman	Coulter).		
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2.7:	Synchrotron	Based	FTIR	Spectroscopy		
2.7.1:	Application	of	Drugs	to	Cells	As	described	in	the	cloning	section	(2.1.2),	cells	were	cloned	and	following	2	weeks	culture,	 clones	were	removed	 from	the	96	well	plates,	by	mixing	 the	media	 in	each	individual	well	 containing	a	 clone	and	collecting	both	 the	 total	media	 (200	µL)	and	cells.	Collected	cells	were	then	seeded	proportionally	 in	3	wells	 in	96	flat-bottomed	plates.	They	were	allowed	to	grow	for	24	hours	at	37	°C	and	5%	CO2.	Following	this	incubation	period,	Imatinib	and	Nilotinib	were	added	as	follows.	Plates	were	spun	at	1200	rpm	for	7	minutes.	Following	this,	100	µL	of	medium	were	removed	and	100	µL	of	fresh	medium	with	different	concentrations	of	Imatinib	or	Nilotinib	were	added	(0	µM,	50	µM	or	100	µM).	Cells	were	allowed	to	grow	for	5	days	at	37	°C	and	5%	CO2	in	order	to	assess	clone	survival.	Five	days	were	decided	in	order	to	establish	if	the	cell	population	was	sensitive	or	resistant	to	the	drug.	It	was	observed	that	keeping	cells	growing	 for	more	 than	5	days	 translated	 into	cells	overgrowing	 in	control	wells	 (in	the	absence	of	Imatinib	or	Nilotinib).	
	
2.7.2:	Clone	Selection	Synchrotron	beam	time	at	Diamond	Light	Source,	Oxford,	UK	and	Synchrotron	Soleil,	France,	are	limited	in	their	time	allocation,	so	I	was	able	to	use	only	few	clones.	Table	II	shows	a	representative	example	of	clones	obtained	from	one	96	well	plate.	Clones	in	which	cells	in	control	wells	were	completely	confluent	were	discarded	as	this	could	modify	 their	metabolical	 and	 proliferative	 properties.	 The	 clones	were	 selected	 by	visually	observing	the	wells	under	the	microscope	and	classed	as	sensitive	where	no	
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cells	 were	 seen	 or	 very	 low	 number	 of	 cells	 in	 the	 well	 were	 identified,	 resistant	clones	were	those	with	semi-confluent	wells	even	at	high	concentration	of	the	drugs	and	semi-resistant/semi-sensitive	clones	were	 those	where	 the	wells	were	half	 full.	When	possible,	these	3	types	of	clones	were	selected	for	further	studies.		
2.7.3:	Sample	Preparation		The	 selected	 clones	 in	 the	 presence	 and	 absence	 of	 Imatinib	 and	 Nilotinib	 were	collected	from	96	well	plates	by	mixing	the	medium	within	the	well	and	collecting	the	cell	 suspension.	 Cells	 were	 then	 spun	 in	 eppendorf	 at	 950	 rpm	 for	 3	 minutes.	Supernatant	was	removed	and	cells	were	re-suspended	in	0.9%	NaCl,	to	wash	off	the	remaining	medium.		Cells	 were	 then	 cytospun	 (cytospin	 is	 a	 technique	 widely	 used	 within	 the	 clinical	environment	 for	cytology	 [Kocjan	2009])	onto	CaF2	slides	 for	1	minute	at	550	rpm,	through	a	cytofunnel	and	filter	card	(Shandon,	UK).	Once	cells	had	been	deposited	on	CaF2	slides	as	a	single	monolayer,	samples	were	placed	in	a	Petri	dish	and	fixed	using	4%	Paraformaldehyde	 (PFA)	 in	 0.9%	NaCl	 for	 20	minutes,	 as	 previously	 described	[Pijanka	2009].	This	was	 followed	by	3	washes	with	0.9%	NaCl	 and	3	washes	with	distilled	water.	 Samples	were	 air-dried	 at	 room	 temperature.	 UV	 grade	 CaF2	 slides	(26	x	22	x	0.5	mm)	suitable	for	both	FTIR	and	Raman	spectroscopy	(Crystan	Ltd,	UK)	were	used.					
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Table	II:	Representative	example	of	 identification	of	K562	Clones	 following	5	days’	incubation	with	 Imatinib	or	Nilotinib	 at	 different	doses.	 2	plus	 signs	 indicate	 semi-confluent	wells;	 one	 plus	 sign	 indicates	wells	with	 cells	 occupying	 roughly	 half	 the	surface	 of	 the	 well;	 plus	 and	 minus	 sign	 indicates	 the	 presence	 of	 very	 few	 cells;	minus	sign	indicates	absence	of	cells.	
	
Clones	 Control	 50	μM	 100	μM	
1	 ++	 +/-	 +/-	
2	 ++	 +	 ++	
3	 ++	 +	 +/-	
4	 ++	 +	 +	
5	 ++	 +	 +	
6	 ++	 +	 +	
7	 ++	 +	 +	
8	 ++	 +	 +	
9	 ++	 +	 +	
10	 ++	 +	 +	
11	 ++	 +	 +/-	
12	 ++	 +	 +	
13	 +-	 +/-	 +/-	
14	 ++	 +/-	 +/-	
15	 ++	 +	 +	
16	 ++	 +/-	 -	
17	 ++	 +/-	 +/-	
18	 ++	 +/-	 -	
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2.7.4:	S-FTIR	Spectroscopy	Measurement	Two	different	synchrotron	sources	were	used	to	obtain	the	FTIR	data,	Diamond	Light	Source,	Oxford,	UK,	and	Soleil	Synchrotron,	Paris,	France.		
 
	
	
	
	
	
	
	
	
	
	
	
	
	
 
 
 	
 
 		The	SMIS	beamline	at	Synchrotron	Soleil,	has	a	Nicolet	continuum	XL	IR	microscope	and	 a	 Nicolet	 5700	 Nexus	 FTIR	 spectrometer	 (Thermo)	 with	 a	 MCT/A	 detector.	Omnic	 software	 (Thermo,	Omnic	 version	 8.2)	was	 used	 to	 register	 the	 spectra	 and	images	via	a	32x	infinity	corrected	Schwarzchild	objective.			
Figure	19:	Diamond	Light	Source,	Oxford,	UK	(top)	and	Synchrotron	Soleil,	Paris,	France	(bottom)	
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	At	 the	 MIRIAM	 (Multimode	 Infrared	 Imaging	 and	 Micro-spectroscopy)	 or	 B22	beamline	at	Diamond	Light	Source,	Oxford	UK,	the	end	station	has	a	Hyperion	3000	microscope	 (Bruker)	 with	 a	 liquid	 nitrogen	 cooled	 Bruker	 80V	 FTIR	 spectrometer	and	a	100	x	100	µm2	MCT/A	detector.	Opus	(Bruker)	software	was	used	to	record	the	spectra	and	images	of	the	samples	using	a	36x	Schwarzchild	objective.			Spectra	were	collected	at	4	cm-1	resolution	with	128	co-added	spectra.	Measurements	were	taken	in	transmission	mode,	using	15×15	μm	aperture	via	a	36x	objective.	The	measurements	 were	 taken	 by	 centring	 the	 aperture	 at	 the	 nucleus	 of	 the	 cells.	Background	spectra	of	the	substrate	were	taken	after	every	15th	cell	measurement.	Images	 of	 the	 studied	 cells	 were	 taken	 so	 they	 could	 be	 identified	 when	 further	studied	 with	 Raman	 spectroscopy.	 About	 50	 or	 more	 cells,	 where	 possible,	 were	collected	from	each	sample.			
Figure	20:	End	station	at	SMIS	beamline,	Synchrotron	Soleil,	France.	
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2.7.5:	S-FTIR	Spectra	Pre-processing	and	Analysis	
 All	S-FTIR	spectra	were	imported	into	Matlab	7.5	(Mathworks,	Natick,	USA)	to	apply	Extended	 Multiplicative	 Signal	 Correction	 (EMSC)	 in	 order	 to	 correct	 for	 Mie	scattering	 effects	 using	 an	 algorithm	 created	 by	 Dr	 Achim	 Kohler	 [Kohler	 2008].	 I	used	this	method	for	the	corrections,	as	the	work	I	already	have	done,	and	the	people	in	diamond	working	on	 the	 same	 line	used	 the	 same	corrections	method.	Resonant	Mie	scattering	correction	was	not	used	as	this	is	not	a	widely-used	method	to	correct	spectral	 data.	 S-FTIR	 Spectra	 were	 processed	 using	 The	 Unscrambler	 Software	(Version	 X,	 Camo,	 Oslo,	 Norway)	 normalised	 (Standard	Normal	 Variate	 (SNV))	 and	smoothed	(Savitzky-Golay).	Following	the	baseline	correction	and	EMSC	application,	spectra	 were	 imported	 into	 Unscrambler	 (VERSION	 X,	 Camo,	 Oslo,	 Norway),	 then	cropped	to	the	area	to	be	analysed	(2700	cm-1	to	3100	cm-1	for	the	lipid	region	and	1000	 cm-1	 to	 1800	 cm-1	 for	 the	 fingerprint	 area)	 and	 normalized	 using	 standard	
Figure	21:	End	station	at	Diamond	Light	Source,	UK.	
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normal	variate	(SNV).	This	removes	the	effect	of	sample	thickness	and	any	baseline	offset	that	may	have	occurred.			Principle	Component	Analysis	(PCA)	was	used	in	the	study	as	an	important	technique	which	helps	by	reducing	the	number	of	parameters	needed	to	represent	the	variance	in	 the	acquired	spectral	dataset.	 It	 is	an	unsupervised	analysis	 that	allows	reducing	big	numbers	of	variables	 into	a	 few	principle	components.	 	PCA	is	a	very	 important	technique	which	can	sort	a	complex	dataset	into	a	few	key	spectral	components	thus	identifying	 and	 isolating	 important	 trends	 within	 the	 dataset.	 The	 application	 and	interpretation	 of	 PCA	 could	 be	 a	 first	 step	 to	 assess	 the	 presence	 or	 absence	 of	differences	 between	 samples.	 However,	 other	 data	 analysis	 techniques	 such	 as	pairwise	 PCA	 (Bonnier	 2012)	 might	 be	 more	 useful	 to	 either	 identify	 bigger	differences	between	 samples	when	compared	 to	PCA	or	 to	 identify	differences	 that	might	 be	 difficult	 to	 see	when	 using	 PCA.	 This	 way,	 I	 was	 able	 to	 understand	 and	grasp	 where	 differences	 in	 my	 data	 sets	 lie. So, PCA	 was	 performed	 using	 the	Unscrambler	 Software	 (VERSION	 X,	 Camo,	 Oslo,	 Norway).	 Loading	 plots	 were	 also	produced	using	the	same	software.		
	
2.8:	Raman	Spectroscopy	A	 Senterra	 Micro	 Raman	 laser	 class	 1	 (Bruker)	 spectroscope	 at	 Diamond	 Light	Source,	 equipped	with	 532	 nm	 Laser	 and	 CCD	 thermoelectrically	 cooled	was	 used.	Opus	 (Bruker)	 software	 was	 used	 to	 obtain	 the	 spectra	 and	 images	 via	 a	 100X	objective.	The	spectra	were	recorded	using	a	Raman	shift	between	40-4450.	Spectra	were	collected	at	9-18	cm-1	resolutions	with	2	co-added	spectra	with	integration	time	of	10	seconds	with	50	µm	pinhole	type	aperture.	The	measurements	were	taken	by	
		
54	
pointing	the	laser	at	the	nucleus	of	the	cell.	Five	spectra	of	each	individual	cell	were	recorded.	 Background	 spectra	 of	 the	 substrate	 were	 taken	 at	 the	 start	 of	measurement.	Spectra	of	50	or	more	cells,	when	possible,	were	collected	 from	each	sample.											
	
2.8.1:	Data	Processing	
Since manual interpretation of several Raman spectra is difficult and time consuming, to 
fully understand the biochemical information present in the data obtained by Raman, 
numerous techniques can be applied. In the present work, I used Principal component 
analysis (PCA) to do data analysis.		The	spectrum	was	processed	using	Unscrambler	(VERSION	X,	Camo,	Oslo,	Norway),	only	baseline	correction	was	done	on	the	data	and	then	PCA	was	performed	to	assess	spectral	differences.		
Figure	22:	Senterra	Micro	 (Bruker)	Raman	Spectroscopy	at	Diamond	Light	Source,	UK		
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Chapter	3	
	
Analysis	of	Volatiles	Organic	Compounds	Released	by	Leukaemia	
Cells.	
Another	Step-in	Leukaemia	Management?		
3.1:	Introduction	Leukaemia	 is	 an	 abnormal	 proliferation	 of	 haematopoietic	 stem	 cells	 in	 the	 bone	marrow,	 which	 leads	 to	 a	 high	 number	 of	 immature	 white	 cells	 in	 blood	 [Davies	2014].	The	initial	diagnostic	procedures	include,	amongst	others,	the	examination	of	blood	samples	and	bone	marrow	biopsies.	These	invasive	techniques	are	also	used	to	assess	 the	 therapeutic	 response	 of	 leukaemia.	 It	 is	 therefore	 imperative	 to	 develop	new	 non-invasive	 techniques	 for	 early	 diagnosis	 of	 leukaemia,	 treatment	 response	and/or	 follow-up.	 Both	 physicians	 and	 patients,	 especially	 the	 younger	 population	and	 their	 relatives,	 would	 welcome	 this.	 Furthermore,	 a	 robust	 technique	 able	 to	quickly	assess	tumour	response	to	treatment	could	also	reduce	the	number	of	blood	samples	and	or/biopsies	helping	to	reduce	hospital	costs	worldwide.			Over	the	last	few	years,	there	has	been	an	increased	interest	in	the	study	of	Volatile	Organic	Compounds	(VOCs)	released	by	cancer	cells	[Smith	2005;	Smith	2011;	Spanel	2011].	 Several	 techniques	 such	 as	Gas	Chromatography	Mass	 Spectrometry,	 Proton	Transfer	Reaction	Mass	Spectrometry,	ion	mobility	spectrometry	(IMS),	and	Selected	Ion	 Flow	Tube	Mass	 Spectrometry	 (SIFT-MS)	 have	 been	 used	 in	 the	 study	 of	 VOCs	released	by	cancer	cells	[Aman	2005].			
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SIFT-MS,	 used	 in	 this	work,	 detects	 accurately	 and	 in	 real	 time	 several	 compounds	simultaneously	down	to	concentrations	of	parts-per-billion	by	volume	(ppbv).	More	importantly,	it	obviates	sample	preparation	that	could	not	only	alter	the	sample	but	also	 take	 up	 valuable	 time	 [Smith	 2005;	 Smith	 2011;	 Spanel	 2011].	 Several	 groups	have	applied	 the	SIFT-MS	technique	to	study	the	release	of	volatiles	by	cancer	cells	[Sulé-Suso	 2009;	 Rutter	 2013;	 Kumar	 2013;	 Navaneethan	 2015]	 aimed	 mainly	 at	developing	applications	of	this	sensitive	technique	for	cancer	diagnosis.		In	breath	analysis,	lung	pathophysiology	and	lung	diseases	have	been	widely	studied,	specially	aimed	at	achieving	an	early	diagnosis	of	lung	cancer	[Chen	2007;	Wehinger 
2007;	 Filipiak	 2008;	 Bajtarevic	 2009;	 Sponring	 2009;	 Filipiak	 2010;	 Fuchs	 2010;	Corradi	 2015,].	 However,	 this	 methodology	 could	 be	 extended	 to	 other	 medical	applications	such	as	 the	study	of	blood	diseases	 thanks	 to	 the	exchange	of	volatiles	through	the	blood-gas	interface	in	lung	alveoli	[Sapoval	2002].	On	this	basis,	I	carried	out	 the	 present	 study	 in	 order	 to	 better	 understand	 the	 metabolism	 behind	 some	VOCs	 released	 by	 2	 leukaemia	 cell	 lines	 and	 compared	 them	 to	 VOCs	 released	 by	healthy	peripheral	blood	mononuclear	cells	(PBMC)	and	bone	marrow	cells.	
	
3.2:	Aims	1. To	 find	 out	 possible	 biomarkers	 (VOCs)	 for	 leukaemia	 diagnosis	 and	management	with	the	help	of	SIFT-MS.	2. To	assess	whether	there	are	any	differences	in	the	VOCs	profile	of	PBMC	when	compared	to	leukaemia	cells.		
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3.3:	Materials	and	Methods	
	
3.3.1:	Leukaemia	Cell	lines	The	cell	lines	used	in	this	study	were	the	K562	cell	line,	and	the	Jurkat	cell	line.		Both	cell	lines	were	cultured	in	suspension	in	75	cm2	cell	culture	flasks	(Sarstedt,	UK)	and	expanded	in	complete	medium	(CM)	made	up	of	RPMI	1640	with	10%	Foetal	Bovine	Serum	(FBS),	2	mM	L-glutamine,	Hepes	buffer,	and	antibiotic/antimycotic	at	37°C	and	5%	CO2.	Every	3-4	days,	dead	cells	and	debris	were	removed	by	spinning	cells	at	950	rpm	 for	 3	 minutes.	 After	 the	 supernatant	 was	 removed,	 the	 cell	 pellet	 was	 gently	dislodged	 and	 cells	 were	 re-suspended	 in	 fresh	 media.	 Viable	 cells	 were	 counted	using	the	trypan	blue	exclusion	method.	
	
3.3.2:	Peripheral	Blood	Mononuclear	Cells	PBMC7	were	 purchased	 from	 ZenBio,	 Inc	 (UK).	 PBMC	 are	 an	 important	 part	 of	 the	blood	components	as	they	play	a	major	role	in	the	immune	system.	PBMC	include	all	mononuclear	blood	cells	such	as	T8	type	and	B9		Type	leukocytes,	natural	killer	cells,	monocytes,	 basophils,	 neutrophils,	 eosinophil	 cells.	 These	 cells	were	 obtained	 from	whole	blood	of	a	healthy	donor.	I	used	these	cells	as	control	cells	against	leukaemia	cell	 lines.	 PBMC	were	 thawed	 and	 cultured	 in	RPMI	 1640	 supplemented	with	 30%	Foetal	 Bovine	 Serum	 (FBS),	 1%	 L-Glutamine,	 1%	 Hepes	 Buffer,	 and	 1%	
                                                	8	T	type	cells	are	lymphocytes,	is	a	main	part	of	cell	mediated	immune	system,	which	does	not	depend	on	the	presence	of	circulating	antibodies.		9	B	type	cells	are	lymphocytes,	characterised	by	the	presence	of	immunoglobulins	on	their	surface,	and	upon	stimulation	with	antigen.	Plays	a	part	in	humoral	immunity.		
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Antibiotic/antimycotic.	 Growth	 conditions	 were	 maintained	 within	 culture	 flasks	(Sarstedt,	UK)	at	37°C	and	5%	CO2.	These	cells	also	grow	in	suspension.		
3.3.3:	Bone	marrow	aspirates	Human	 bone	 marrow	 aspirates	 (BMA)	 from	 the	 iliac	 crest	 of	 3	 different	 healthy	donors	were	purchased	from	Lonza,	USA.	Whole	bone	marrow	samples	were	seeded	at	 a	 density	 of	 7.5	 x	 106	 cells	 in	 20	 mL	 of	 Dulbecco’s	 Modified	 Eagle’s	 Medium	(DMEM)	 supplemented	 with	 5	 ml	 Hepes	 buffer,	 5%	 FBS,	 1%	 L-glutamine	 and	 1%	NEAA	 on	 10	 ng/ml	 fibronectine-coated	 T-75	 tissue	 culture	 flasks	 (Sigma,	 UK).	Samples	were	incubated	at	37	°C	and	5%	CO2.			
3.3.4:	Sample	Preparation		Following	6	hours’	incubation,	PBMC	cells	were	collected	and	centrifuged	at	400	g	for	10	minutes.	 Supernatant	was	discarded	 and	 the	 cell	 pellet	was	 gently	 resuspended	into	fresh	RPMI	1640	CM.	Cells	were	counted	using	the	trypan	blue	exclusion	method.				Leukaemia	cells	were	removed	from	the	culture	flasks	as	described	above.	After	the	supernatant	 was	 removed,	 the	 cell	 pellet	 was	 gently	 dislodged	 and	 cells	 were	 re-suspended	in	fresh	media.	Viable	cells	were	counted	using	the	trypan	blue	exclusion	method.		For	Bone	Marrow,	following	7	days	of	culture,	half	the	volume	of	media	was	removed	and	 fresh	 DMEM	 culture	medium	 added.	 On	 the	 second	week,	whole	medium	was	
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replaced	with	complete	fresh	DMEM	medium.	After	further	24	hours	incubation,	cells	were	trypsinized,	collected	and	seeded	in	50	mL	of	medium	in	150	mL	glass	bottles.			All	 cells	 were	 seeded	 in	 150	ml	 glass	 bottles	 sealed	 with	 lids	 and	 septa	 in	 a	 final	volume	 of	 50	 mL	 of	 CM	 prior	 to	 carry	 out	 he	 SIFT-MS	 experiments.	 Cells	 were	incubated	 for	 8	 hours	 with	 the	 lid	 of	 each	 bottle	 slightly	 open	 to	 allow	 the	 air	 to	exchange	with	 the	 incubator	environment	 (37	 °C	 in	5%	CO2	atmosphere)	 to	ensure	they	remained	suitably	oxygenated	during	this	initial	period.	Following	this	stage,	the	air	 space	 in	 each	 bottle	was	 purged	with	 dry	 cylinder	 air	 and	 the	 lids	were	 tightly	closed	and	sealed	with	parafilm.	Cells	were	then	incubated	for	a	further	16	hours	at	37	 °C	 in	 order	 to	 allow	 the	 headspace	 to	 develop	 and	 equilibrate,	 as	 it	 has	 been	previously	 described	 [Sulé-Suso	 2009].	 For	 the	 duration	 of	 the	 SIFT-MS	measurement,	bottles	were	placed	within	a	37°C	heated	water	bath,	to	mimic	in	vivo	conditions.	
	
3.4:	Selected	ion	Flow	Tube	Mass	Spectrometry		Both	the	principle	of	the	SIFT-MS	technique	[Smith	2005;	Smith	2011;	Španėl	2011],	and	 the	measurements	 of	 volatile	 biomarkers	 in	 the	 headspace	 of	 the	 cell	 cultures	using	a	Profile	3	SIFT-MS	instrument	(Trans	Spectra	Limited,	UK)	[Rutter	2013]	have	been	previously	described	in	the	introduction	chapter.		
3.4.1:	Data	Processing	(Water	Correction)	Data	 processing	 for	 SIFT-MS	 has	 been	 previously	 described	 in	 chapter	 2.	 For	 each	acquired	sample,	a	6%	water	correction	was	applied	during	MIM	mode	of	SIFT-MS	for	
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the	H3O+	precursor	only.	Each	measurement	was	first	brought	up	to	6%	water	level	using	the	flow	rate	adjustment	built	in	the	SIFT-MS	software.		
	
3.4.2:	Data	Analysis	
 SIFT-MS	 data	was	 transferred	 from	 SIFT-MS	 software	 to	Microsoft	 Excel.	 Principal	Component	 Analysis	 was	 carried	 out	 using.	 Unscrambler	 software	 (Camo,	 Oslo,	Norway)	 and	 visualised	 using	 Graph	 Pad	 Prism	 6.	 The	 data	 presented	 here	established	the	basis	for	further	studies	with	a	higher	number	of	experiments	whose	data	analysis	will	include	also	p-values.		
3.5:	ALDEFLUORTM	test	The	 ALDEFLUOR™	 kit	 test	 (Stem	 Cell	 Technologies	 Inc)	 was	 used	 to	 identify	 the	expression	of	 the	enzyme	aldehyde	dehydrogenase	(ALDH)	in	cells	according	to	the	manufacturer’s	instructions.	Following	the	conversion	of	the	Aldefluor	substrate	into	a	 fluorescent	product	retained	in	cells,	 the	amount	of	 intracellular	fluorescence	was	measured	 using	 flow	 cytometry.	 The	 Beckman	 Coulter	 Cytomics	 FC500	model	was	used	to	gather	both	forward	scatter	and	side	scatter	information;	105	events/sample	being	collected	on	FL1.	Cyflogic	1.2.1	software	was	then	used	to	interpret	and	analyse	the	data	by	gating	the	population.		
3.6:	Results	and	Discussion	The	system	allows	a	rapid	switch	between	both	methods,	without	loss	of	sensitivity.	I	first	looked	at	acetaldehyde	(AA),	an	aldehyde	known	to	interfere	with	DNA	synthesis	and	 repair	 [Seitz	 2007],	 and	 to	 have	 mutagenic	 and	 carcinogenic	 effects	
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[Lanchenmeier	2009].	I	also	studied	and	expected	that	the	addition	of	disulfiram,	an	inhibitor	 of	 the	 enzyme	 acetaldehyde	 dehydrogenase	 (ALDH)	 (Figure	 23),	 would	increase	the	amount	of	acetaldehyde	present	in	the	headspace	of	cultured	cells.	ALDH	is	the	enzyme	responsible	for	the	transformation	of	acetaldehyde	into	acetate.												
	It	has	been	reported	that	high	expression	of	ALDH	is	related	to	 leukaemia	stem	cell	features	[Ran	2009],	poor	prognosis	[Ran	2009]	and	relapses	from	leukaemia	[Gerber	2012].	It	has	also	been	reported	that	high	expression	of	ALDH	has	significant	effects	on	 cell	 proliferation	 and	 drug	 resistance	 [Marcato	 2011;	Moreb	 2012].	 It	 has	 been	reported	that	disulfiram	has	anticancer	effects	and	that	might	even	increase	survival	in	lung	cancer	patients,	as	recently	shown	in	a	clinical	trial	[Nechushtan	2015].		
Ethanol	CH3CH2OH	
Alcohol	
dehydrogenase	
(ADH)	 Acetaldehyde	CH3CHO	
NAD+	 NADH+	
Aldehyde	
dehydrogenase	
(ALDH)	
NAD+	 NADH+	
Acetic	Acid	C2H4O2	
Figure	23:	Schematic	representation	of	the	metabolical	pathway	of	ethanol	and	acetaldehyde.	
		
62	
Table	III:	Cell	survival	following	16	hours	incubation	in	150	mL	glass	bottles.	All	data	are	the	mean	of	3	independent	experiments.	
 
 	Further	work	is	required	to	better	understand	the	toxic	effects	of	disulfiram	in	cells	and	more	importantly,	whether	this	cytotoxic	effect	could	translate	into	a	full	clinical	application.	Disulfiram	was	used	in	this	work	to	assess	the	level	of	inhibition	of	ALDH	in	 cells	 and	 the	 release	 of	 acetaldehyde	 by	 cells	 following	 the	 inhibition	 with	
	 RPMI	medium	 DMEM	medium	
Number	of	
cells	 %	Survival	 SD	(±)	 %	Survival	 SD	(±)	
PBMC	 	 	 	 	
	 	 	 	 	
10	x106	 88.95	 4.77	 -	 -	
	 	 	 	 	
K562	 	 	 	 	
	 	 	 	 	
10	x106	 84.14	 3.36	 92.52	 3.94	
20	x	106	 90.00	 3.97	 94.13	 0.59	
40	x	106	 94.33	 2.48	 89.39	 1.47	
	 	 	 	 	
Jurkat	 	 	 	 	
	 	 	 	 	
10	x106	 93.37	 3.02	 92.41	 4.25	
20	x	106	 93.87	 1.25	 93.24	 1.93	
40	x	106	 94.64	 1.86	 91.68	 0.99	
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disulfiram.	 Disulfiram	 is	 dissolved	 in	 dimethyl	 sulphoxide	 (DMSO),	 which	 has	 a	relatively	 low	 vapour	 pressure	 (1.8	 mbar	 at	 37	 °C),	 thus	 it	 was	 not	 expected	 to	interfere	significantly	with	headspace	analyses	[Chippendale	2012].		
	Preliminary	 work	 was	 carried	 out	 to	 assess	 cell	 survival	 in	 the	 experimental	conditions.	As	 can	be	 seen	 in	Table	 III,	 cell	 survival	 remained	high	 for	all	 cell	 lines.	Leukaemia	cell	survival	in	DMEM	will	be	discussed	later.		It	was	also	important	to	assess	whether	the	addition	of	disulfiram	to	culture	medium	could	affect	cell	 survival.	As	can	be	seen	 in	Table	 IV,	 the	addition	of	disulfiram	to	a	final	concentration	of	40	µM	did	not	affect	PBMC	survival.		However,	a	significant	decrease	in	cell	survival	for	both	leukaemia	cell	lines	K562	and	Jurkat	even	at	the	lower	dose	of	20	µM	was	seen.	In	order	to	confirm	that	DMSO,	used	to	dissolve	disulfiram,	did	not	cause	this	decreased	survival	in	K562	and	Jurkat,	both	cell	lines	were	also	incubated	with	DMSO	alone	as	controls,	with	the	same	volumes	of	DMSO	used	to	prepare	20	µM	(50	µL	DMSO)	and	40	µM	(100	µL	DMSO)	of	disulfiram.	Table	IV	shows	that	DMSO	alone	did	not	markedly	affect	cell	survival.			The	next	step	was	to	compare	the	levels	of	acetaldehyde	released	by	PBMC	and	both	leukaemia	 cell	 lines	 in	 the	 absence	 and	 presence	 of	 disulfiram.	 As	 can	 be	 seen	 in	Figure	24,	 the	release	of	acetaldehyde	 in	 the	headspace	of	PBMC,	did	not	show	any	significant	changes	when	compared	to	the	acetaldehyde	level	to	of	the	control	media	without	 cells.	 Furthermore,	 the	 exposure	 of	 PBMC	 to	 40	 µM	 of	 disulfiram,	 did	 not	cause	 major	 changes	 either.	 On	 the	 other	 hand,	 while	 the	 levels	 of	 acetaldehyde	
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released	 did	 not	 significantly	 differ	 between	 the	 control	 media	 and	 the	 leukaemia	cells	 incubated	 in	 the	 absence	 of	 disulfiram,	 the	 addition	 of	 disulfiram	 to	 both	leukaemia	cell	lines	translated	into	an	increase	in	the	levels	of	acetaldehyde	released.	Interestingly,	the	increase	of	this	ratio	was	smaller	for	Jurkat	cells	(table	V).		
Table	IV:	Cell	survival	following	the	addition	of	disulfiram	reconstituted	with	DMSO,	and	DMSO	alone.	All	data	are	the	mean	of	3	independent	experiments.	
 
Number	of	cells	10	x	106	 %	Survival	 SD	(±)	
PBMC	+	40	µM	disulfiram	 91.77	 3.07	
	 	 	
K562	+	20	µM	disulfiram	 68.21	 6.77	
K562	+	40	µM	disulfiram	 68.15	 5.78	
K562	+	50	µL	DMSO	 89.37	 9.11	
K562	+	100	µL	DMSO	 84.49	 9.41	
	 	 	
Jurkat	+	20	µM	disulfiram	 68.56	 2.10	
Jurkat	+	40	µM	disulfiram	 64.56	 9.34	
Jurkat	+	50	µL	DMSO	 88.77	 2.74	
Jurkat	+	100	µL	DMSO	 89.89	 3.86	
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Figure	 24:	Means	 of	 acetaldehyde	 released	 by	 10	 x	 106	 cells	 in	 the	 headspace	 of	culture	medium	in	the	absence	or	presence	of	disulfiram.	Jurkat	(Blue),	K562	(Red),	and	PBMC	(Green)	(mean	of	3	independent	experiments).	
 
 It	 has	 been	 previously	 described	 that	 SIFT-MS	 identifies	 acetaldehyde	 in	 the	headspace	of	culture	medium	alone,	coming	from	the	foetal	calf	serum	present	in	the	media.	 [Sulé-Suso	 2009].	 It	 could	 be	 argued	 that	 the	 increased	 ratios	 following	 the	addition	of	disulfiram	could	be	partially	due	to	a	decrease	in	the	number	of	cells	due	to	the	cytotoxic	effects	of	disulfiram,	and,	 therefore,	 to	a	reduction	 in	ALDH	activity	which	 could	 translate	 into	 increased	 acetaldehyde	 levels.	 However,	 the	 levels	 of	acetaldehyde	 in	 control	medium	were	 similar	 to	 those	 present	 in	 the	 headspace	 of	cells	incubated	in	the	absence	of	disulfiram.	This	would	not	be	the	case	for	PBMC	as	there	was	no	increase	in	the	levels	of	acetaldehyde	and,	furthermore,	the	survival	of	PBMC	was	not	affected	by	the	addition	of	disulfiram.	
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Table	V:	Mean	 ratios	of	 acetaldehyde	 released	by	10	 x	106	 cells	 over	 acetaldehyde	present	in	the	headspace	of	culture	media	(mean	of	3	independent	experiments).	
 
 	Hence,	 to	verify	 this,	 I	 studied	the	expression	of	ALDH	in	both	K562	and	 Jurkat	cell	lines	 and	 PBMC.	 Figure	 25	 shows	 a	 representative	 example	 of	 ALDH	 expression	 in	PBMC	(Figure	25A	and	25B),	K562	(Figure	25C	and	25D),	and	Jurkat	(Figure	25E	and	25F)	cell	lines	using	the	AldefluorTM	test.	Using	this	test,	the	expression	of	ALDH	was	present	in	3.47%	(SD	±2.56),	48.1	%	(SD	±6.0)	and	12.2	%	(SD	±	1.2)	in	PBMC,	K562	and	 Jurkat	 cells,	 respectively	 (mean	 of	 3	 independent	 experiments).	 These	 results	indicate	that	 the	 increased	presence	of	acetaldehyde	 in	the	headspace	of	K562	cells	and	 following	 the	 addition	 of	 disulfiram	 is	 definitely	 due	 to	 inhibition	 of	 the	ALDH	enzyme.	However,	 in	 the	case	of	 Jurkat	cells,	 the	 lower	expression	of	ALDH	enzyme	would	 explain	 the	 lesser	 increase	 in	 the	 release	 of	 acetaldehyde	 following	 the	addition	of	disulfiram.		
	
Cell	Lines	
	
Mean	
			
	SD	(±)	
	 	 	
K562	 0.22	 0.11	
10	x	106	+	20	µM	disulfiram	 1.60	 0.83	
10	x	106	+	40	µM	disulfiram	 1.55	 0.56	
	 	 	
Jurkat	 1.21	 0.20	
10	x	106	+	20	µM	disulfiram	 1.82	 0.58	
10	x	106	+	40	µM	disulfiram	 1.51	 0.11	
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Figure	25:	Representative	examples	of	ALDH	expression	in	PBMC	(25	A	and	B),	and	K562	(25	C	and	D)	and	Jurkat	(25	E	and	F)	cell	lines	using	the	AldefluorTM	test.	Cells	were	 labelled	 with	 aldefluor	 (BAAA)	 (Figures	 25	 A,	 25	 C,	 and	 25	 E)	 and	 without	(Figures	25	B,	25	D,	and	25	F)	the	ALDH	inhibitor	DEAB.		
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It	has	been	previously	reported	that	K562	cells	express	ALDH	[Moreb	2012].	In	fact,	K562	 is	 one	 of	 the	 cells	 lines	 suggested	 to	 be	 used	 as	 a	 positive	 control	 in	 the	AldefluorTM	test	by	the	manufacturers.	Taken	together,	 the	data	would	 indicate	that	leukaemia	 cell	 lines	 release	 acetaldehyde	 but	 that	 it	 is	metabolised	 quickly,	 thus	 it	cannot	be	detected	in	the	headspace	of	these	cells	in	culture.	The	inhibition	of	ALDH	translates	 into	 an	 increase	 of	 acetaldehyde	 in	 the	 headspace	 of	 these	 cells.	Furthermore,	 PBMC	 might	 not	 be	 producing	 acetaldehyde	 as	 the	 inhibition	 of	 the	enzyme	does	not	translate	into	increased	levels	of	acetaldehyde	in	the	headspace	of	these	cells	in	culture.	Further	work	is	needed	to	confirm	this	and,	more	importantly,	to	assess	whether	the	production	of	acetaldehyde	by	leukaemia	cells	could	have	value	both	 in	 a	 diagnostic	 set	 up	 and	 to	 assess	 tumour	 response	 to	 treatment.	 In	 fact,	correlation	 between	 levels	 of	 acetaldehyde	 released	 and	 cell	 number	 has	 been	described	before	in	lung	cancer	cell	lines	[Sulé-Suso	2009;	Rutter	2013].		Another	compound	for	which	a	differential	was	found	between	its	release	by	cells	and	its	 presence	 in	 the	 headspace	 of	 control	 medium	 was	 ethanol.	 I	 have	 carried	 out	previous	 work	 showing	 that	 the	 presence	 of	 ethanol	 in	 the	 headspace	 of	 control	medium	is	due,	 like	in	the	case	of	acetaldehyde,	to	the	presence	of	foetal	calf	serum	[Sulé-Suso	2009].			It	 is	widely	known	that	ethanol	 is	 involved	 in	 the	development	of	different	 types	of	cancer,	including	leukaemia	in	mice	[Garaycoechea	2012].	As	can	be	seen	in	Table	VI,	the	 ratio	 of	 ethanol	 production	 by	 leukaemia	 cells	 and	 ethanol	 present	 in	 the	headspace	 of	 control	 media	 increases	 with	 the	 number	 of	 cells	 in	 culture.	 This	differential	is	greater	for	K562	cells	when	compared	to	Jurkat	cells.	This	was	not	the	
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case	for	PBMC	(data	not	shown).	Further	work	is	needed	to	assess	whether	and	how	ethanol	could	be	a	biomarker	related	to	leukaemia	cell	numbers	in	blood.			
Table	VI:	Mean	levels	of	ethanol	released	by	leukaemia	cells	and	in	the	headspace	of	culture	media,	and	mean	ratios	of	ethanol	released	by	leukaemia	cells	over	ethanol	in	the	headspace	of	culture	media.	All	data	are	the	mean	of	3	independent	experiments.	
 
 
																		 Ethanol							
release	(ppbv)	
Ratio	of	ethanol	released	by	cells	
over	ethanol	from	culture	medium	
	
Cell	Lines	
	
Means	
	
SD	(±)	
	
Mean	
	
SD	(±)	
	
K562	
	 	 	 	
CM	 1215	 305	 	 	
10	x106	 1680	 574	 1.37	 0.16	
20	x	106	 1968	 466	 1.63	 0.10	
40	x	106	 2268	 1003	 2.17	 0.45	
	 	 	 	 	
Jurkat	 	 	 	 	
CM	 1664	 358	 	 	
10	x106	 1831	 301	 1.11	 0.06	
20	x	106	 2063	 421	 1.24	 0.08	
40	x	106	 2343	 664	 1.40	 0.24	
	 	 	 	 		
		
70	
When	large	dataset	 is	to	be	analysed,	reduction	in	the	dimensionality	of	the	dataset	while	retaining	most	of	the	variable	in	the	data,	is	desired,	PCA	is	the	best	algorithmic	technique	 to	 attain	 this.	 To	 confirm	 whether	 different	 leukaemia	 cell	 lines	 can	 be	differentiated	 using	 SIFT-MS	 on	 the	 basis	 of	 VOCs	 released	 by	 these	 cell	 lines	 I	performed	PCA	of	full	scan	data	of	each	cell	line	at	different	concentrations	along	with	PBMC	(Figure	26A).	Figure	26A	is	the	representative	graph	showing	PCA	of	ratios	of	analytes	 from	 cells	 over	media	 headspaces	measured	with	 SIFT-MS	 from	K562	 cell	line,	 Jurkat	 cell	 line	 and	 PBMC.	 Each	 data	 point	 is	 the	 mean	 of	 3	 independent	experiments.	 It	 is	 clear	 from	 the	 PCA	 (Figure	 26A)	 that	 there	 is	 clear	 separation	between	 the	 VOCs	 released	 by	 the	 leukaemia	 cell	 lines	 versus	 VOCs	 released	 from	PBMC.													
Figure	26	A:	PCA	of	ratios	of	analytes	from	cells	over	media	headspaces	measured	with	 SIFT-MS	 from	 K562	 cell	 line	 (squares),	 Jurkat	 cell	 line	 (circles)	 and	 PBMC	(diamonds).	The	numbers	indicate	cell	concentration	in	50	mL	of	medium.	Each	data	point	is	the	mean	of	3	independent	experiments.	
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Furthermore,	I	performed	PCA	of	the	full	scan	data	of	VOCs	from	leukaemia	cell	lines	(Figure	 26B).	 It	 is	 very	 clear	 that	 there	 is	 significant	 separation	 between	 the	VOCs	released	 by	 both	 Leukaemia	 cell	 lines	 (Figure	 26B),	 which	 shows	 promising	implementation	of	SIFT-MS	in	distinguishing	different	types	of	the	disease.				
	During	 this	 project,	 bone	 marrow	 (BM)	 cells	 were	 acquired	 in	 order	 to	 study	 the	release	of	VOCs	 from	 these	cells.	 In	 these	experiments,	mononuclear	BM	cells	were	obtained	 in	 the	 first	 passage	 and	 seeded	 in	 150	mL	 glass	 bottles	 in	 50	mL	 of	 CM.	However,	 before	 these	 experiments	were	 done,	 I	 had	 to	 take	 into	 account	 that	 BM	cells	 grew	 in	DMEM	while	 leukaemia	 cells	 grew	 in	RPMI.	 In	order	 to	 eliminate	 any	possible	 confounding	 factors	 caused	 by	 different	 media	 on	 the	 release	 of	 VOCs,	
Figure	26	B:	PCA	of	ratios	of	analytes	from	cells	over	media	headspaces	measured	with	 SIFT-MS	 from	 K562	 cell	 line	 (squares)	 and	 Jurkat	 cell	 line	 (circles).	 The	numbers	 indicate	 cell	 concentration	 in	 50	 mL	 of	 medium.	 Each	 data	 point	 is	 the	mean	of	3	independent	experiments.	
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leukaemia	 cells	 were	 incubated	 in	 DMEM	 as	 these	 cells	 are	 more	 resilient	 and	therefore	easier	to	grow	in	other	cell	culture	media	when	compared	to	BM	cells.			Preliminary	experiments	were	carried	out	to	assess	cell	survival	in	these	new	culture	conditions.	As	can	be	seen	in	Table	III,	cell	survival	remained	high	for	both	cell	lines	incubated	 for	 16	 hours	 in	 150	 mL	 glass	 bottles	 in	 the	 same	 culture	 conditions	 as	before	except	for	changing	RPMI	medium	to	DMEM.		PCA	of	ratios	of	analytes	 from	cells	over	media	headspaces	measured	with	SIFT-MS	from	K562	cell	 line,	 Jurkat	 cell	 line	and	bone	marrow	cells	are	shown	 in	Figure	27.	There	is	a	remarkable	separation	among	VOCs	released	by	the	Bone	marrow	and	both	leukaemia	cell	 lines	grown	in	DMEM.	Figure	28	is	the	PCA	of	VOCs	released	by	both	cell	lines	grown	in	DMEM,	a	similar	pattern	of	separation	was	observed	among	VOCs	released	by	both	leukaemia	cell	lines	suggesting	SIFT-MS	could	have	a	potential	in	the	management	of	leukaemia.		The	 next	 step	was	 to	 look	 at	 the	 analytes	 present	 in	 different	 concentration	 in	 the	headspace	of	PBMC,	leukaemia	cells	and	BM	cells.	Out	of	170	analytes,	2	were	present	in	 higher	 concentration	 in	 the	 headspace	 of	 BM	 cells	 when	 compared	 to	 the	headspace	of	10	x	106	leukaemia	cells	and	PBMC.	These	were	m/z	47	analyte	and	m/z	57	analytes	using	H3O+.	The	ppbv	values	 for	 the	 former	were	568	±	115	and	1,085	±186	for	PBMC	and	bone	marrow	cells,	respectively.	They	were	402	±	83	ppbv	and	272	±	60	ppbv	 for	K562	and	 Jurkat	 in	RPMI,	 respectively,	and	439	±	215	ppbv	and	529	±	203	ppbv	 for	K562	 and	 Jurkat	 in	DMEM,	 respectively.	 This	 analyte	has	been	linked	 to	 ethanol	 or	 formic	 acid.	 [Michalcikova	 2014].	 Further	 work	 is	 needed	 to	
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better	 characterise	 not	 only	 the	 exact	 contribution	 of	 each	 compound	 but	 also	whether	other	compounds	could	modify	the	values	of	m/z	47	analytes.	On	the	other	hand,	the	ppbv	values	for	m/z	57	analytes	were	809	±	164	and	1,137	±	176	for	PBMC	and	bone	marrow	cells,	respectively.	They	were	645	±	223	ppbv	and	755	±	333	ppbv	for	K562	and	 Jurkat	 in	RPMI,	 respectively,	 and	796	±	126	ppbv,	684	±	18	ppbv	 for	K562	 and	 Jurkat	 in	 DMEM,	 respectively.	 M/z	 57	 analyte	 has	 been	 linked	 to	 the	presence	of	acrolein	[Španěl	2012].	Acrolein,	 together	with	other	aldehydes	such	as	methacrolein,	is	a	major	product	of	lipid	peroxidation	[Onyango	2012]	and	might	be	involved	 in	 apoptotic	 effects	 on	 cancer	 cells	 [Onyango	 2012].	 Increasing	 the	concentration	of	leukaemia	cells	up	to	40	x	106	cells	did	not	translate	into	an	increase	in	the	concentration	of	these	2	analytes	(data	not	shown).													
Figure	27:	PCA	of	ratios	of	analytes	from	cells	over	media	headspaces	measured	with	SIFT-MS	 from	 K562	 cell	 line	 (squares),	 Jurkat	 cell	 line	 (circles)	 and	 bone	 marrow	cells	(triangles).	The	numbers	indicate	cell	concentration	in	50	mL	of	medium.	Each	data	point	is	the	mean	of	3	independent	experiments.	
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Taken	 together,	 these	 data	 would	 indicate	 that	 SIFT-MS	 could	 be	 a	 potential	technique	 to	 identify	 VOCs	 released	 by	 leukaemia	 cells	 which	 differ	 from	 those	released	by	healthy	BM	cells.	However,	further	work	is	required	to	fully	characterise	the	metabolical	pathways	behind	the	release	of	VOCs	by	both	leukaemia	and	BM	cells,	and	 to	 assess	 whether	 SIFT-MS	 might	 be	 able	 to	 separate	 individual	 types	 of	leukaemia	based	on	their	VOCs’	profile.	
Figure	28:	PCA	of	ratios	of	analytes	from	cells	over	media	headspaces	measured	with	SIFT-MS	from	K562	cell	line	(squares),	Jurkat	cell	line	(circles).	The	numbers	indicate	cell	concentration	in	50	mL	of	medium.	Each	data	point	is	the	mean	of	3	independent	experiments.	
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3.7:	Conclusion	In	 this	work,	 the	 feasibility	of	measuring	both	qualitatively	and	quantitatively	VOCs	released	by	PBMC,	 leukaemia	cells	and	BM	cells	 in	vitro	has	been	shown.	The	use	of	PCA	along	with	SIFT-MS	proved	very	 important	method	as	one	could	clearly	notice	the	differences	of	the	VOCs	profile	even	among	different	leukaemia	cells	lines	as	well	as	from	PBMCs	and	bone	marrow.	It	is	very	much	clear	from	the	results	shown	in	this	study	 that	 PCA	 is	 the	 best	 way	 to	 analyse	 the	 SIFT-MS	 measurements.	 The	 data	presented	here	indicate	that	the	VOCs’	profile	of	leukaemia	cells	might	differ	from	the	VOCs’	profile	of	PBMC,	and	BM	cells.	The	analysis	of	VOCs	released	by	leukaemia	cells	and	the	use	of	PCA,	could	thus	be	useful	 in	better	understanding	the	metabolism	of	leukaemia	cells.	These	differences	 in	the	VOCs	release	could	be	exploited	towards	a	clinical	application	in	the	diagnosis	of	the	disease	and	to	assess	tumour	response	to	treatment.	However,	further	work	is	needed	to;	1.	Better	understand	the	metabolical	pathways	in	blood	cells	leading	to	a	specific	VOCs	profile.	2.	Confirm	that	the	study	of	VOCs	released	by	leukaemia	cells	and,	by	extension,	present	in	the	breath	of	patients	with	leukaemia	could	have	an	application	in	the	management	of	this	disease.				
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Chapter	4	
	
Quantification	of	Volatiles	Released	by	Leukaemia	Cells	Following	
the	Addition	of	Drugs	by	The	Selected	Ion	Flow	Tube	Mass	
Spectrometry	
		
	
4.1:	Introduction	Volatile	 organic	 compounds	 represent	 a	 chemically	 diverse	 group	 of	 metabolites	present	 in	 biological	 fluids	 with	 a	 boiling	 point	 less	 then	 300	 °C	 [Patti	 2012].	 At	different	 stages	 of	 metabolism,	 VOC	 concentration	 tend	 to	 change,	 as	 these	 are	intermediate	products	 of	metabolic	pathways	 [Patti	2012].	Thus,	 their	 levels	 in	 the	breath/headspace	may	provide	a	good	understanding	of	the	mechanisms	involved	in	the	cellular	processes,	disease	diagnosis	and	monitoring,	[Probert	2009].	Breath	VOCs	are	 normally	 collected	 from	 human	 breath.	 Since	 Pauling,	 reported	 around	 250	different	VOCs	in	breath	in	1971,	more	than	3000	different	VOCs	have	been	reported	in	human	breath	[Phillips	1999].	These	VOCs	in	breath	range	from	parts	per	million	by	 volume	 to	 parts	 per	 trillion	 by	 volume.	 However,	 information	 about	 the	mechanism	behind	the	production	of	these	VOCs	is	 limited,	and,	at	present,	 it	 is	not	well	understood	for	many	of	them	[Hakim	2012].			Over	the	last	few	years,	breath	analysis	for	VOCs	has	gained	growing	significance	in	both	 the	 scientific	 and	 clinical	 communities.	 In	 terms	 of	 cancer	 diagnosis	 and	therapeutic	 response,	 analysis	 of	 exhaled	 breath	 for	 detection	 and	 absolute	quantification	of	VOCs	has	a	promising	potential.	Thanks	to	the	non-invasive	nature	of	 this	 technique	 and	 no	 or	minimal	 sample	 preparation,	 breath	 analysis	 has	 great	appeal	 for	both	clinicians	and	patients.	Developments	 in	 the	methodology	 for	VOCs	
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analysis	in	clinical	breath	testing	for	specific	cancers	may	potentially	by-pass	some	of	the	invasive	procedures	for	the	detection	and	management	of	the	disease.	However,	the	clinical	application	of	breath	analysis	remains	limited.	The	C-urea	breath	testing	for	 H.	 pylori	 bacterium,	 hydrogen	 test	 for	 small	 bowel	 bacteria	 overgrowth	 and	breath	test	of	nitric	oxide	 in	the	management	of	asthma	are	 just	 few	routinely	used	clinical	 tests	 [Kharitonov	 1994;	 Kawai	 2008].	 Thus,	 there	 is	 still	 major	 scientific	interest	in	developing	breath	analysis	for	disease	detection	and	management.			A	 lot	 of	 work	 carried	 out	 in	 recent	 years	 to	 identify	 breath	 biomarkers	 has	 been	conducted	 by	 several	 groups	 studying	 different	 types	 of	 cancer	 i.e.	 leukemia,	 lung,	prostate,	 breast	 and	 colon	 cancers,	 using	 different	 analytical	 techniques	 [Phillips	1994;	Phillips	1999;	Phillips	2003;	Phillips	2007;	Spanĕl	2008;	Shin	2009].	Some	very	promising	results	regarding	VOCs	being	associated	with	cancer	have	been	published	[Liu	1998;	Smith	2003;	Deng	2004;	Shin	2009].	Shin	et	al.	(2009)	reported	release	of	acetaldehyde	 and	 hexanaldehyde	 from	 the	 head	 space	 of	 HL60	 cells,	 in	 time	dependent	manner.			The	most	commonly	used	analytical	technique	for	breath	analysis	is	GC/MS.	However	due	 to	 its	 requirement	 of	 adsorption	 devices	 and	 long	 processing	 time	 along	with	quantifying	problems	of	 some	 important	 trace	agents,	 it	has	not	 translated	yet	 into	clinical	 practice.	 Recently,	 other	mass	 spectrometry	 techniques,	 i.e.	 proton	 transfer	reaction	mass	 spectrometry	 (PTR-MS)	 and	 SIFT-MS	 have	 attracted	 interest	 for	 the	detection	of	VOCs	for	breath	analysis	[Smith	2005;	Zhan	2013].			SIFT-MS	offers	quantification	of	several	VOCs	in	exhaled	breath	thanks	to	its	ability	to	
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use	 three	 reagent	 ions,	H3O+,	NO+,	 and	O2+	 [Smith	2005].	This	 technique	allows	 the	simultaneous	quantification	of	several	trace	gasses	in	the	sample	without	the	need	of	sample	 preparation	 [Smith	 2005].	 In	 recent	 years,	 SIFT-MS	 has	 also	 been	 used	 in	disease	diagnosis	and	to	assess	therapeutic	response	[Amann	2005;	Kumar	2013].	In	this	 chapter,	 I	 have	 shown	 the	 capabilities	 of	 this	 technique	 in	 the	management	 of	leukemia.			Reciprocal	translocation	between	chromosome	9	and	22	produces	BCR-ABL	gene	that	is	the	main	cause	of	chronic	myeloid	Leukemia	(CML).	 	 Imatinib	is	the	first	tyrosine	kinase	targeting	BCR-ABL	for	the	treatment	of	CML	[Bumbea	2010].	Imatinib	binds	to	ATP	biding	site	of	this	BCR-ABL,	inhibiting	its	kinase	activity	resulting	in	the	start	of	the	 apoptotic	 process.	 Nilotinib	 is	 also	 one	 of	 the	 most	 important	 anti	 Leukemia,	second-generation	tyrosine	kinase	inhibitor	used	in	the	treatment	of	chronic	myeloid	Leukemia.	Nilotinib	not	only	inhibits	the	kinase	activity	of	BCR-ABL	but	also	inhibits	c-KIT	and	platelet	derived	growth	factor	(PDGFR)	[Weisberg	2006].	It	is	an	effective	drug	in	Imatinib	resistant	cases.			I	 have	 previously	 investigated	 VOCs	 in	 the	 headspace	 of	 normal	 leukemia	 cells	(Jurkat,	and	K562)	and	PBMC	along	with	bone	marrow	cells	(Chapter	3).	In	the	study,	few	compounds	were	detected	to	differ	from	the	headspace	of	the	leukemia	cell	lines	when	compared	to	the	PBMC	and/or	healthy	bone	marrow	cells.	In	the	present	study,	I	conducted	experiments	 to	assess	any	possible	differences	 in	 the	VOCs	released	by	leukemia	cells	after	their	exposure	to	drugs,	in	the	search	of	any	possible	biomarkers	that	could	help	in	assessing	tumor	response	to	treatment.		
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4.2:	Aims		1. To	 identify	 possible	 VOCs	 that	 could	 be	 used	 as	 biomarkers	 to	monitor	 the	tumour	response	of	both	leukaemia	cell	lines	after	their	exposure	to	Imatinib	or	Nilotinib.		2. To	 assess	whether	 changes	 in	VOCs	 released	by	 leukaemia	 cells	 correlate	 to	drug	concentration.		
	
4.3:	Material	and	Methods	
	
4.3.1:	Cell	lines	The	cell	lines	used	in	this	study	were	K562	cell	line,	and	Jurkat	cell	line.	Both	cell	lines	were	cultured	in	suspension	in	75	cm2	cell	culture	flasks	(Sarstedt,	UK)	and	expanded	in	 complete	medium	 (CM)	made	 up	 of	 RPMI	 1640	with	 10%	 Foetal	 Bovine	 Serum	(FBS),	 2	mM	L-glutamine,	Hepes	buffer,	 and	antibiotic/antimycotic	 at	37°C	and	5%	CO2.	Every	3-4	days,	dead	cells	and	debris	were	removed	by	spinning	cells	at	950	rpm	for	 3	 minutes.	 After	 the	 supernatant	 was	 removed,	 the	 cell	 pellet	 was	 gently	dislodged	 and	 cells	 were	 re-suspended	 in	 fresh	 media.	 Viable	 cells	 were	 counted	using	the	trypan	blue	exclusion	method.		
4.3.2:	Sample	Preparation		Leukaemia	cells	were	removed	from	the	culture	flasks	as	described	above.	After	the	supernatant	 was	 removed,	 the	 cell	 pellet	 was	 gently	 dislodged	 and	 cells	 were	 re-suspended	 in	 fresh	 RPMI	 1640	 medium	 supplemented	 with	 10%	 Foetal	 Bovine	
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Serum	 (FBS),	 1%	 L-Glutamine,	 1%	 Hepes	 Buffer,	 and	 1%	 Antibiotic/antimycotic.	Viable	cells	were	counted	using	the	trypan	blue	exclusion	method.			Cells	were	seeded	in	150	ml	glass	bottles	sealed	with	lids	and	septa	in	a	final	volume	of	50	ml.	Cells	were	incubated	for	2	hours	with	the	lid	of	each	bottle	slightly	open	to	allow	 the	 air	 to	 exchange	 with	 the	 incubator	 environment	 (37	 °C	 in	 5%	 CO2	atmosphere)	to	ensure	they	remained	suitably	oxygenated	during	this	initial	period.	Following	2	hours’	incubation,	the	drugs	(Imatinib	or	Nilotinib)	were	added	at	a	final	concentration	of	50	µM	or	100	µM	and	cells	were	incubated	for	further	6	hours	with	the	 lids	 slightly	 open.	 A	 control	 case	 with	 cells	 without	 either	 drug	 was	 also	formulated.	 Following	 these	 6	 hours	 incubation,	 the	 air	 space	 in	 each	 bottle	 was	purged	with	dry	cylinder	air	and	the	lids	were	tightly	closed	and	sealed	with	parafilm.	Cells	 were	 then	 incubated	 for	 a	 further	 16	 hours	 at	 37	 °C	 in	 order	 to	 allow	 the	headspace	to	develop	and	equilibrate,	as	previously	described	[Sulé-Suso	2009].	For	the	duration	of	the	SIFT-MS	measurement,	bottles	were	placed	within	a	37°C	heated	water	bath	to	mimic	in	vivo	conditions.		
4.4:	Selected	ion	Flow	Tube	Mass	Spectrometry		Both	the	principle	of	the	SIFT-MS	technique	[Smith	2005;	Smith	2011;	Španĕl	2011],	and	 the	measurements	 of	 volatile	 biomarkers	 in	 the	 headspace	 of	 the	 cell	 cultures	using	a	Profile	3	SIFT-MS	instrument	(Figure	1)	(Trans	Spectra	Limited,	UK)	[Rutter	2013]	have	been	previously	described.		
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4.4.1:	Data	Processing	(Water	Correction)	Data	 processing	 for	 SIFT-MS	 has	 been	 previously	 described	 in	 chapter	 2.	 For	 each	acquired	 sample,	 a	 6%	water	 correction	method	was	 applied	 during	MIM	mode	 of	SIFT-MS	for	the	H3O+	precursor	only.	Each	measurement	was	first	brought	up	to	6%	water	level	using	the	flow	rate	adjustment	built	in	the	SIFT-MS	software.			
4.4.2:	Data	Analysis	SIFT-MS	 data	 was	 transferred	 form	 SIFT-MS	 software	 to	 Microsoft	 Excel	 to	 the	corrections	 and	 Principal	 Component	 Analysis	 was	 carried	 out	 using.	 Unscrambler	software	(Camo,	Oslo,	Norway)	and	visualised	using	Graph	Pad	Prism	6.	
	
4.5:	Results	and	Discussions	Survival	of	10	x	106	cells	incubated	in	the	absence	or	presence	of	Imatinib	or	Nilotinib	at	three	different	doses	(10	µM,	50	µM	or	100	µM)	is	shown	in	Table	VII.	For	Imatinib,	cell	survival	ranges	from	97.33	±	1.15	%	to	67.00	±	8.19	%,	and	from	98.34	±	0.81	%	to	54.49	±	14.49	%	for	Jurkat	and	K562,	respectively.	Cell	survival	is	markedly	lower	for	Nilotinib	when	compared	to	the	same	doses	of	Imatinib	confirming	that	Nilotinib	is	more	potent	than	Imatinib	[Wei	2014].	Based	upon	these	drug	survival	data,	10	µM,	50	µM	and	100	µM	doses	of	both	drugs	were	used	 for	 this	study.	The	survival	with	500	µM	of	either	dose	was	0	for	both	cell	lines.			Acetaldehyde	has	been	shown	as	a	possible	VOC	that	could	be	linked	to	cancer	[Sulé-Suso	 2009;	 Schmidt	 2015],	 although	 the	 results	 published	 in	 the	 literature	 have	
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sometimes	been	equivocal	[Filipiak	2008].	Therefore,	the	release	of	acetaldehyde	by	cell	cultures	in	the	absence	or	presence	of	either	drug	was	assessed.			As	can	be	seen	 in	Figures	29	and	30,	 the	 levels	of	acetaldehyde	 increased	 for	K562	cells	 following	 the	 addition	 of	 Imatinib	 or	 Nilotinib.	 However,	 there	were	 no	 clear	differences	 in	 the	 levels	 of	 acetaldehyde	 for	 Jurkat	 cells	 following	 the	 addition	 of	Imatinib	or	Nilotinib.	For	both	cell	lines,	increasing	the	dose	of	Imatinib	or	Nilotinib	to	100	µM	did	not	translate	into	further	increases	in	the	levels	of	acetaldehyde.	It	is	not	yet	clear	as	 to	why	there	 is	an	 increase	 in	 the	acetaldehyde	production	by	both	the	cells	exposed	to	Nilotinib	and	not	so	clear	when	cells	are	exposed	to	Imatinib.			It	could	be	hypothesised	that	this	effect	is	due	to	a	combination	of	several	factors	i.	e.,	cells’	 death,	 cell	 in	 different	 phases	 of	 apoptosis	 and	 changes	 in	 some	metabolical	pathways	amongst	others.	All	these	together	might	affect	the	activity	of	ALDH	and/or	the	 production	 of	 acetaldehyde.	 ALDH	 belongs	 to	 a	 family	 of	 cytosolic	 enzymes	involved	 in	 various	 biological	 processes	 [Yoshida	 1998;	Duester	 2000].	High	ALDH	activity	has	been	 identified	 in	various	 tumor	 types,	 including	breast,	 lung,	and	 liver	cancer	[Croker	2008;	Chu	2009].		Recent	data	has	shown	that	ALDH	is	highly	expressed	in	leukemic	stem	cells	[Pearce	2005;	 Hess	 2006]	 and	 has	 specific	 roles	 in	 stem	 cell	 function	 and	 chemotherapy	resistance	[Wang	2001;	Chute	2006].	Further	work	is	needed	to	clarify	these	issues.				
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Table	VII.	Cell	survival	of	Jurkat	and	K562	cells	exposed	to	Imatinib	and	Nilotinib	
 
		
	
Leukemia	cells	survival	with	drug	exposure	(10	x	106	cells)	
	
Sample	 Imatinib	(%	±	SD)	 Nilotinib	(%	±	SD)	
	
Jurkat	 	 	
Control	 97.33	±	1.15	 99.0	±	1	
10	µM	 95.33	±	1.53	 53.00	±	23.67	
50	µM	 69.67	±	7.09	 39.00	±	11.57	
100	µM	 67.00	±	8.19	 24.00	±	6.35	
K562	 	 	
Control	 98.34	±	0.81	 97.13	±	0.74	
10	µM	 96.99	±	1.33	 71.06	±	11.11	
50	µM	 85.19	±	2.52	 48.57	±	2.48	
100	µM	 54.49	±	14.49	 31.58	±	15.43	
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Figure	30:	 Average	 release	 of	 AA	 in	 the	 headspace	 of	media,	media+100	 µM	 of	Nilotinib,	and	Jurkat	and	K562	(Blue	and	Red	respectively)	cells	incubated	with	0	µM,	10	µM,	50	µM,	and	100	µM	of	Nilotinib	(using	H3O+	precursor	ion).	
Figure	29	 Average	 release	 of	 acetaldehyde	 in	 the	 headspace	 of	media,	media	 +100				µM	of	Imatinib,	and	Jurkat	and	K562	(Blue	and	Red	respectively)	cells	incubated	with	0	µM,	10	µM,	50	µM,	and	100	µM	of	Imatinib	(using	H3O+	precursor	ion).	
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The	next	step	was	to	 look	at	the	full	scan	data	and	carry	out	PCA	in	order	to	assess	whether	a	separation	between	cells	incubated	in	the	presence	or	absence	of	Imatinib	or	Nilotinib	could	be	identified.	After	the	pre-processing	and	correcting	the	data,	PCA	is	 the	 first	 analysis	method	 I	 used.	 PCA	 is	widely	 used	 technique	 that	 extracts	 and	displays	the	characteristics	causing	the	variance	in	great	term	within	the	data	set	and	loadings	reveal	how	much	is	the	contribution	of	each	variable	between	the	samples	[Spooner	2009].	Figures	31	to	34	show	the	PCA	for	cells	incubated	with	Imatinib	and	Nilotinib,	respectively,	and	their	corresponding	loadings.	
	
	
Figure	31:	PCA	of	Full	Scans	of	the	headspace	of	control	media	(no	cells)	with	100	µM	of	Imatinib,	and	cells	incubated	with	0	µM,	10	µM,	50	µM,	and	100	µM	of	Imatinib	(using	H3O+	reagent	ion).			
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The	 PCA	 scores	 plots	 in	 Figures	 31	 and	 33	 show	 a	 clear	 difference	 between	 the	signals	from	media	with	100	µM	of	Imatinib	or	Nilotinib	versus	cells	incubated	in	the	absence	or	presence	of	either	 Imatinib	or	Nilotinib.	 Interestingly,	 there	 is	also	clear	separation	between	both	cell	lines	(Jurkat	and	K562)	and,	at	the	same	time,	PCA	was	able	to	indicate	certain	separation	amongst	cells	incubated	in	different	doses	of	either	drug	 within	 the	 same	 cell	 line,	 especially	 when	 comparing	 control	 cells	 with	 cells	incubated	 with	 the	 highest	 dose	 of	 Imatinib	 or	 Nilotinib.	 This	 would	 indicate	 that	SIFT-MS	might	have	a	role	in	assessing	tumor	response	to	treatment	and	PCA	could	be	used	to	explore	it												
Figure	32:	PCA	loading	of	 full	scans	 from	headspace	of	control	media	with	no	cells	but	with	100	µM	of	Imatinib	and	cells	incubated	with	0	µM,	10	µM,	50	µM,	or	100	µM	of	Imatinib.	
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Figure	33:	PCA	of	Full	Scans	of	 the	headspace	of	control	media	(no	cells)	with	100	µM	 of	 Nilotinib,	 and	 cells	 incubated	 with	 0	 µM,	 10	 µM,	 50	 µM,	 and	 100	 µM	 of	Nilotinib	(using	H3O+	reagent	ion).	
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Figure	34:	PCA	loadings	of	Full	Scans	of	the	headspace	of	control	media	(no	cells)	with	100	µM	of	Nilotinib,	and	cells	incubated	with	0	µM,	10	µM,	50	µM,	and	100	µM	of	Nilotinib	(using	H3O+	reagent	ion).	
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The	next	step	was	to	 look	for	those	analytes	that	could	explain	these	differences.	In	the	 case	 of	 Imatinib,	 the	 loading	 plot	 (Figure	 32)	 of	 PCA	 	 (Figure	 31)	 showed	differences	 as	 follows:	 m/z	 31,	 associated	 with	 formaldehyde;	 m/z	 45,	 associated	with	 acetaldehyde;	 m/z	 47,	 associated	 with	 formic	 acid	 and	 ethanol;	 m/z	 57,	associated	 with	 acrolein;	 m/z	 59,	 associated	 with	 acetone	 and	 propanal;	 m/z	 63,	associated	with	 dimethyl	 sulphide;	m/z	 77,	 associated	with	 carbon	 disulphide	 and	thioacetic	 acid;	m/z	 83,	 associated	with	 4-methyl-1,	 3-pentadiene;	m/z	 65,	 not	 yet	been	assigned	(all	these	associations	have	been	obtained	from	the	SIFT-MS	library).			In	the	case	of	Nilotinib	(Figure	34),	the	main	differences	reside	in:	m/z	63,	associated	with	dimethyl	 sulphide;	m/z	79,	 associated	with	benzene	and	dimethyl	 sulphoxide;	m/z	 83,	 associated	 with	 4-methyl-1,	 3-pentadiene;	 m/z	 91,	 associated	 with	phynylmethanol;	 and	 m/z	 97,	 associated	 mostly	 with	 fluorobenzene	 and	furancarboxaldehyde	 (all	 these	 associations	 have	 been	 obtained	 from	 the	 SIFT-MS	library).		It	is	not	clear	from	this	preliminary	work	which	would	be	the	analyte	or	combination	of	 analytes	 that	 could	help	 in	assessing	 leukaemia	 response	 to	drugs.	However,	 the	data	 is	very	encouraging	and	should	 lead	 towards	 further	work	 in	which	 individual	metabolical	pathways	 can	be	 enhanced	or	 inhibited	 to	better	understand	 their	 role	following	the	addition	of	drugs	to	leukaemia	cells.						
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4.6:	Conclusion	The	VOCs	exhaled	by	humans	are	a	valuable	source	of	 information	about	the	body’s	metabolism.	 The	 different	 body	 compartments	 produce	 a	 large	 variety	 of	 VOCs,	 a	considerable	 part	 of	which	 is	 found	 in	 the	 breath	 [De	 Lacy	 Costello	 2014].	Mostly,	these	 are	metabolic	 products,	 so	 the	 exhaled	 breath	may	 contain	 the	 footprints	 of	cellular	 activities.	 Analysis	 of	 breath	 can	 reveal	 those	 pathologies	 that	 alter	 the	metabolism	induced	by	the	drugs	(Imatinib,	Nilotinib).	 In	the	lungs,	at	the	blood-air	interface,	the	volatile	metabolic	compounds	may	be	transferred	from	blood	to	air	and	released	in	breath.		Collecting	information	contained	in	breath	is	attracting	research	interest	and	breath	analysis	is	emerging	as	a	major	promising	field	of	interest.		The	 interest	 in	 using	 exhaled	 gases	 as	 non-invasive	markers	 in	 clinical	 diagnostics	and	 therapeutic	 monitoring	 has	 steadily	 increased	 over	 the	 past	 ten	 years.	 Hence,	substantial	work	has	been	done	to	understand	the	underlying	source	and	metabolism	of	volatiles.	The	current	study	demonstrates	that	several	VOCS	might	be	useful	in	the	monitoring	 of	 therapeutic	 response.	However,	 further	 studies	 are	 needed	 to	 assess	VOCs	produced	by	cells	from	a	particular	cancer	type,	and	to	compare	between	in	vivo	and	in	vitro	situations.			Furthermore,	 work	 is	 needed	 to	 assess	 whether	 each	 type	 of	 cancer	 could	 have	 a	different	VOCs	profile,	how	varied	they	might	be	between	cancers	types	and	how	they	might	change	 following	the	addition	of	drugs.	A	great	deal	of	work	still	needs	 to	be	done	in	vitro	before	this	technique	is	taken	into	a	clinical	set	up.		
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Chapter	5	
	
Development	of	a	Methodology	to	Study	Volatiles	from	Breath	for	
Clinical	Applications	of	SIFT-MS	
	
5.1:	Introduction	Research	 in	medical	 science	has	advanced	rapidly	 in	recent	years	and	has	achieved	higher	survival	rates	for	many	chronic	diseases,	yet	cancer	remains	the	leading	cause	of	the	death	in	western	world.	Early	detection	of	any	type	of	cancer	is	a	key	issue	in	the	 management	 of	 the	 disease.	 It	 also	 applies	 to	 leukemia,	 as	 in	 most	 cases	 the	disease	goes	un-noticed	for	a	long	time.	 	Several	techniques	have	been	developed	to	detect	cancer	but	these	screening	methods	are	mostly	time	consuming,	invasive	and	costly.	Yet,	 for	 leukemia,	none	of	 them	has	been	proved	 to	become	a	gold	 standard	due	 to	 their	 limited	 reliability.	 Therefore,	 there	 is	 a	 need	 to	 develop	 non-invasive,	reliable,	fast	and	cheaper	diagnostic	techniques	to	detect	leukemia	at	early	stages,	as	it	is	widely	accepted	that	survival	is	higher	the	earlier	the	disease	is	diagnosed.		
	Breath	 analysis	 to	 identify	 VOCs	 has	 received	 increasing	 attention	 from	 both	 the	clinical	 and	 scientific	 points	 of	 view	 in	 the	 past	 two	 decades.	 There	 are	 research	groups	actively	 targeting	biomarkers	 in	 exhaled	breath	 for	medical	diagnoses	or	 to	monitor	therapeutic	strategies.	Breath	analysis	techniques,	can	also	be	applied	to	in-
vitro	 studies	 to	 analyze	 volatile	 organic	 chemical	 compounds	 produced	 during	cellular	metabolism	and	cell-to-cell	 interaction.	Phillips	1999,	stated	there	are	3481	different	 compounds	 in	 exhaled	 breath	 which	 have	 been	 observed	 at	 different	concentrations	ranging	from	ppbv	to	pptv,	which	also	vary	from	person	to	person.	Of	
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these,	about	1753	compounds	were	observed	showing	positive	alveolar	gradient,	i.	e.,	their	 concentration	 was	 higher	 in	 exhaled	 breath	 than	 inhaled	 air	 [Phillips	 1999].	Therefore,	it	could	be	hypothesised	that	some	of	these	compounds	could	be	linked	to	specific	diseases,	including	leukaemia,	and	their	changes	in	concentration	in	exhaled	breath	could	be	used	for	diagnosis	and	management	of	the	disease.			Breath	analysis	has	great	potential	 in	 term	of	disease	detection	and	 its	 response	 to	the	 treatment	 thanks	 to	 real	 time	 quantification	 of	 trace	 gases.	 The	 non-invasive	nature	 and	 rapid	 sample	 analysis	 are	 the	major	 advantages	 of	 the	 breath	 analysis	techniques	for	both	clinical	and	laboratory	use	[Kumar	2013].		 	To	date,	GCMS	is	a	technique	widely	used	in	laboratories	for	the	detection	of	VOCs	in	the	 exhaled	 breath.	 However,	 it	 requires	 breath	 absorption	 devices	 and	 particular	column	calibration	for	specific	compounds	which	could	be	a	time-consuming	process.	At	the	same	time,	it	has	limits	when	quantifying	some	trace	gases	present	in	exhaled	breath	[Kumar	2013].	Thus,	other	MS	techniques	such	as	PTR-MS	and	SIFT-MS	have	gained	more	interest	in	recent	years	due	to	their	real	time	absolute	quantification	of	trace	gases	at	very	low	concentration.			All	 these	 techniques	 are	 still	 evolving	 in	 breath	 analysis	 due	 to	 the	 important	challenges	they	have	to	face.	VOCs	in	exhaled	breath	are	produced	from	metabolical	processes	 taking	place	 in	different	organs	 in	 the	body	 including	 the	oral	 cavity	and	gut	 from,	 amongst	 other,	 bacteria	 present	 in	 these	 cavities.	 Age	 of	 the	 individual,	gender,	 food	 and	 drink	 intake	 and	 smoking	 amongst	 other	may	 result	 in	 different	VOCs	 profiles	 identified	 in	 breath.	 Furthermore,	 many	 VOCs	 may	 come	 from	 the	
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environment	 rather	 than	metabolical	 processes.	Hence,	 human	breath	 is	 a	 complex	mixture	of	volatile	organic	and	inorganic	compounds.	More	important,	some	of	them	could	become	confounding	factors	when	studying	breath	for	disease	management.	It	is	 therefore	 very	 important	 to	 understand	 the	 baseline	 physiology	 of	 the	 human	breath	prior	to	developing	these	techniques	into	clinical	practice.		The	 next	 challenge	 is	 breath	 sampling.	 It	 has	 to	 be	 very	 well	 established	 how	 to	collect	 breath	 samples,	 i.	 e.,	 the	 environment	 (clean	 room),	 time	 of	 the	 day	 (early	morning	 prior	 to	 eating	 or	 drinking	 anything),	 sample	 collection	 (directly	 into	 the	instrument	or	using	specially	developed	containers),	number	of	exhaled	breaths	(one	or	 several).	 Storage	 and	 transport	 of	 samples	 is	 one	 the	biggest	 challenges	due	 the	possible	 loss	 of	 trace	 gases	 present	 in	 exhaled	 breath.	 Also,	 contamination	 of	 the	sample	by	other	VOCs	could	affect	the	analysis.	It’s	not	always	possible	to	collect	the	breath	directly	from	the	patient,	may	be	due	to	their	condition	or	may	be	due	to	the	mobility	 issues	 of	 the	machine	 being	 used	 for	 the	 analysis.	 So,	 breath	 needs	 to	 be	collected,	stored,	transported	and	analysed.	This	could	take	a	lot	of	time	to	collect	the	breath	 and	 transport	 it	 to	 the	 place	 for	 analysis.	 Therefore,	 it	 is	 very	 important	 to	establish	 a	proper	methodology	with	 robust	 reproducibility	 and	 reliability	 so	 these	techniques	can	be	taken	into	the	clinics.			At	present,	there	are	no	gold	standard	methods	for	VOCs	sampling	and	analysis.	The	American	Thoracic	Society	proposed	the	first	guidelines	for	breath	sampling	in	1999,	aimed	at	monitoring	NO	in	breath	[Offline	1999].	Previously,	polymer-sampling	bags	have	been	used	to	study	the	stability	of	selected	breath	species	with	the	help	of	PTR-MS	 and	 GC-MS	 [Mochalski	 2009;	 Mochalski	 2013].	 Tedlar	 bags	 (PTFE-
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Polytetrafluoroethylene)	are	the	most	commonly	used	breath	sampling	container	at	present	 [O’Hara 2008]. Nalophan	 bags	 (PET-polyethylene	 terephthalate)	 are	 also	being	used	by	many	researchers	in	the	field.	Other	breath	sampling	methods	include:		
• Flex	foil	bags	(PET/NY/AL/CPE-polyethylene	terephthalate/nylon/aluminium	foil/	chlorinated	polyethylene).	
• Glass	bottles	
• Thermal	Desorption	tubes	(Different	absorbents)	
• Metal	Canisters			In	this	chapter,	three	different	sampling	methods	for	breath	analysis	were	used,	i.	e.	exhaling	 directly	 into	 the	 SIFT-MS	 instrument,	Nalophan	 bags,	 and	 glass	 bottles.	 In	order	to	take	this	technique	into	a	clinical	application,	the	best	sampling	model	needs	to	 be	 well	 characterised.	 On	 this	 basis,	 the	 breath	 of	 7	 healthy	 control	 cases	 was	studied.	 In	 this	 chapter,	 the	 best	 suitable	 sampling	 technique	 among	 the	 ones	presently	being	used	in	our	laboratory	were	explored.	The	VOC	of	interest	chosen	to	assess	the	best	sampling	technique	of	breath	was	acetaldehyde.	This	compound	has	been	 chosen	 based	 on	 previous	 work	 in	 our	 laboratory	 [Sulé-Suso	 2009]	 and	 the	studies	carried	out	in	chapters	3	and	4.			
5.2:	Aims	of	the	study		I. To	 establish	 the	 best	 methodology	 suitable	 for	 the	 acquisition	 of	 breath	samples.	II. To	identify	changes	in	VOCs’	concentration	over	a	storage	time	ranging	from	0	to	24	hours.	III. 	To	identify	the	best	suitable	breath	volume	for	a	clinical	application.	
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5.3:	Materials	and	methods	
	
5.3.1:	Control	Group		Healthy	participants	within	a	breath	analysis	study	were	included	in	this	project.	The	study	had	received	ethical	approval	form	the	Local	Ethics	Committee.	This	is	an	on-going	study	and	the	results	of	only	7	individuals	have	been	included	in	this	chapter.	Table	VIII	summarises	the	study	methodology.		
5.3.2:	Sampling	Methods		The	participants	entering	the	study	were	requested	not	to	eat	or	drink	anything	apart	from	water	the	morning	before	providing	a	breath	sample.	Participants	were	allowed	to	 take	any	medication	 they	had	been	prescribed.	Participants	were	also	 requested	not	to	brush	their	teeth	on	the	morning	of	sampling.	Samples	were	always	obtained	at	9.00	o’clock	 in	 the	morning	Prior	 to	providing	a	breath	sample,	a	cup	of	water	was	provided	to	rinse	the	mouth	with.	Breath	samples	(direct	breath	or	collected	in	bags	or	bottles)	were	always	obtained	 in	 the	same	room.	Furthermore,	2	bags	were	also	filled	with	room	air	using	a	50	mL	syringe,	 in	order	to	provide	a	control	air	sample.	The	bags	were	 then	sealed	with	a	 lure	 lock	syringe	 inserted	 into	 the	sampling	pipe	and	parafilmed.			
		
95	
Table	VIII:	Summary	of	the	study	methodology	
 
Participants	 Reagent	Ions	
Used	
Mode	of	
Acquisition	
Sampling	
Method	
Time	Points	(hours)	 	Exhalations										
	
	
Healthy	
Participants	
	
	
	
H3O+,	NO+	
	
	
	
MUI,	FSM	
	
Direct	
	
0	(in	triplicate)		
	
1	
	
Bag		
	
0	(in	triplicate),	1,	3,	6,	24	
	
3,	5	
	 	 	 	
Bottle	
	
0	(in	triplicate),	1,	3,	6,	24	
	
3,5		
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5.3.3:	Sampling	into	Bottles			Participants	were	asked	to	fill	150	mL	sterile	glass	bottles	using	a	straw	of	10	cm	in	length,	 8	 cm	 of	 which	 inserted	 into	 the	 bottles	 (Figure	 35).	 Participants	 were	requested	 to	 fill	 the	bottles	with	3	breaths	 (3	bottles)	or	5	breaths	 (3	bottles).	The	bottles	were	then	immediately	tightly	sealed	with	lids	containing	a	septum,	suitable	for	puncture	by	the	SIFT-MS	sampling	needle.	Bottles	were	then	sealed	with	parafilm	around	 the	 lid	 of	 the	 bottle	 until	 sampled.	 These	 sealed	 bottles	were	 kept	 at	 room	temperature	prior	to	SIFT-MS	experiments.	However,	they	were	brought	to	37	°C	by	keeping	them	in	a	water	bath	immediately	prior	to	running	the	SIFT-MS	experiments. 
 
5.3.4:	Sampling	into	Nalophan	Bags		Nalophan	tube	sheeting	was	cut	into	30	cm	length	and	a	3	cm	poly-tubing	length	was	introduced	into	one	end,	fixing	it	into	place	with	a	cable	tie	and	sealed	with	parafilm	(Figure	 36).	 The	 far	 end	 was	 also	 sealed	 using	 a	 cable	 tie	 and	 parafilm	 over	 it.	
Figure 35: SIFT-MS sampling 150ml bottle, with steel screw cap and penetrable rubber 
septum.	
	
		
97	
Participants	were	 asked	 to	 fill	 each	 bag	with	 at	 least	 3	 breaths,	 exhaling	 normally.	Each	 bag	was	 then	 sealed	with	 a	 lure	 lock	 syringe	 and	wrapped	 in	 parafilm.	 Bags	were	 stored	 at	 room	 temperature,	 under	 ambient	 conditions	 until	 sampling	 time.	They	were	brought	to	37	°C	by	keeping	them	in	a	temperature	controlled	box	before	running	the	SIFT-MS	experiments.		
 
 
 
 
 
 
 			
 
 
 
 
 
 
Figure 36: SIFT-MS sampling bag comprised of a Nalophan sheet, cable ties and poly 
tubing sampling orifice. 
	
5.3.5:	Direct	Breath	Sampling	
 A	sterile	sampling	tube	was	attached	to	the	sampling	arm	of	the	SIFT-MS	by	replacing	the	 sampling	 needle.	 Participants	 were	 requested	 to	 exhale	 one	 long,	 continuous	breath	 into	 the	 sampling	 tube	 attached	 to	 SIFT-MS	 sampling	 arm,	 in	 order	 to	maximise	the	amount	of	exhaled	breath	for	analysis	(figure	37).	Breath	was	acquired	in	 triplicate	 for	 each	 precursor	 ion	 (H3O+	 and	 NO+).	 Direct	 breath	 sampling	 was	acquired	at	the	same	time	as	bottle	and	bag	samples	were	sampled.			
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5.4:	Selected	Ion	Flow	Tube	Mass	Spectrometer	Sampling	
 The	 profile	 3	 SIFT-MS	 (Figure	 37)	 instrument	 was	 used	 to	 analyse	 the	 breath	samples.	Two	reagent	 ions,	H3O+	and	NO+	were	used	 in	this	study.	Both	operational	mode	of	SIFT-MS,	MUI	(to	 identify	specific	compounds)	and	FSM	(to	study	 full	scan	data)	 were	 also	 used.	 For	 bottle-sampled	 breath,	 the	 bottle	 environment	 pressure	was	 equilibrated	by	using	 a	bag	of	dry	purged	air	 attached	 to	 a	puncturing	needle,	placed	through	the	septum	of	the	sampling	bottles.	For	bags	sampling,	the	needle	in	the	SIFT-MS	sampling	arm	was	directly	inserted	into	the	bags	by	puncturing	the	bag.		For	direct	sampling,	a	sterile	sampling	tube	was	attached	to	the	sampling	arm	of	the	SIFT-MS	 by	 replacing	 the	 sampling	 needle.	 Air	 in	 bottle	 and	 bag	 samples	 was	measured	with	 SIFT-MS	 for	 1	minute.	Direct	 sampling	 breath	was	measured	 for	 as	long	as	the	participant	was	able	to	exhale	in	one	single	breath.	
Figure	37:	Direct	Sampling	into	the	Profile	3	SIFT-MS	instrument	
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5.5:	Data	Processing	(Water	Correction)	Data	 processing	 for	 SIFT-MS	 has	 been	 previously	 described	 in	 chapter	 2.	 For	 each	acquired	 sample,	 a	 6%	water	 correction	method	was	 applied	 during	MIM	mode	 of	SIFT-MS	for	the	H3O+	precursor	only.	Each	measurement	was	first	brought	up	to	6%	water	level	using	the	flow	rate	adjustment	built	in	the	SIFT-MS	software.			
5.6:	Data	Analysis	SIFT-MS	data	was	transferred	form	SIFT-MS	software	to	Microsoft	Excel.			
5.7:	Results	
	
5.7.1:	Number	of	breath	exhalation		As	it	has	already	been	stated	in	the	Introduction	chapter,	a	single	breath	might	not	be	a	true	representation	of	the	physiology	of	the	body.	Therefore,	the	first	3	participants	were	 asked	 to	 fill	 in	 glass	 bottles	 with	 either	 3	 or	 5	 exhalations.	 Breath	 was	 then	measured	and	the	results	are	shown	in	Figure	38.	The	bars	show	no	major	differences	between	 the	 measurements	 of	 3	 or	 5	 exhalations.	 The	 results	 indicate	 that	 when	collecting	 breath	 samples	 in	 bottles,	 3	 exhalations	 provide	 good	 data	 and	 no	improvement	is	seen	by	increasing	the	number	of	exhalations.			
5.7.2:	 Loss	 of	 Humidity	 Among	 Different	 Sampling	 Methods	 Over	
Time	There	has	been	a	great	debate	regarding	loss	of	humidity	during	sampling	and	over	the	time	period	for	sample	storage	[Offline 1999; Diskin	2003;	Lourenço	2014].	In	this	
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study,	 the	 results	 indicate	 that	 there	 is	 a	 clear	 loss	 of	 humidity	 over	 the	 time	 of	storage	depending	upon	the	sampling	approach	(Figure	39).		
	
	The	storage	of	breath	samples	in	bags	translates	into	a	rapid	loss	of	humidity	over	a	period	of	24	hours.	This	is	noticeable	even	after	one	hour	of	storage.	However,	this	is	not	the	case	for	breath	samples	stored	in	bottles.	Direct	sampling	confirmed	the	6%	humidity	in	physiological	conditions.	 				
0%	 10%	 20%	 30%	 40%	 50%	 60%	 70%	 80%	 90%	 100%	ACETONE
ACETALDEHYDEETHANOL
PROPANOLBUTANOL
PENTANOLACETIC_ACID
HEXANALBUTYRIC_ACID
PENTENETERPENES
BENZENE
Figure	38:	3	Exhalation	(blue)	vs	5	Exhalation	(red)	for	specific	compounds	measured	with	SIFT-MS	(all	data	are	mean	of	three	independent	controls).	
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5.7.3:	Identification	of	Best	Sampling	Technique	for	Breath	
Sampling	 
 Representative	 data	 examples	 of	 breath	 samples	 obtained	 with	 the	 3	 techniques	(direct,	bag	or	bottle)	at	time	point	0	are	shown	in	Figures	40	and	41	using	H3O+	or	NO+	 precursors,	 respectively.	 The results indicate that the best methods to identify VOCs 
are collecting the breath in bottles or bags, especially for those VOCs that might be present 
in a very low concentration. An example is propanol where the concentration in breath was 
detected at lower levels in direct breath when compared to breath samples collected in 
either bags or bottles. 
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Figure 39: Loss of Humidity over the time from 0 to 24 hours among three methods of 
sampling, direct method (red), bottles (grey), and bags (yellow). 	
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Figure	40:	Representative	 examples	 of	 breath	 samples	 collected	 at	 0	 hours	 by	 all	three	 methods	 direct	 breath	 (blue),	 bags	 (red),	 and	 bottles	 (grey)	 using	 the	 H3O+	precursor.	(All	compounds	are	mean	of	five	independent	controls).	
Figure	41:	Representative	 examples	 of	 breath	 samples	 collected	 at	 0	 hours	 by	 all	three	 methods	 direct	 breath	 (blue),	 bags	 (red),	 and	 bottles	 (grey)	 using	 the	 NO+	precursor.	(All	compounds	are	mean	of	five	independent	controls).	
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5.7.4: Measurement of breath sample over time 
The next step was to assess how storage of breath samples over time could affect the 
measurement of VOCs especially regarding diffusion and/or absorption of VOCs to the 
sample vessel. Figures 42 to 45 show representative examples of the concentration of 
analytes measured at 0, 6 and 24 hours.  
 
The data obtained did not show a clear pattern of decrease or increase of VOCs 
concentration that could be applied to all participants for samples collected either in bags 
or in bottles. The concentration of some analytes decreased with storage time while in 
other cases it remained similar. The results would indicate that storage might affect the 
concentration of each analyte in different ways, therefore, it would be advisable to measure 
breath samples as soon as they have been collected.  
Figure	42:	Representative	examples	of	breath	from	participants	collected	in	bags	and	measured	 at	 0	 (blue),	 6	 (brown)	 and	 24	 (grey)	 hours	 after	 collection	 using	 H3O+	precursor.	(all	compounds	are	mean	of	five	independent	controls).	
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Figure	 43:	 Representative	 examples	 of	 breath	 from	 participants	 collected	 in	bags	and	measured	at	0	(blue),	6	(brown)	and	24	(grey)	hours	after	collection	using	NO+	precursor.	(all	compounds	are	mean	of	five	independent	controls).	
Figure	44:	Representative	examples	of	breath	from	participants	collected	 in	bottles	and	measured	at	0	(blue),	6	(brown)	and	24	(grey)	hours	after	collection	using	H3O+	precursor.	(all	compounds	are	mean	of	five	independent	controls).	
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However, this might not be the case for full scan data. Figures 46 to 49 show the full scans 
for breath collected in bags using H3O+ precursor for the breath of the same participants’ 
breath data presented in Figures 42 and 44. Figures 50 to 52 show the full scans for breath 
collected in bottles. The results indicate there is a bigger variation between the full scan 
profiles of breath measured at different time points including the absence of some analytes 
at 6 and 24 hours. Furthermore, the differences at these time points seem to be higher in 
the case of breath stored in bags when compared to the breath stored in bottles. Similar 
data was obtained when using NO+ as precursor. The data presented here further 
strengthens the case to analyse breath samples a soon as they have been collected. Further 
work is needed to better understand the reasons behind these changes in VOCs 
concentration at different time points.  
Figure	45:	Representative	 examples	 of	 breath	 from	participants	 collected	 in	 bottles	and	measured	at	0	 (blue),	6	 (brown)	and	24	 (grey)	hours	after	 collection	using	NO+	precursor.	(all	compounds	are	mean	of	five	independent	controls).	
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Figure	46:	Full	scan	mode	data	of	control	1	collected	in	bags	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	47:	Full	scan	mode	data	of	control	2	collected	in	bags	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	48:	Full	scan	mode	data	of	control	3	collected	in	bags	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	49:	Full	scan	mode	data	of	control	4	collected	in	bags	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	50:	Full	scan	mode	data	of	control	1	collected	in	bottles	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	51:	Full	scan	mode	data	of	control	2	collected	in	bottles	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	52	Full	scan	mode	data	of	control	3	collected	in	bottles	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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Figure	53:	Full	scan	mode	data	of	control	4	collected	in	bottles	and	measured	at	0	(blue),	6	(red),	and	24	(grey)	hours	of	collection	using	H3O+	precursor.	
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5.8: Discussions   Breath	samples	are	performed	for	single	or	multiple	breaths,	but	the	composition	of	single	breath	may	not	necessarily	be	representative	of	the	alveolar	gas	due	to	the	fact	that	 breath	 samples	might	 considerably	 vary	 from	 one	 to	 other	 even	 for	 the	 same	individual	[Herbig	2008;	O’Hara	2008;	Filipiak	2012].	Multiple	breaths	are	preferable	to	 reduce	 this	 risk	 and	 to	 acquire	 reproducible	 breath	 samples.	 As	 an	 example,	 a	highly	soluble	compound	such	as	acetone	that	is	produced	in	the	airways	rather	than	in	alveoli	 and	 therefore	 its	 levels	might	not	 fully	 correlate	with	 levels	of	acetone	 in	blood	 [Anderson	2007],	might	be	difficult	 to	measure	 in	a	highly	reproducible	way.	This	would	 indicate	 that	more	 than	 1	 exhalation	might	 be	 required	 to	 obtain	 good	reproducible	 data.	 In	 fact,	 it	 has	 been	 described	 that	 the	 smaller	 the	 sample,	 the	greater	 the	 losses	of	analytes	are	 [Harreveld	2003].	The	data	presented	here,	 show	that	 the	 levels	 of	 analytes	 identified	 are	 lower	when	measured	 in	 direct	 breath	 in	comparison	to	breath	collected	in	bottles	or	bags,	would	support	this.		Another	issue	in	breath	analysis	is	the	humidity	of	the	sample	and	how	this	changes	in	 time.	 Studies	 using	 Nalophan	 bags	 have	 proved	 that	 the	 sample	 decays	 during	storage	 between	 4-40	 hours	 after	 the	 sampling	 [Harreveld	 2003].	 At	 least	 10%	difference	 in	 dry	 and	 wet	 conditions	 was	 reported	 while	 using	 Tedlar	 bags	 as	samplers	 [Groves	 1996].	Water	 vapour	may	 diffuse	 through	most	 of	 the	materials	that	make	the	bags	used	 in	breath	analysis	although	the	 loss	rate	will	depend	upon	the	material	 of	 the	 bag	 [Gilchrist	 2012]. In	 this	 study,	 there	was	 a	 loss	 of	 humidity	even	within	one	hour	from	the	acquisition	of	the	breath	sample	using	bags.	However,	bottles	were	able	 to	maintain	a	 stable	water	vapour	pressure	even	up	 to	24	hours.	The	 levels	 of	 humidity	 have	 a	 great	 impact	 on	 the	 volatile	 species	 present	 in	 the	
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sample,	as	high	levels	of	humidity,	and	therefore	condensation,	in	the	exhaled	breath	cause	 significant	 decrease	 in	 vapour	 concentrations	 for	 those	 compounds	 that	 are	highly	 soluble	 in	 water	 [Mochalski	 2013].	 Water	 vapour	 can	 also	 be	 affected	 by	temperature.	 As	 the	 temperature	 of	 the	 breath	 sample	 falls	 down	 below	 the	 body	temperature	(37	°C),	water	vapour	may	condense	on	the	walls	of	the	sampler,	which	could	 result	 in	 a	 decrease	 of	 the	 concentration	 of	 the	 more	 water	 soluble	 volatile	compounds.	 So,	 keeping	 the	 sample	 at	 37	 °C	 is	 very	 important	 to	 avoid	 the	 risk	 of	losing	water-soluble	volatile	organic	compounds.		
 It	 has	 been	 reported	 that	 VOCs	 might	 remain	 stable	 during	 the	 first	 12	 hours	following	sample	acquisition	[Harreveld	2003].	However,	while	no	major	differences	were	seen	when	studying	few	compounds,	this	did	not	apply	when	carrying	out	a	full	scan	of	the	breath	samples.	This	would	indicate	that	stability	over	time	might	vary	for	different	VOCs,	especially	those	present	in	smaller	concentrations.			From	 the	 work	 presented	 here	 and	 the	 work	 published,	 it	 is	 obvious	 that	 further	studies	 are	 required	 to	 better	 understand	 the	 pathophysiology	 of	 VOCs	 present	 in	breath.	 These	 studies	 need	 to	 take	 into	 account	 not	 only	 the	metabolical	 pathways	but	also	confounding	factors	such	as	age	of	the	individual,	gender	and	food	and	drink	intake,	smoking	and	environmental	exposure.	Other	aspects	of	sampling	which	are	of	great	debate	among	the	scientific	community	are	body	posture	of	the	subject	during	sampling,	 hyperventilation,	 control	 of	 the	 flow	 or	 volume	 of	 the	 breath	 during	collection,	sampling	via	nose	or	mouth,	number	of	breaths	exhaled,	respiratory	rate,	and	heart	beat	[Gilchrist	2012].	
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5.9:	Conclusion		Direct	sampling	is	the	most	convenient	method	of	sampling,	which	could	avoid	loss	of	the	many	important	VOCs	by	diffusion	and/or	absorption.	Since	it	is	not	very	easy	to	obtain	 direct	 breath	 in	 some	 occasions	 due	 to	 reasons	 such	 as	 age	 of	 the	 patient,	inability	 to	 exhale	 for	 a	 period	 of	 time	 long	 enough,	 or	 the	 non-portability	 of	 the	instrument,	 appropriate	 storage	 of	 exhaled	 breath	 and	 transportation	 are	 very	important	issues	to	be	considered.	There	were	no	major	differences	observed,	during	multi	 ion	 mode.	 However,	 this	 did	 not	 apply	 when	 carrying	 out	 a	 full	 scan	 of	 the	breath	samples.	This	would	indicate	that	stability	over	time	might	vary	for	different	VOCs,	especially	those	present	in	smaller	concentrations.	All	these	aspects	of	breath	analysis	 need	 to	 be	 taken	 into	 consideration	 if	 the	 technique	 is	 to	 be	 applied	 in	clinical	practice.															
		
117	
Chapter	6		
	
Synchrotron	Based	FTIR	(S-FTIR)	Spectroscopy	Identifies	Sensitive	
and	Resistant	Leukaemia	Cells	to	Chemotherapy	Drugs	
 
Part of this chapter Published in Analyst: Effects of nilotinib on leukaemia cells using 
vibrational microspectroscopy and cell cloning 
M. R. Siddique, A. V. Rutter, K. Wehbe, G. Cinque, G. Bellisola and J. Sulé-Suso 
	
6.1:	Introduction	Several	studies	have	determined	the	problems	and	complexities	along	with	the	risks	involved	in	the	diagnosis	and	management	of	leukaemia.	Currently	there	are	several	parameters	 to	 assess	 leukaemia,	 such	 as	 blood	 count,	 immunophenotyping,	 and	presence	of	blast	in	peripheral	blood	and	bone	marrow	biopsy.			Imatinib	Mesylate	 is	a	 tyrosine	kinase	 inhibitor	and	 first	 line	 treatment	 for	Chronic	Myeloid	 Leukaemia	 (CML)	 [Thota  2014; Gambacorti-Passerini 2015].	 In	 a	 study	 trial,	Imatinib	achieved	an	83%	response	rate	in	patients	with	newly	diagnosed	CML	[Erba	2011].	 However	 previous	 studies	 have	 shown	 CML	 in	 advanced	 phases	 might	 be	resistant	to	Imatinib.	The	main	mechanisms	of	resistance	to	Imatinib	in	patients	with	CML	are	mutations	in	the	Bcr-Abl	tyrosine	kinase	domain	that	obviate	binding	to	the	drug	 target,	 amplification	 of	 the	 BCR-ABL	 gene	 or	 clonal	 evolution	 [Nikolas	 2006].	Nilotinib,	 a	 second-generation	 tyrosine	 kinase	 inhibitor,	 has	 been	 developed	 to	override	the	resistance	phenomenon	[Burke	2003;	Weisberg	2005].	 It	 is	a	new	ABL	kinase	 inhibitor	 that	 has	 higher	 potency	 than	 Imatinib,	 especially	 in	 Imatinib	resistant	cells.	Nilotinib	can	be	used	against	many	Imatinib	resistant	mutants	of	Bcr-Abl	reducing	the	incidence	of	resistant	mutants	[Welsberg	2005].	Nilotinib	has	shown	
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greater	 efficacy	 than	 Imatinib	 in	 patients	 with	 newly	 diagnosed	 Philadelphia	chromosome10	(Ph)	 (appendix	 3)	 positive	 CML	 in	 chronic	 phase	 after	 a	 minimum	follow-up	of	12	months	[Kantarjian	2011].	These	results	support	Nilotinib	as	a	first-line	 treatment	option	 for	patients	with	newly	diagnosed	disease	 [Kantarjian	2011],	but	Weisberg	E	et	al.	 (2005)	has	also	reported	some	mutants,	which	also	displayed	significant	 resistance	 to	 Nilotinib	 [Weisberg	 2005].	 The	 choice	 of	 chemotherapy	agents	 and	 combinations	 in	 the	 treatment	 of	 leukaemia	 is	 based	 on	 multicentre	studies.	However,	within	each	 individual	 type	of	 leukaemia,	 cells	do	not	exhibit	 the	same	sensitivity	 to	 the	delivered	drug	and,	 as	 such,	 it	 is	not	 clear	yet	how	 the	best	drug	 or	 combination	 of	 drugs	 can	 be	 identified	 for	 each	 individual	 patient.	Companion	 diagnostics	 are	 a	 key	 part	 of	 personalized	 medicine	 and	 will	 likely	continue	 to	 rapidly	 increase	 in	 number	 and	 application	 to	 disease	 areas	 [Agarwal	2015,	Olsen.	2013],	as	 I	discussed	 in	 introduction	chapter,	despite	of	 the	promising	results,	there	are	also	complications	associated	with	companion	diagnostic	assays	i.e.	developing	 a	 successful	 companion	 diagnostic	 with	 its	 complementary	 drug	 is	complex,	 disintegrated	 and	 apprehensive	 with	 several	 challenges.	 Therefore,	 it	 is	obvious	that	further	developments	are	needed	for	a	better	and	faster	identification	of	leukaemia	cells’	sensitivity	to	drugs.	This	would	lead	to	improved	leukaemia	patient	tailored	treatment.		Over	 the	 last	 few	years,	 there	has	been	an	 increasing	 interest	 in	Fourier	Transform	Infrared	(FTIR)	microspectroscopy	as	a	tool	to	study	cell	sensitivity	to	drugs	[Krishna 
                                                10	A	piece	of	chromosome	9	and	a	piece	of	chromosome	22	break	off	and	trade	places.	The	BCR-ABL	gene	 is	 formed	 on	 chromosome	 22	 where	 the	 piece	 of	 chromosome	 9	 attaches.	 The	 changed	chromosome	22	is	called	the	Philadelphia	chromosome,	abbreviated	as	Ph.			
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2006; Bellisola	2012;	Rutter	2013].	Vibrational	spectroscopy	has	been	used	to	study	leukaemia	 cells’	 sensitivity/resistance	 to	 drugs	 in	 vitro	 [Le	 Gal	 1993;	 Liu	 2001;	Gaigneaux	2002;	Gault	2003;	Liu	2003;	Krishna	2006;	Moritz	2010;	Machana	2012;	Ceylan	2012;	Travo	2012;	Baran	2013;	Bellisola	2013;;	Yandim	2016;]	and	to	assess	tumour	 response	 in	 patients	with	 leukaemia	 [Ramesh	 2002;	 Sahu	 2006;	 González-Solís,	 2014].	The	 ability	 of	 FTIR	 coupled	with	PCA	 to	distinguish	BCR/ABL	positive	cells	 from	 normal	 or	 BCR/ABL	 negative	 cells	 has	 already	 been	 reported.	 Bellisola	2015,	stated	that	FTIR	spectroscopy	can	distinguish	between	BCR/ABL	positive	and	BCR/ABL	negative	cells.	Babrah	2008	reported	 that	 it	 is	possible	 to	classify	 cells	of	different	 lineage	 via	 its	 spectral	 signature	 [Babrah	 2008].	 All	 these	 studies	 have	proven	that	vibrational	spectroscopy	using	either	FTIR	or	Raman	microspectroscopy	could	not	only	distinguish	between	the	sensitivity	and	resistance	of	given	cell	line	to	the	particular	drug	[Krishna 2006] but	also	able	to	identify	changes	in	leukaemia	cells	prior	 to	 and	 after	 the	 addition	 of	 drugs	 that	 could	 relate	 to	 leukaemia	 cell	sensitivity/resistance	to	drugs.	Furthermore,	the	possibility	of	studying	the	effects	of	drugs	 on	 cancer	 cells	 at	 sub-cellular	 level	 using	 synchrotron	 based	 FTIR	 (S-FTIR)	microspectroscopy	 could	 help	 to	 better	 characterize	 spectral	 biomarkers	 of	 cancer	cells	 sensitivity	 to	 drugs.	 However,	 cell	 morphology	 can	 introduce	 spectral	deformations	as	well	 [Diem	2012]	such	as	 those	associated	with	Mie	scattering	and	dispersive	 artefact	 caused	 mostly	 by	 the	 cell	 nucleus	 [Bassan	 2010;	 Rutter	 2014].	Although	 several	 algorithms	have	been	developed	 to	 correct	 for	Mie	 scattering	and	the	 dispersive	 artefact	 none	 of	 them	 is	 widely	 used.	 Therefore,	 this	 poses	 an	important	 problem	 when	 studying	 cells	 following	 the	 addition	 of	 chemotherapy	drugs	 since	 spectral	 biochemical	 changes	 have	 to	 be	 identified	 separately	 from	 the	morphologically	 induced	 spectral	 changes.	 The	 ideal	 alternative	 I	 followed	 in	 this	
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work	was	 to	 obtain	 S-FTIR	 spectra	 of	 sensitive	 and	 resistant	 cells	 to	 Imatinib	 and	Nilotinib	prior	to	adding	the	drug	so	neither	biochemical	nor	morphological	changes	caused	 by	 the	 drug	 itself	 interfered	 with	 their	 S-FTIR	 spectra.	 This	 could	 provide	more	 robust	 data	 leading	 towards	 a	 better	 characterization	 of	 possible	 spectral	biomarkers	 of	 cell	 sensitivity	 to	 chemotherapy.	 This	 should	 help	 in	 the	 future	 to	figure	 out	 for	 each	 individual	 patient	 whether	 he/she	 would	 respond	 to	 a	 given	treatment.			
6.2:	Aims	1. To	better	characterize	spectral	biomarkers	of	cell	sensitivity	to	chemotherapy	for	leukaemia	following	the	addition	of	the	drug.	2. To	be	able	to	identify	sensitivity/resistance	of	 leukaemia	cells	to	a	given	drug	prior	to	the	addition	of	the	drug.	
	
6.3:	Materials	and	Methods	
	
6.3.1:	Cell	line	The	K562	 (kind	gift	of	Dr	G.	Bellisola),	 a	CML	cell	 line	was	used	 in	 this	 study.	Cells	were	 cultured	 and	 maintained	 in	 suspension	 in	 RPMI	 1640	 with	 10%	 FBS	 1%	 L-Glutamine	 (200nM),	 1%	Hepes	 buffer	 (1M)	 and	 1%	 Antibiotic/Antimycotic	 (100x)	and	incubated	at	37°C	and	5%	CO2.	Culture	medium	was	changed	every	3-4	days.		
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6.3.2:	Cell	survival	Parental	K562	cells	were	incubated	in	24	well	plates	at	105	cells/well	in	the	absence	and	presence	of	Imatinib	or	Nilotinib	(0	µM,	50	µM	or	100	µM)	for	5	days.			
	
6.3.3:	Cell	cloning	The	K562	cell	line	was	cultured	under	standard	conditions	as	mentioned	in	Chapter	2.	Cells	were	collected	before	reaching	confluence	and	counted	with	the	trypan	blue	exclusion	method	after	centrifuging	at	950	rpm	for	3	minutes.	Cells	were	seeded	 in	flat-bottomed	96	well	plates	at	a	concentration	of	0.5	cells/well	and	topped	up	to	200	μL	of	fresh	complete	medium.	In	order	to	get	a	reasonable	number	of	clones,	5	x	96	well	plates	were	seeded.	After	the	addition	of	the	medium,	plates	were	wrapped	with	foil	to	avoid	dehydration	and	incubated	at	37°C	and	5%	CO2.	Clones	were	inspected	regularly	so	those	wells	with	more	than	1	clone	could	be	discarded	(see	Chapter	2).	Medium	was	changed	after	one-week	culture	by	spinning	the	plates	at	1200	rpm	for	7	minutes.	 Following	 this,	 100	 μL	 of	 medium	 were	 removed	 and	 100	 μL	 of	 fresh	complete	medium	was	added.	Plates	were	further	incubated	at	37°C	and	5%	CO2	for	one	week	to	allow	the	clones	to	develop.			
6.4:	Addition	of	Drugs	to	Clones	Imatinib	and	Nilotinib	were	used	in	this	study	at	two	different	concentrations,	50	µM	and	100	µM.	These	two	doses	were	chosen	based	on	preliminary	studies	showing	that	clonal	cells	survived	with	10	µM	of	either	drug	and	there	was	little	cell	survival	with	500	µM	of	either	drug.		
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Following	 2	 weeks’	 culture,	 clones	 were	 collected	 and	 seeded	 proportionally	 in	 3	wells	in	96	flat-bottomed	plates.	Cells	were	allowed	to	grow	for	24	hours	at	37	°C	and	5%	 CO2.	 Following	 this	 incubation	 period,	 Imatinib	 or	 Nilotinib	 were	 added	 as	follows.	 Plates	 were	 spun	 at	 1200	 rpm	 for	 7	 minutes.	 Following	 this,	 100	 µL	 of	medium	were	removed	and	100	µL	of	fresh	media	with	different	final	concentrations	of	Imatinib	or	Nilotinib	were	added	(0	µM,	50	µM	or100	µM).	Clones	were	allowed	to	grow	 for	 5	 days	 at	 37	 °C	 and	5%	CO2	 in	 order	 to	 assess	 clone	 survival.	Wells	with	control	 cells	 (0	 µM	 Imatinib	 or	Nilotinib)	 started	 to	 become	 fully	 confluent	 after	 5	days	culture.	Therefore,	 it	was	decided	to	collect	cells	at	day	5	after	 the	addition	of	the	drugs.			Synchrotron	beam	time	at	Diamond	Light	Source,	Oxford,	UK	and	Synchrotron	Soleil,	France,	 is	 limited	 in	 its	 allocation,	 so	 only	 few	 clones	 were	 selected	 for	 analysis.	Clones	 in	which	cells	 in	 control	wells	were	completely	 confluent	were	discarded	as	this	 could	 modify	 their	 metabolical	 and	 proliferative	 properties.	 The	 clones	 were	selected	 by	 visually	 observing	 the	 wells	 under	 the	 microscope	 and	 classed	 as	sensitive,	where	there	were	no	cells	or	very	low	number	of	live	cells	in	the	well	(-	-);	resistant,	where	 the	well	 is	 at	 least	 semi-confluent	 (+	 +);	 and	 semi-resistant/semi-sensitive	where	the	well	is	half	full	(+	-).	Resistant,	sensitive	and	semi-resistant/semi-sensitive	clones	to	different	doses	of	Imatinib	or	Nilotinib	were	selected	(table	IX)	
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6.5:	Clone	Selection		
Table	IX:	Representative	example	of	K562	Clones	 following	5	days	 incubation	with	Imatinib	 or	 Nilotinib	 at	 different	 doses.	 2	 plus	 signs	 indicate	 semi-confluent	wells;	one	 plus	 sign	 indicates	wells	with	 cells	 occupying	 less	 than	 half	 the	 surface	 of	 the	well;	plus/minus	sign	 indicates	 the	presence	of	very	 few	cells;	minus	sign	 indicates	absence	of	cells.			
	
																				
	
Clones	
	
Control	
	
50	µM	
	
100	µM	
1	 ++	 +/-	 +/-	
2	 ++	 +	 +	
3	 ++	 +	 +/-	
4	 ++	 +	 +	
5	 ++	 +	 +	
6	 ++	 +	 +/-	
7	 ++	 +	 +	
8	 ++	 +	 -	
9	 ++	 ++	 +	
10	 ++	 +	 +/-	
11	 ++	 +	 +/-	
12	 ++	 +	 +	
13	 +-	 +/-	 +/-	
14	 ++	 -	 -	
15	 ++	 +	 +	
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6.6:	Sample	Preparation		UV	graded	CaF2	slides	(26	x	22	x	0.5	mm)	(Crystan	Ltd,	UK)	were	chosen	as	they	are	polished	slides	suitable	for	both	FTIR	and	Raman	microspectroscopy	[Grills 2015].		Following	 the	 incubation	 with	 either	 drug,	 clones	 were	 selected	 as	 described	 in	section	6.5	 (Table	XI),	 collected	 and	 spun	 in	 eppendorfs	 at	 950	 rpm	 for	5	minutes.	Cells	 were	 then	 cytospun	 onto	 CaF2	 slides	 for	 1	 minute	 at	 550	 rpm,	 through	 a	cytofunnel	 and	 filter	 card	 (Shandon,	 UK).	 Once	 cells	 had	 been	 deposited	 on	 CaF2	slides	 in	 single	monolayer,	 samples	were	placed	 in	a	Petri	dish	and	 fixed	using	4%	Paraformaldehyde	 (PFA)	 in	 0.9%	 NaCl	 for	 20	 minutes	 as	 previously	 described	[Pijanka	 2009],	 followed	 by	 3	washes	with	 0.9%	NaCl	 and	 3	washes	with	 distilled	water	and	then	air-dried	at	room	temperature.		
	
6.7:	S-FTIR	microspectroscopy	Synchrotron	sources,	Diamond	Light	Source,	Oxford,	UK,	and	Soleil	Synchrotron	Paris,	France,	were	used	 to	obtain	 the	data	because	of	 the	 limitations	of	 the	beamtime	at	each	centre.	In	both	beamlines,	spectra	were	collected	at	4	cm-1	resolution	with	128	co-added	spectra.	Measurements	were	taken	in	transmission	mode,	using	15×15	μm	aperture	 with	 a	 36x	 objective.	 The	 measurements	 were	 taken	 by	 centring	 the	aperture	at	the	nucleus	of	the	cells.	Background	spectra	of	the	substrate	were	taken	after	 every	 15	 cells’	 measurement.	 Images	 of	 the	 studied	 cells	 with	 FTIR	microspectroscopy	 were	 taken	 so	 they	 could	 be	 easily	 identified	 when	 further	studied	with	Raman	Spectroscopy.		
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For	 each	 individual	 sample,	 a	minimum	 of	 50	 spectra	 for	 50	 individual	 cells	 were	collected.	 However,	 in	 those	 cases	 were	 cells	 were	 sensitive	 to	 either	 drug,	 the	number	of	cells	could	be	lower	than	50.	In	these	cases,	as	many	cells	as	possible	were	analysed.	 Images	of	 the	cell	population	were	obtained	throughout	and	cells	 labelled	so	each	cell	was	analysed	only	once.				
6.7.1:	S-FTIR	Spectra	Pre-Processing	and	Analysis	All	S-FTIR	spectra	were	imported	into	Matlab	7.5	(Mathworks,	Natick,	USA)	to	apply	Extended	 Multiplicative	 Signal	 Correction	 (EMSC)	 in	 order	 to	 correct	 for	 Mie	scattering	 effects	using	 an	 algorithm	created	by	Dr	Achim	Kohler	 [Kohler	2008].	 S-FTIR	 Spectra	 were	 processed	 using	 The	 Unscrambler	 Software	 (Version	 X,	 Camo,	Oslo,	 Norway)	 for	 normalisation	 (Standard	 Normal	 Variate	 (SNV))	 and	 smoothing	(Savitzky-Golay).									
	
	Following	EMSC	 application,	 spectra	were	 imported	 into	Unscrambler	 (VERSION	X,	Camo,	Oslo,	Norway),	then	cropped	to	the	area	to	be	analysed	(2700	cm-1	to	3100	cm-
Figure	54:	Image	of	cytospun	cells,	depicting	the	number	labelled	cells	from	which	FTIR	measurement	had	been	taken	in	order	to	only	analyse	each	cell	once.		
100	µm100	µm
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1	 for	 the	 lipid	 region	 and	 1000	 cm-1	 to	 1800	 cm-1	 for	 the	 fingerprint	 area)	 and	normalized	using	standard	normal	variate	(SNV).	This	removes	the	effect	of	sample	thickness	and	any	baseline	offset	that	may	have	occurred.			
6.7.2:	Analysis	Principal	Components	Analysis	(PCA)	is	an	unsupervised	analysis	method	that	allows	to	 reduce	big	numbers	of	variables	 into	a	 few	principle	components.	This	allows	 to	understand	 where	 possible	 differences	 in	 data	 sets	 might	 lie.	 PCA	 was	 performed	using	 The	 Unscrambler	 Software	 (VERSION	 X,	 Camo,	 Oslo,	 Norway).	 Loading	 plots	were	also	produced	using	the	same	software.			
6.8:	Results	
	
Table	X:	Survival	for	K562	in	the	presence	and	absence	of	Imatinib	or	Nilotinib.		
 
K562	 Imatinib	Survival	(%±	SD)	 Nilotinib	Survival	(%±	SD) 
0	µM	 98.34	±	0.81	 97.13	±	0.74 
50	µM	 85.19	±	2.52	 48.57	±	2.48 
100	µM	 54.49	±	14.49	 31.58	±	15.43 
		S-FTIR	spectroscopy	is	a	technique	that	investigates	biological	systems	at	molecular	level	 enabling	 the	 study	 of	 the	 structural	 composition	 of	 macromolecules	 such	 as	
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lipids,	 proteins,	 and	 nucleic	 acids	 (DNA,	 RNA)	 [Ramesh	 2002;	 Toyran	 2005;	Dogan	2007].	 Hence,	 in	 this	 study,	 this	 technique	 was	 used	 to	 assess	 the	 resistance	 and	sensitivity	 of	 leukaemia	 cells	 to	 Imatinib	 or	Nilotinib	 and	 identify	 possible	 spectral	biomarkers.										
 
 
 
 
 
 
 
 
 
Figure	55:	Representative	example	of	an	FTIR	spectrum	of	a	K562	cell	in	the	900-3600	cm-1	region.			Figure	55	shows	the	average	FTIR	spectra	of	the	control	K562	cells	in	the	900-3600	cm-1	spectral	region.	Major	bands	assigned	in	Figure	55	are	presented	in	Table	XI.	An	S-FTIR	 spectrum	 of	 K562	 cells	 contains	 several	 bands	 due	 to	 the	 contribution	 of	different	 functional	 macromolecules.	 The	 spectra	 for	 the	 following	 regions,	 2800-3600	cm-1	 for	protein	and	 lipids,	and	1000-1800	cm-1	 for	 the	 fingerprint	area	were	analysed.		
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Table	XI:	List	of	peaks	assigned	to	K562	cells’	spectra	in	the	absence	of	drugs.	
	
Peaks	 Approximate	
Frequency	cm-1	
Assignments	
1	 3290-3300	 Amide	A:	Mainly	N-H	stretching	of	proteins	with	little	O-H	stretching	of	polysaccharides	[Lyng 2015].	
2	 3075	 Amide	B:	C-N	stretching	of	Protein	and	N-H	stretching	of	proteins	[Movasaghi	2008]	
3	 2960	 CH3	asymmetric	stretching:	lipids,	protein	side	chains	and	some	carbohydrates	[Lyng 2015].	
4	 2925	 CH2	asymmetric	stretching:	lipids,	and	little	proteins	and	carbohydrates	[Movasaghi	2008;	Lyng 2015].	
5	 2870	 CH3	symmetric	stretching:	protein	side	chains,	lipids	and	some	carbohydrates	and	nucleic	acid	[Baran	2013].	
6	 2850	 CH2	symmetric	stretching:	mainly	lipids,	little	proteins,	nucleic	acids,	and	carbohydrates	[Movasaghi	2008;	Lyng 
2015].	
7	 1740	 Ester	C=O	Stretching:	triglycerides	and	cholesterol	esters	[Movasaghi	2008].	
8	 1600-1700	 Amide	I:	C=O	Stretching:	proteins	[Movasaghi	2008;	Lyng 
2015].	
9	 1520-1550	 Amide	II:	N-H	bending	and	C-N	stretch:	proteins	[Movasaghi	2008;	Lyng 2015].	
10	 1465	 CH2	bending:	lipids,	with	little	proteins,	CH3	symmetric	bending:	methyl	group	of	proteins	[Baran	2013].	
11	 1250-1400	 COO-	symmetric	stretch:	lipids	with	little	proteins,	CH3	symmetric	bending:	methyl	group	of	proteins	[Movasaghi	2008].	
12	 1240	 PO2-asymmetric	stretch:	mainly	nucleic	acid	with	little	from	phospholipids	[Lyng 2015].	
13	 1080	 PO2-	symmetric	stretch:	nucleic	acid	and	phospholipids	[Lyng 2015].	
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Figure	56:	Mean	spectra	of	 resistant	 clone	10	cells	 in	 the	absence	of	 Imatinib	 (top	spectrum),	 in	 the	presence	of	50	µM	of	 Imatinib	 (middle	 spectrum)	and	100	µM	of	Imatinib	(bottom	spectrum).	Each	spectrum	is	the	mean	of	50	individual	spectra	from	50	individual	cells.	Spectra	are	offset	for	clarity		
Figure	57:	Mean	spectra	of	semi-resistant	clone	3	cells	 in	 the	absence	of	 Imatinib	(top	spectrum),	in	the	presence	of	50	µM	of	Imatinib	(middle	spectrum)	and	100	µM	of	Imatinib	(bottom	spectrum)	Each	spectrum	is	the	mean	of	50	individual	spectra	from	50	individual	cells	except	bottom	spectrum	which	is	the	mean	of	20	individual	spectra	from	20	individual	cells.	Spectra	are	offset	for	clarity.	
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	As	previously	reported,	various	degrees	of	sensitivity	and	resistance	to	a	given	drug	can	 be	 identified	 in	 cells	 following	 cell	 cloning	 [Rutter	 2014].	 Based	 on	 their	therapeutic	 response,	 I	 classed	 these	 clones	 as	 sensitive,	 semi-sensitive/semi-resistant	and	resistant	clones.	Figures	56	to	58	show	representative	mean	spectra	of	three	individual	K562	clones	with	varying	degree	of	sensitivity	to	Imatinib	incubated	with	 different	 doses	 of	 the	 drug.	 Figure	 56	 shows	 the	 spectra	 of	 clone	 10,	 which	proved	resistant	to	both	doses	of	Imatinib	(50	µM	and	100	µM).	Figure	57	shows	the	spectra	of	clone	3,	semi-sensitive/semi-resistant,	i.	e.,	resistant	to	50	µM	Imatinib	but	only	20	cells	could	be	identified	in	the	presence	of	100	µM	Imatinib.	Figure	58	is	the	mean	 spectra	of	 clone	7,	which	was	 sensitive	 to	 Imatinib	 at	100	µM	 (no	 cells	were	
Figure	58:	Mean	spectra	of	sensitive	clone	7	cells	to	100	µM	Imatinib	in	the	absence	of	Imatinib	(bottom	spectrum),	in	the	presence	of	50	µM	of	Imatinib	(top	spectrum).	Bottom	spectrum	 is	 the	mean	of	50	 individual	 spectra	 from	50	 individual	 cells	 and	top	 spectrum	 is	 the	mean	of	12	 individual	 spectra	 from	12	 individual	 cells.	 Spectra	are	offset	for	clarity.		
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identified)	 and	 only	 12	 cells	 were	 recovered	 following	 incubation	 with	 50	 µM	Imatinib.		It	 is	 obvious	 from	Figures	57	 to	58	 that	 Imatinib	 induces	 changes	 in	 the	 spectra	of	cells	 sensitive	 and	 semi-sensitive/semi-resistant	 to	 Imatinib.	 More	 important,	changes	can	also	be	seen	in	the	spectra	of	resistant	cells	incubated	with	100	µM	and	even	with	50	µM	of	Imatinib	(Figure	56).			The	main	changes	following	the	addition	of	Imatinib	are	a	decrease	in	the	intensity	of	the	bands	at	1080	cm-1	and	1240	cm-1,	a	decrease	in	the	intensity	of	the	peak	at	1740	cm-1,	changes	in	the	shape	of	amide	I	and	II	bands	and	an	increase	in	the	intensity	of	the	peak	at	2850	cm-1	when	compared	to	the	peak	at	2870	cm-1.			The	peak	1740	cm-1	band	is	mainly	assigned	to	the	C=O	ester	stretching	vibration	of	triglycerides	and	cholesterol	esters	[Movasaghi	2008].	The	peak	at	1740	cm-1	appears	as	 a	 shoulder	 in	 the	 spectra	 of	 cells	 incubated	 in	 the	 absence	 of	 Imatinib	 while	 it	becomes	a	small	peak	when	cells	have	been	incubated	with	either	50	µM	or	100	µM	of	Imatinib	(Figures	56,	57,	and	58).	The	band	at	1650	cm-1	corresponds	to	the	Amide	I.	Cells	 incubated	 in	 the	absence	of	 Imatinib	present	a	 sharp	Amide	 I	band.	However,	following	the	incubation	with	Imatinib	at	either	50	µM	or	100	µM,	this	band	becomes	broader	and	intensity	increases	around	1630	cm-1	(Figures	56,	57,	and	58).	Similarly,	the	 Amide	 II	 band	 at	 1540	 cm-1	 also	 becomes	 broader	 following	 the	 addition	 of	Imatinib	 at	 either	 50	 µM	or	 100	µM	with	 increasing	 intensity	 at	 around	1520	 cm-1	(Figures	 56,	 57,	 and	 58).	 Any	 change	 in	 these	 two	 bands	 is	 an	 indication	 of	 the	changes	 in	 the	proteomes	of	 cells	 as	 these	 two	bands	 are	known	 to	be	 sensitive	 to	
		
132	
protein	conformation	and	are	used	to	determine	the	secondary	structure	of	proteins	[Dogan	2007].	 	On	 the	other	hand,	 the	nucleic	 acid	 related	bands	at	1240	 cm-1	 and	1080	cm-1	attributed	to	PO2	asymmetric	and	symmetric	stretch	[Ramesh	2002;	Lyng 
2015]	show	loss	of	intensity	in	the	spectra	of	cells	exposed	to	Imatinib.						
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCA	 was	 carried	 out	 in	 order	 to	 identify	 any	 possible	 differences	 between	 cells	incubated	in	the	absence	or	the	presence	of	Imatinib.	As	can	be	seen	in	Figure	59,	PCA	could	separate	between	cells	incubated	in	the	absence	of	Imatinib	and	in	the	presence	of	Imatinib	in	the	fingerprint	region	for	resistant	clone	10.		
Figure	59:	PCA	of	clone	10	(resistant	to	both	50	µM	and	100	µM	of	Imatinib)	for	cells	incubated	with	0	µM	Imatinib	(diamonds),	50	µM	Imatinib	(squares),	and	100	µM	Imatinib	(triangles)	for	fingerprint	(A)	and	lipid	(C)	regions	and	loading	plots,	respectively	(B	and	D).	
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Figure	60:	PCA	of	clone	3	(semi-resistant	to	both	50	µM	and	100	µM	of	Imatinib)	for	cells	 incubated	with	0	µM	 Imatinib	 (diamonds),	50	µM	 Imatinib	 (squares),	 and	100	µM	 Imatinib	 (triangles)	 for	 fingerprint	 (A)	 and	 lipid	 (C)	 regions	 and	 loading	 plots,	respectively	(B	and	D).	
Figure	61:	PCA	of	clone	7	(sensitive	to	100	µM	of	Imatinib)	for	cells	incubated	with	0	µM	Imatinib	(diamonds)	and	50	µM	Imatinib	(squares),	for	fingerprint	(A)	and	lipid	(C)	regions	and	loading	plots,	respectively	(B	and	D).		
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There	 is	 trend	to	separate	between	cells	 incubated	with	either	50	µM	or	100	µM	of	Imatinib	 for	 clone	 10.	 However,	 there	 were	 no	 clear	 differences	 between	 cells	incubated	in	the	absence	or	presence	of	Imatinib	for	the	lipid	region	(Figure	59	C).		In	 the	 case	 of	 clone	 3	 (semi-resistant/semi-sensitive),	 there	 was	 clear	 separation	between	 cells	 incubated	 in	 the	 absence	 of	 Imatinib	 and	 those	 incubated	 in	 the	presence	 of	 Imatinib	 for	 both	 the	 fingerprint	 and	 the	 lipid	 regions	 (Figure	 60).	Furthermore,	there	was	a	higher	separation	between	cells	incubated	in	the	absence	of	Imatinib	 and	 those	 incubated	 with	 100	 µM	 Imatinib	 (Figure	 60)	 for	 both	 regions	(Fingerprint	 and	 lipids).	 Again,	 for	 clone	 7,	 a	 separation	 was	 seen	 between	 cells	incubated	 in	 the	 absence	 of	 Imatinib	 and	 those	 incubated	 with	 50	 µM	 Imatinib.	However,	the	difference	was	less	for	the	lipid	region	(figure	61).	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 		
Figure	62:	Mean	spectra	of	 resistant	 clones	4	and	10	 (resistant	 to	both	50	µM	and	100	 µM	of	 Imatinib)	 for	 cells	 incubated	with	 0	 µM	 Imatinib	 (Blue	 and	 red)	 and	 of	sensitive	clones	12	and	13	(sensitive	to	both	50	µM	and	100	µM	of	Imatinib)	for	cells	incubated	with	0	µM	Imatinib	(Green	and	purple).	Spectra	are	offset	for	clarity.	
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	Figure	62	shows	the	comparison	between	resistant	clones	4,	10	and	sensitive	clones	12,	 13.	 It	 is	 obvious	 there	 are	 no	major	 differences	 among	 resistant	 and	 sensitive	clones	spectra,	but	slight	changes	 in	bands	related	to	CH2	symmetric	stretching	and	bending	of	lipids	with	little	contribution	of	protein	and	carbohydrates,	increase	in	the	intensities	 of	 2925	 cm-1	 and	 1740	 cm-1	in	 sensitive	 clone	 spectra	 as	 compared	 to	resistant	clone	spectra.	Hence	increases	in	2850	cm-1	along	with	2925	cm-1	indicates	significant	increased	lipid	and	protein	contents	in	sensitive	clone	cells.			
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Figure	63:	PCA	of	resistant	clones	4	and	10	(resistant	to	both	50	µM	and	100	µM	of	Imatinib)	 for	 cells	 incubated	 with	 0	 µM	 Imatinib	 (diamonds	 and	 squares,	respectively)	and	of	sensitive	clones	12	and	13	(sensitive	to	both	50	µM	and	100	µM	of	 Imatinib)	 for	 cells	 incubated	 with	 0	 µM	 Imatinib	 (crosses	 and	 triangles,	respectively)	for	fingerprint	(A)	and	lipid	(C)	regions	and	loading	plots,	respectively	(B	and	D).		
		
136	
PCA	 score	 plots	 (figure	 63)	 show	 that	 there	 was	 no	 clear	 separation	 between	resistant	 and	 sensitive	 clones	 to	 Imatinib	 incubated	 in	 the	 absence	 of	 the	 drug.	Furthermore,	these	would	have	indicated	that	even	being	different	clones,	PC	was	not	able	 to	 separate	 them	 for	 this	 fact.	 This	would	 indicate	 that	 cloning	 K562	 leads	 to	obtaining	 cell	 clones	 that	 might	 not	 differ	 much	 between	 themselves	 based	 on	 IR	spectral	 data.	 Further	work	 is	 required	 to	 assess	whether	 this	 is	 the	 case	 in	 other	leukaemia	cell	 lines.	On	the	other	hand,	 the	results	presented	here	 indicate	that	the	changes	in	the	spectra	of	cells	incubated	in	the	presence	of	imatinib	are	probably	due	to	 sensitive	 cells	 to	 imatinib	 that	 were	 still	 alive	 or	 entering	 apoptosis	 when	 they	were	collected	and	cytospun	to	prepare	the	samples	for	S-FTIR	microspectroscopy.																			
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Figure	 64:	Mean	 spectra	 of	 clone	 4	 (resistant)	 cells	 in	 the	 absence	 of	 Nilotinib	 (top	spectrum),	 in	 the	presence	of	50	µM	Nilotinib	 (middle	 spectrum)	and	100	µM	Nilotinib	(bottom	 spectrum).	 Each	 spectrum	 is	 the	 mean	 of	 50	 individual	 spectra	 from	 50	individual	cells.	Spectra	are	offset	for	clarity	
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Further	 experiments	 were	 carried	 out	 with	 Nilotinib,	 another	 drug	 used	 in	 the	management	of	leukaemia.	Figures	64	and	65	show	the	mean	spectra	for	a	resistant	clone	 to	 both	 50	 µM	 and	 100	 µM	 of	 Nilotinib	 and	 a	 sensitive	 clone	 to	 100	 µM	 of	Nilotinib.	Due	to	time	constraints	during	our	beamtime	at	Diamond	Light	Source,	only	these	2	clones	were	studied.	During	 the	same	beamtime,	 these	clones	were	studied	with	Raman	spectroscopy	(Chapter	7).		The	 incubation	 of	 resistant	 clone	 4	 (figure	 64)	 in	 the	 presence	 of	 Nilotinib	 caused	spectral	changes,	mainly	in	the	amide	bands	and	in	the	peaks	at	1080	cm-1,	1240	cm-1,	1740	cm-1,	2850	cm-1,	and	2925	cm-1.	The	addition	of	the	drug	caused	a	broadening	of	both	 the	Amide	 I	 and	 II	 as	 it	was	 seen	 in	 the	 case	of	 cells	 incubated	with	 Imatinib.	Furthermore,	 there	was	a	decrease	 in	 the	 intensity	of	 the	peaks	at	1080	cm-1,	1240	cm-1	and	1740	cm-1	in	cells	 incubated	with	either	50	µM	or	100	µM	Nilotinib,	Again,	this	 is	 in	 accordance	 with	 the	 data	 obtained	 for	 cells	 incubated	 with	 Imatinib.	Therefore,	although	cells	were	able	to	survive	at	higher	doses	of	Nilotinib,	 it	caused	changes	 in	 cells’	 chemical	makeup	 (Figure	65).	 Similar	data	was	 seen	 for	 the	 semi-sensitive/semi-resistant	clone	7.		PCA	of	resistant	clone	(clone	4)	did	show	separation	between	the	cells	incubated	with	0	 µM,	 50	 µM	 or	 100	 µM	 of	 Nilotinib	 for	 both	 fingerprint	 and	 lipid	 regions	 of	 the	spectra	 (figure	 66).	 In	 the	 case	 of	 sensitive	 clone	 7	 (figure	 67),	 there	 was	 a	 clear	separation	 between	 control	 cells	 incubated	 in	 the	 absence	 of	 Nilotinib	 and	 those	incubated	 with	 50	 µM	 of	 Nilotinib.	 The	 results	 clearly	 indicated	 that	 S-FTIR	microspectroscopy	can	definitely	separate	between	cells	incubated	in	the	presence	or	absence	of	Nilotinib.		
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Figure	 65:	 Mean	 spectra	 of	 clone	 7	 (semi-sensitive/semi-resistant)	 cells	 in	 the	absence	 of	 Nilotinib	 (top	 spectrum)	 and	 in	 the	 presence	 of	 50	 µM	 of	 Nilotinib	(bottom	spectrum).	Spectra	are	offset	for	clarity.	 
	
Figure	66:	PCA	 of	 clone	 4	 (resistant	 to	 both	 50	 and	 100	 µM	 of	 Nilotinib)	 for	 cells	incubated	 with	 0	 µM	 Nilotinib	 (diamonds),	 50	 µM	 Nilotinib	 (squares),	 and	 100	 µM	Nilotinib	 (triangles)	 for	 fingerprint	 (A)	 and	 lipid	 (C)	 regions	 and	 loading	 plots,	respectively	(B	and	D).	
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	The	 results	 obtained	 showed	 that	 this	 technique	 can	 identify	 cells	 sensitive	 and/or	resistant	 cells	 to	 drugs	 which	 could	 be	 used	 in	 clinics	 for	 the	 management	 of	 the	leukaemia	and	help	clinicians	to	tailor	treatment	to	each	individual	patient.		Figure	 68	 shows	 comparison	 spectra	 of	 resistant	 clones	 versus	 sensitive	 clones.	Although,	there	are	not	many	remarkable	differences	between	resistant	and	sensitive	clone	spectra,	yet	some	band	changes	can	be	seen	such	as	increase	in	the	intensities	of	bands	at	2925	cm-1,	2850	cm-1	and	1740	cm-1	for	resistant	clones	as	compared	to	sensitive	 clones.	There	were	 also	 changes	 in	 shape	of	 the	peaks	 at	1400,	 1240	and	1080	cm-1.	A	lower	peak	at	1400	cm-1	is	seen	in	the	spectra	of	sensitive	clone.		
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Figure	67:	PCA	of	 clone	7	 (Sensitive	 to	 both	50	 µM	 and	100	 µM	of	Nilotinib)	 for	 cells	incubated	with	0	µM	Nilotinib	(diamonds),	50	µM	Nilotinib	(squares),	for	fingerprint	(A)	and	lipid	(C)	regions	and	loading	plots,	respectively	(B	and	D).	
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Figure	68:	Mean	spectra	of	resistant	clones	(resistant	to	both	50	µM	and	100	µM	of	Nilotinib)	for	cells	incubated	with	0	µM	Nilotinib	(top	spectrums	blue	and	red)	and	of	sensitive	clones	(sensitive	to	both	50	µM	and	100	µM	of	Nilotinib)	for	cells	incubated	with	0	µM	Nilotinib	(bottom	spectrums,	green	and	purple).		
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Figure	69:	PCA	of	 resistant	 clones	4	 and	2	 (resistant	 to	both	50	µM	and	100	µM	of	Nilotinib)	 for	 cells	 incubated	 with	 0	 µM	 Nilotinib	 (Triangle	 and	 Squares)	 and	 of	sensitive	clone	1	and	7	(sensitive	to	50	µM	of	Nilotinib)	for	cells	incubated	with	0	µM	Nilotinib	(crosses	and	diamonds)	for	fingerprint	(A),	and	lipid	(C)	regions,	and	loading	plots	(B	and	D),	respectively)	
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An	increase	in	the	intensities	for	resistant	clone	could	be	due	to	the	fact	that	resistant	clone	to	Nilotinib	have	higher	lipid	and	protein	in	their	cellular	matrix.			The	 PCA	 results	 of	 Nilotinib	 resistant	 clones	 versus	 Nilotinib	 sensitive	 clones	incubated	in	the	absence	of	Nilotinib	showed	clear	separation	between	resistant	and	sensitive	 clones	 in	 both	 fingerprint	 and	 lipid	 regions	 (Figure	 69).	 PC1	 versus	 PC2	loading	(Figure	69	B	and	D)	for	both	fingerprint	and	lipid	regions	also	showed	a	clear	separation.	These	results	could	 indicate	 that	S-FTIR	microspectroscopy	can	 identify	sensitive	 clones	 to	a	drug.	However,	 it	has	 to	be	acknowledged	 that	 the	differences	could	 just	 be	 due	 to	 the	 fact	 these	 are	 different	 clones.	 Further	 work	 is	 therefore	needed	to	assess	to	what	extent	S-FTIR	microspectroscopy	can	identify	sensitive	cells	to	drugs.			
6.9:	Discussion	Tyrosine	 kinase	 inhibitor	 Imatinib	 mesylate,	 in	 a	 randomized	 study,	 achieved	 a	complete	 cytogenetic	 response	 rate	 of	 84%	 in	 patients	with	 newly	 diagnosed	 CML	after	 42-month	 follow	 up	 [Guilhot	 2004].	 However,	 it	 has	 been	 reported	 that	 in	advanced	phase	of	CML,	 response	 to	 Imatinib	mesylate	may	be	 short	 lived	 [Druker	2001].	Mutations	in	the	BCR-ABL	gene,	clonal	evolution	and	amplification	of	BCR-ABL	gene	hindering	the	binding	of	the	drug	to	the	target	site	are	the	main	causes	behind	clinical	resistance	to	Imatinib	mesylate	[Gorre	2001;	Hochhaus	2002].	An	alternative	BCR-ABL	 kinase	 inhibitor	 Nilotinib	 was	 developed	 and	 is	 already	 in	 clinical	 use.	Nilotinib	has	shown	promising	results	in	patients	with	Imatinib	mesylate	resistance.	It	 is	 more	 potent	 than	 Imatinib	 mesylate	 in	 suppressing	 BCR-ABL	 tyrosine	 kinase	activity	 and	 cell	 growth	 of	 BCR-ABL	 transformed	 cells.	 Nilotinib	 is	 also	 capable	 of	
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suppressing	 Imatinib	 mesylate	 resistant	 cells	 and	 mutant	 forms	 of	 BCR-ABL	 [La	Rosee	2002;	Weisberg	2005].	It	has	been	suggested	that	Imatinib	and	Nilotinib	both	have	 different	 binding	 properties	 to	 the	 BCR-ABL	 kinase	 domain	 [Weisberg	 2005].	Therefore,	specific	resistance	profiles	for	different	kinase	inhibitors	can	be	expected	to	 emerge	 in	 treated	 patients.	 On	 this	 basis,	 it	 might	 be	 important	 to	 know	 these	resistant	 profiles	 upfront	 which	 would	 guide	 clinicians	 in	 decision	 making	 for	 the	management	of	leukemia.		One	of	the	major	problems	in	the	management	of	leukaemia	is	the	nonhomogeneous	characteristic	of	 the	cancer	cells.	For	any	cancer,	 some	cells	will	be	sensitive	 to	 the	drug	 and	 some	will	 present	 resistance	 to	 the	 drug	with	 all	 the	 variations	 between	these	 two	 possibilities.	 There	 are	 several	 techniques	 such	 as	 gene	 expression	profiling	[Chang	2003;	Robert	2004],	in	vitro	clonogenic	and	proliferation	assays,	cell	metabolic	activity	assays,	molecular	assays,	in	vivo	tumor	growth	and	survival	assays,	and	 in	 vivo	 imaging	 assays	 amongst	 other	 [Blumenthal	 2007;	 Cree	 2009]	 that	 are	used	to	assess	cell	sensitivity	to	drugs.	However,	tumour	cell	sensitivity	or	resistance	prior	to	treatment	is	not	being	checked	in	clinics	at	present.			Many	studies	have	shown	S-FTIR	microspectroscopy	as	a	powerful	and	potential	tool	to	screen	cancer	cells	to	chemotherapy	drugs	and	to	study	tumour	progression.	It	has	been	evaluated	as	a	possible	technique	for	cancer	diagnosis	and/or	for	the	detection	of	 chemical	 abnormalities	 in	 cells	 and	 body	 fluids	 [Neviliappa	 2002;	Wong	 2002].	This	 study	 has	 been	 focused	 on	 the	 biochemical	 information	 available	 in	 infrared	spectra	 to	 assess	 possible	 spectral	 changes	 in	 cells	 incubated	 in	 the	 presence	 or	absence	of	drugs	[Krishna 2006].		
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My	studies	have	shown	that	there	are	changes	in	the	spectra	of	cell	clones	following	the	addition	of	Imatinib	or	Nilotinib	(Figures	56,	57,	58,	64	and	65).	The	decrease	in	lipids’	absorption,	can	be	attributed	 to	 the	presence	of	apoptotic	cells	 following	 the	addition	of	the	drugs.	The	main	changes	are	an	increase	in	the	peak	at	1740	cm-1	and	a	decrease	in	the	intensity	in	the	region	from	1000	cm-1	to	1300	cm-1	and	changes	in	the	amide	I	and	II	peaks	for	cells	incubated	in	either	Imatinib	or	Nilotinib.	An	increase	in	the	intensity	of	the	peak	at	1740	cm-1	has	been	associated	with	spectral	markers	of	oxidative	stress	[Vileno	2010].	Furthermore,	the	increased	intensity	in	this	peak	has	been	reported	as	appearing	in	dying	cells	[Holman	2000].	Apoptotic	cells	are	known	to	have	a	 series	of	 changes	 in	phospholipid	 composition	and	structure	 [Hengartner	2000;	Ramesh	2002],	which	induces	changes	in	lipid	absorption	in	the	IR	spectra.	In	fact,	it	has	been	reported	in	in	vitro	studies	for	leukemia	cell	lines	that	an	increase	in	lipid	 absorption	 is	 present	 following	 incubation	 with	 cytotoxic	 drugs	 [Zelig	 2009].	Furthermore,	apoptosis	is	also	associated	with	increased	oxidative	damage	[Holman	2000].	In	our	study	cells,	the	peak	at	1740	cm-1	presents	as	a	small	shoulder	in	cells	incubated	 in	 the	 absence	 of	 Imatinib.	 However,	 once	 cells	 are	 incubated	 with	 the	drug,	 the	 peak	 becomes	 clearer	 even	 in	 resistant	 cells	 incubated	 with	 the	 drug.	Similar	 data	 are	 seen	 for	 sensitive	 cells	 incubated	 with	 Nilotinib.	 From	 previous	published	data	and	the	data	obtained	in	this	work,	it	could	be	hypothesized	that	this	peak	 could	 be	 a	 marker	 of	 cell	 death	 and/or	 help	 to	 identify	 in	 which	 stage(s)	 of	apoptosis	 cells	might	be	present	 following	 the	addition	of	 a	drug.	However,	 further	studies	are	needed	to	confirm	this.	
	
		
144	
The	bands	at	1080	cm-1	and	1240	cm-1	are	associated	with	nucleic	acids.	The	1240	cm-1	 band	 is	 due	 to	 asymmetric	 phosphate	 stretching	 and	 1080	 cm-1	 is	 due	 to	symmetric	 phosphate	 stretching	 of	 the	 nucleic	 acids	 [Wang	1997;	 Chiriboga	 1998].	The	changes	in	the	intensities	of	the	bands	at	this	region	indicate	changes	in	nuclear	morphology	and	architecture	[Ramesh	2002].	It	has	already	been	reported	that	multi	drug	 resistance	 is	 linked	 with	 nuclear	 morphological	 changes	 [Dufer	 1995;	
Mannechez 2005].	 Furthermore,	 changes	 in	 some	 of	 these	 bands	 were	 found	 in	apoptotic	 cells	 [Pocaly	 2008].	 The	 results	 of	 this	 study	 showing	 decrease	 in	 the	intensity	of	these	bands	indicate	that	the	incubation	of	cells	in	the	presence	of	either	Imatinib	or	Nilotinib	causes	alterations	in	nuclear	composition	that	can	be	translated	into	changes	in	the	cells’	S-FTIR	spectra.	
	
The	 third	main	 change	 observed	 in	 the	 study	 cells	 in	 the	 presence	 of	 drugs	was	 a	broadening	 of	 the	 amide	 I	 and	 II	 peaks,	 mainly	 in	 sensitive	 cells.	 However,	 slight	changes	in	these	peaks	could	also	be	seen	in	resistant	cells.	It	has	been	described	that	such	 changes	 might	 imply	 conformational	 changes	 in	 tissue	 proteins	 or	 the	expression	of	a	new	set	of	proteins	[Jackson	1998].	As	an	example,	the	presence	of	a	toxic	external	agent	such	as	drugs	can	initiate	a	stress	response	causing	expression	of	new	proteins	in	the	cell	to	protect	itself.	That	could	explain	in	part	why	the	proteome	of	the	sensitive	and	resistant	cells	differs	between	them	[Pocaly	2008].	
	There	 are	 numerous	 chemotherapy	 drugs	 and	 combinations	 of	 drugs	 used	 in	 the	management	 of	 cancer.	 However,	 it	 is	 not	 unusual	 for	 cancer	 cells	 to	 develop	
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resistance	 to	 these	 drugs.	 A	 better	 understanding	 of	 these	 processes	 would	 help	clinicians	 to	 tailor	 treatment	 to	 each	 individual	 patient.	 The	 results	 presented	here	not	only	confirm	previously	reported	data	but	also	further	indicate,	using	cell	cloning,	that	S-FTIR	microspectroscopy	could	help	to	better	 identify	resistant/sensitive	cells	to	 drugs.	 However,	 it	 is	 important	 to	 identify	 the	 biological	 processes	 leading	 to	specific	 spectral	 changes	 and	 cross-validate	 these	 data	 with	 already	 established	techniques.			
Conclusion		The	 results	of	 this	 study	have	 revealed	 that	 the	addition	of	 Imatinib	or	Nilotinib	 to	K562	 cell	 clones	 induces	 changes	 in	 cell	 biology	 and	 cellular	 structure	 which	translates	into	changes	in	the	S-FTIR	spectra	of	cells.	These	data	further	highlight	the	potential	 of	 S-FTIR	 microspectroscopy	 as	 a	 technique	 to	 assess	 cell	 sensitivity	 to	drugs	 which	 could	 have	 a	 clinical	 application	 in	 the	 management	 of	 leukemia.	However,	further	work	is	required	to	confirm	this.	
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Chapter 7     
 
Application of Raman Spectroscopy in the Management of 
Leukaemia 
 
Part of this chapter Published in Analyst: Effects of nilotinib on leukaemia cells using 
vibrational microspectroscopy and cell cloning 
M. R. Siddique, A. V. Rutter, K. Wehbe, G. Cinque, G. Bellisola and J. Sulé-Suso 
 
 
7.1: Introduction  
 
Raman spectroscopy is a well-established analytical method, which can provide valuable 
information about biological samples [De Gelder 2007; Movasaghi 2007]. It is viewed as a 
complementary technique to IR spectroscopy but shows remarkable advantages for many 
applications, especially biological [Byrne 2011]. The basics of Raman spectroscopy are 
inelastic scattering of photons by molecular bond vibrations. When a small portion of the 
incident photons is scattered by interaction with the bonds, it results in a shift toward lower 
frequencies. The energy difference between the incident and scattered photons corresponds 
to the vibrational energy of the specific molecular bond studied. Raman Spectroscopy has 
the ability to obtain rich biochemical information from single cells without staining or 
labelling the cells. Changes in cellular biochemistry as indicators of cell behaviour can be 
detected using Raman microspectroscopy. Raman scattering can be used in the UV, 
visible, or near infrared regions of the spectrum [Singh 2015]. A Raman spectrum taken 
from cells or tissues is a molecular fingerprint of the studied sample, which reveals 
detailed information on molecular constituents such as proteins (amino acids and 
conformational structures), nucleic acids (DNA and RNA) and lipids (cholesterol and CH2 
groups) [Pully 2011; Matthews 2011; Palonpon 2013; Pascut 2013]. This technique is not 
only fast but also has potential as novel, non-invasive and non-destructive diagnostic tool 
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for cancer detection [Huang 2003; Crow 2004; Min 2005] and identification of malignancy 
at various stages [Mahadevan-Jansen 1998; Clare 2006; Chen 2016]. Due to recent 
developments in Raman instrumentation that includes high quality lasers, CCD cameras 
and optical elements, mapping whole single cells can be done within minutes. Single cell 
analysis has great importance for biomedical, cell biology, and pharmacology research 
amongst other.   
 
A Raman spectrum provides information on molecular interactions within a cell that 
enables the study of metabolic changes involved in specific cell–drug interactions. Guo et 
al. (2009) reported Raman spectroscopy studies on the interaction of malignant 
hepatocytes with the antitumor drug doxorubicin, and their study established that 
doxorubicin affected the secondary structure and the environment of the proteins of the 
cells. H. Yao et al. (2009) studied the effects of the anticancer drug 5- fluorouracil on 
gastric carcinoma cells. Reduction in the intensity of vibrational bands generated by 
cellular lipids, proteins and nucleic acids as a result of apoptosis were observed [Yao 2009; 
Fu 2014]. Also, many groups have reported that it can successfully differentiate dead cells 
from live cells [Uzunbajakava 2003; Notingher 2007]. More important, Draux et al. 
(2009), were able to obtain not only Raman spectra of live cells but also to monitor the 
effects of sub toxic doses of a chemotherapy drug on single living cancer cells [Draux 
2011].  
 
However, there is an issue that has not been fully dealt in Raman spectroscopy of cells. All 
animal cells either freshly isolated or established cell lines are usually maintained in 
incubators with atmospheric oxygen levels, that is 21% and 5% CO2. However, in vivo 
conditions of cells are very different as levels of oxygen vary from 12% in arterial blood to 
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3-5% in tissues [Caldwell 2001]. Immune cell development and activation happens in 
primary, secondary or tertiary lymphoid organs with different infrastructure and oxygen 
supply [Caldwell 2001]. Since immune cells migrate between blood and various tissues 
during their development, they could be exposed to various levels of oxygen from high 
(normoxia) to very low (hypoxia) levels [Westermann 1999]. The oxygen level in 
peripheral blood is much lower than in air, and the smaller the arteries, the lower the 
oxygen level is. In in vitro conditions, growing cells are usually maintained in air 
supplemented with 5% CO2, which is several folds higher than in vivo conditions [de 
Souza 2007]. Therefore, most of the knowledge to date about white cell behaviour in vitro 
is taken from the experiments on the T cells at much higher oxygen level than in vivo [de 
Souza 2007]. It has been reported that the mean oxygen level experienced by T cells 
ranges from 1- 10% [Caldwell 2001; Atkuri 2007]. Several groups have reported that 
incubator oxygen levels can affect the cells in several ways such as modulating their 
metabolism, changes in gene expression [Haddad 2004; Chi 2006] and function of primary 
cells [Carswell 2000; Caldwell 2001; Atkuri 2005].  
 
There are recent advances in cell culture techniques including the use of improved media 
avoiding the addition of animal derived serum that might cause artefacts [Larbi 2010]. Yet, 
one very important and critical parameter being neglected over the decades is the level of 
oxygen to which cells are being exposed in vitro. Therefore, it is very important to 
understand cell culture systems that more closely relate to in vivo conditions, thus making 
the findings more relevant to understand truly physiological processes. Incubators 
equipped with atmospheric oxygen level of 21% clearly raises the questions of whether 
current cell culture conditions are appropriate for the cell functions to closely relate to in 
vivo situations. Already several groups have studied the effects of different incubators 
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environment upon cell proliferation [Krieger 1996], cytolysis [Caldwell 2001], and 
cytokine [Derevianko 1996; Caldwell 2001] and antibody production. However, the 
outcomes of these studies vary considerably, with no clear understanding on how and to 
what extent the behaviour of cells cultured at atmospheric oxygen mimics in vivo 
behaviour. To address this issue, clonal populations of leukaemia cell line K562 were 
obtained, and cultured in incubators at which the gas phase is set at atmospheric oxygen 
level of 21% or at lower oxygen levels of 10%. The influence of these oxygen conditions 
on the effects of drugs on cells was also assessed.  
 
The choice of the most effective chemotherapy drug for an individual patient and 
monitoring the efficacy of ongoing chemotherapy are important steps in the management 
of cancer. Thereby, an objective method able to assess tumour cell sensitivity/resistance to 
a given drug prior to giving the drug would be most welcomed. Early biochemical changes 
can be identified using Raman spectroscopy [Lyng 2007; Fu 2014]. In this work, Raman 
spectroscopy has been used to investigate changes in cells’ biochemistry prior to and after 
the addition of a drug and at different oxygen concentrations (10% and 21%). Control cells 
(cultured in the absence of a drug) were used to assess effects of oxygen concentration on 
cells’ biochemistry.  
 
To the best of my knowledge, no cancer studies using Raman spectroscopy have so far 
been done on the effect of different oxygen concentration on cells and their response to 
drugs.  
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7.2: Aims  I. To	 identify	 biochemical	 changes	 in	 cells	 grown	 in	 different	 oxygen	concentrations,	 and	 its	 impact	 on	 the	 effects	 of	 drugs	 on	 cells	 using	 Raman	microspectroscopy.		II. To	 better	 characterize	 spectral	 biomarkers	 of	 cell	 sensitivity/resistance	 to	drugs	for	leukaemia,	using	Raman	microspectroscopy		
7.3: Materials and Methods 
 
7.3.1: Cell line 
K562 cell line, a chronic myelogenous Leukaemia (CML) cell line was used in this study. 
Cells were cultured and maintained in suspension in RPMI 1640 with 10% Foetal Bovine 
Serum (FBS), 1% L-Glutamine (200 nM), 1% Hepes buffer (1 M) and 1% 
Antibiotic/Antimycotic (100x) and incubated at 37°C and 5% CO2. Medium was changed 
every 3-4 days.  
 
7.3.2: Cell survival 
Parental K562 cells were incubated in 24 well plates at 105 cells/well in the absence and 
presence of Nilotinib (10, 50 and 100 µM) for 5 days at both oxygen concentrations 10% 
and 21%. Cell survival was assessed using the Trypan blue exclusion method. 
 
7.3.3: Cell cloning 
As it has already been stated in section 2.1.2, in-vitro cell culture work is mostly conducted 
with mixed cell populations. In a mixed population, a mixture of sensitive and resistant 
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cells to a given drug will be present. In order to maintain a higher level of homogeneity 
across a cellular population, clonal culture methods were established (see Materials and 
Methods chapter 2). 
 
The K562 cell line was cultured under standard conditions as mentioned in chapter 2. 
Before reaching confluence, cells were collected, spun at 950 rpm for 3 minutes and 
counted with the trypan blue exclusion method. The detailed protocol for cell cloning has 
already been discussed in Materials and Methods. Once the clones were selected, they 
were divided into six wells in two separate 96 well plates. One plate was incubated at 
standard conditions (21% O2, 37 °C and 5% CO2), while the second one was incubated at 
10% O2, 37 °C and 5% CO2 for 24 hours for clones to adapt to the new culture conditions. 
 
7.3.4: Application of Drugs to clones 
Nilotinib was used in this study at two different concentrations, 50 µM and 100 µM. These 
two doses were chosen based on preliminary studies on clonal populations as described in 
Materials and Methods. Following 24 hours of incubation at 21% O2 or 10% O2, 37 °C and 
5% CO2, Nilotinib was added as follows. Plates were spun at 1200 rpm for 7 minutes. 
Following this, 100 µL of media were removed and 100 µL of fresh media with different 
final concentrations of Nilotinib was added (0 µM, 50 µM, or 100 µM). Following the 
addition of the drug, cells were allowed to grow for 5 days at 21% O2 and 10% O2, 37 °C or 
5% CO2. Five days were chosen based on preliminary studies on clonal populations as 
described in Materials and Methods.  
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7.3.5: Clone Selection 
Clones were selected for analysis as follows. Clones in which cells in control wells were 
completely confluent were discarded as this could modify their metabolical and 
proliferative properties. Clones were selected by visually observing the wells under the 
microscope and classed as sensitive where there were no cells or very low number of live 
cells in the well; as described in previous chapter 6 section 6.5 and table XI, resistant 
clones where cells were semi-confluent even at high concentration of the drug and semi-
resistant/semi-sensitive where the well was half full. Clones were selected based on their 
quality and choosing examples of sensitive clones (few live cells incubated with 50 µM 
Nilotinib but no cells incubated with 100 µM Nilotinib), resistant clones (good number of 
cells at both 50 µM and 100 µM incubation) and semi-resistant/semi-sensitive clones (few 
live cells at 100 nM incubation and good number of cells at 50 µM incubation). Each 
individually selected clone included cells incubated in the presence or absence of Nilotinib 
in either 21% or 10% O2 concentration.  
 
7.3.6: Sample Preparation  
UV graded CaF2 slides (26 x 22 x 0.5 mm) (Crystan Ltd, UK) windows were selected as 
substrate due to their suitability for Raman and S-FTIR spectroscopies. Following 
incubation in the presence or absence of the drug, selected clones were collected and spun 
in Eppendorfs at 950 rpm for 3 minutes. Supernatant was discarded and the cell pellet was 
dislodged and re-suspended in 0.9% NaCl. Cell suspension was then cytospun onto CaF2 
slides for 1 minute at 550 rpm through a cytofunnel and a filter card (Shandon, UK). Once 
cells have been deposited on CaF2 slides in a single monolayer, slides were placed in a 
Petri dish and fixed using 4% Paraformaldehyde (PFA) in 0.9% NaCl for 20 minutes as 
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previously described [Pijanka 2009], followed by 3 washes with 0.9% NaCl and 3 washes 
with distilled water and then air-dried at room temperature.  
 
7.3.7: Raman Spectroscopy 
Raman spectra were obtained by a Senterra Micro Raman laser class 1 (Bruker) 
spectroscope at Diamond Light Source, equipped with a 532-nm Laser. An Olympus 
microscope objective with 100x magnification was used to focus the incident laser light on 
the individual cells and backscattered Raman light was collected with a CCD 
thermoelectrically cooled detector in the range of 40-4450 cm-1, with the help of Opus 
(Bruker) software using Neon emission lamp for Raman as source.  Spectra were collected 
at 9-18 cm-1 resolutions with 2 co-added spectra with integration time of 10 second with 50 
µm pinhole type aperture by using spot size of 2F µm. The measurements were taken by 
pointing the laser at the nucleus of the cell. Five spectra of each cell were recorded. The 
laser was pointed at the nucleus especially as the drug I was using, interrupts the DNA 
synthesis and replication Spectra obtained from the nucleus of the cell would better 
describe the possible effect of the drug on the cells. Background spectra of the substrate 
were taken at the start of measurement. Spectra of at least 50 cells where possible were 
collected from each sample.  
 
7.3.8: Data Processing 
The spectrum was processed using Opus (Bruker). The data was cropped between 400-
1800 cm-1 and baseline corrected. Following baseline correction, data was normalized 
using SNV using The Unscrambler Software (VERSION X, Camo, Oslo, Norway). 
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PCA is generally known as a technique for presenting the variation in a multivariate data 
set. It is used as an effective approach to visualize and to mine information from data set 
with a large number of variables such as those contained in Raman spectra.  PCA was 
performed using The Unscrambler Software (VERSION X, Camo, Oslo, Norway). 
Loading plots were also produced using the same software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4: Results and Discussion 
Raman spectra of the study cells were obtained from 3 different areas within the cell and 
averaged. Figure 70 shows a representative example of few cells with the areas from where 
Figure	 70:	 Image	 of	 cytospun	 cells,	 depicting	 the	 labelled	 cells	 that	 Raman	measurement	had	been	taken	from.	
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the spectra were obtained and figure 71 shows a representative example of a Raman 
spectrum of a single K562 cell.  
 
Based on previous studies summarized in Table XII, Figure 71 shows the peaks present in 
K562 cell spectra and among them, observed peaks primarily show twisting doublet at 620 
and 640 cm-1 belonging to tyrosine/phenylalanine, while a doublet for the tyrosine ring 
breathing was observed at 829 and 852 cm-1 [Poon 2012]. The phenylalanine symmetric 
breathing mode peak was observed at 1003 cm-1 [Poon 2012]. Major intense peaks are 
1657 cm-1 (Protein, Amide I), 1613 cm-1 (Tyrosine, Tryptophan, Protein C=C), 1550 cm-1 
(Guanine, Tryptophan), 1448 cm-1 (protein, C-H2 deformation), and 1335 cm-1 (C-H3 
deformation of protein and lipids, nucleic acid) amongst other [Kneipp 2003; Short 2005; 
Chan 2006; Akyuz 2011; Byrne 2011; Poon 2012; Lyng 2015]. Previously it has been 
claimed that Nilotinib and Imatinib exhibit strong Raman peaks in the regions of 1300, 
1370 and 1600 cm-1 [Fu 2014], in my studies I did not observe any peaks at these regions 
in the spectra of the clones exposed to Nilotinib. 
 Preliminary	work	was	carried	out	to	assess	any	possible	differences	between	control	cells	(incubated	with	0	μM	Nilotinib)	incubated	at	21	or	10%	oxygen.	Figures	72	and	73	 show	 the	mean	 spectra	of	 50	 individual	 cells	 from	a	 resistant	 clone	 to	Nilotinib	and	a	sensitive	clone	to	100	μM	to	Nilotinib,	respectively.	The	spectra	of	the	resistant	control	cells	did	not	show	major	differences	 in	 the	spectra	regardless	whether	 they	had	 been	 incubated	 with	 21%	 or	 10	 %	 oxygen.	 However	 slight	 changes	 in	 the	intensities	 could	 be	 observed	 in	 the	 spectra	 in	 Figure	 72.	 These	 changes	 are	 slight	increase	 in	 the	 intensities	 of	 1243	 cm-1	 belonging	 to	 protein	 of	Amide	 III	 and	DNA	backbone	breathings,	1031	cm-1	for	C-N	stretch	of	proteins	and	phenylalanine,	1003	
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cm-1	 belonging	 to	 protein,	 and	 ring	 breathing	 mode	 of	 phenylalanine,	 and	 a	 slight	decrease	at	1092	cm-1	attributed	to	DNA/RNA	O-P-O	symmetric	stretch,	and	929	cm-1	belonging	 to	 proteins	 and	 lipids	 for	 the	 mean	 spectra	 of	 cells	 incubated	 at	 10%	oxygen	as	compared	to	the	mean	spectra	of	cells	incubated	at	21%	oxygen.	
 However,	 for	 the	 sensitive	 clone	 to	 100	 μM	 (figure	 73)	 there	 were	 significant	differences	 between	 the	 Raman	 spectra	 of	 cells	 incubated	 in	 21%	 or	 10%	O2.	 The	major	changes	were	shown	at	characteristic	nucleic	acid	bands.		
 
 
Figure	71:	Representative	example	of	a	Raman	spectrum	of	a	K562	cell	
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Table	XII:	List	of	frequencies	in	a	Raman	Spectrum	[Kneipp	2003;	Short	2005;	Chan	2006;	Akyuz	2011;	Byrne	2011;	Poon	2012]		
	
	
NO	
	
Raman	
frequency	units	
(cm-1)	
	
Assignment	
1	 620	 Protein	C-C	twist	
2	 640	 Protein	C-S	stretching	and	C-C	twist	of	tyrosine	
3	 668	 Guanine,	Thymine,	Tyrosine,	
4	 728	 Adenine,	Lipid	
5	 748	 Tryptophan,	Thymine	
6	 782	 Cytosine,	Uracil,	Thymine,	
7	 828	 O-P-O	asymmetric	stretch,	Tyrosine	
8	 852	 Tyrosine,	Lipid	
9	 929	 Protein,	Lipids	
10	 952	 Protein,	Lipids	
11	 1003	 Protein:	ring	breathing	Phenylalanine	
12	 1031	 Phenylalanine,	Protein	C-N	stretch	
13	 1092	 DNA/	RNA:	O-P-O	symmetric	stretch	
14	 1125	 Protein	C-N	stretch	
15	 1157	 Protein	C-C,	C-N	stretching	
16	 1174	 Tyrosine,	Phenylalanine,	Protein	C-H	bend	
17	 1209	 Adenine,	Thymine,	Protein	Amide	III	
18	 1243	 Adenine,	Thymine,	Protein	Amide	III	
19	 1306	 Protein	Amide	III,	lipid,	Nucleic	acids	
20	 1335	 C-H3	deformation	(Protein,	Lipid),	Nucleic	Acid	
21	 1448	 Protein	C-H2	deformation	
22	 1553	 Protein:	C=C	stretching,	Tryptophan	
23	 1575	 DNA/RNA:	ring	mode	(Guanine,	Adenine)	
24	 1616	 Tyrosine,	Tryptophan,	Protein	C=C	
25	 1660	 Protein	Amide	I	
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These	include	an	increase	in	the	prominent	bands	at	668,	728,	728,	782,	1092,	1243,	1335,	and	1575	cm-1	[Kneipp	2003;	Akyuz	2011;	Byrne	2011;	Poon	2012]	along	with	the	appearance	of	distinct	shoulders	at	1366	cm-1	and	1486	cm-1	also	attributed	to	the	nucleic	 acid,	 and	 significant	 decrease	 at	 the	 peak	 1448	 cm-1	belonging	 to	 protein	deformation,	in	the	spectra	of	the	cells	incubated	at	21%	O2	(Figure	73).	This	increase	in	nucleic	 acid	 bands	may	be	 the	 result	 of	 increased	proliferation	of	 the	 leukaemia	cells	 at	 21%	O2	[Byrne	 2011].	 This	would	 indicate	 increased	DNA	 concentration	 in	sensitive	cells	incubated	in	21%	O2.	While	it	could	be	hypothesised	that	the	growth	in	different	 O2	 concentrations	 could	 lead	 to	 different	 spectra	 between	 resistant	 and	sensitive	clones	to	Nilotinib,	it	has	to	be	recognised	these	are	2	different	clones.		
	
Figure	72:	Mean	spectra	of	50	cells	of	a	resistant	clone	control	cells	incubated	with	0	μM	Nilotinib	and	incubated	at	10%	(red)	and	21%	(green)	oxygen.	Spectra	are	offset	for	clarity.	
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Figure	73:	Mean	spectra	of	50	cells	of	a	sensitive	clone	to	100	μM	of	Nilotinib	control	cells	incubated	with	0	μM	Nilotinib	and	at	10%	(Red)	and	21%	(Blue)	oxygen.	Spectra	are	offset	for	clarity.	
Figure74:	Mean	spectra	of	50	 cells	of	 control	 from	sensitive	 clone	 cells	 (red)	vs	mean	spectra	of	resistant	clone	cells	(blue)	incubated	at	10%	O2.	Spectra	are	offset	for	clarity	Spectra	are	offset	for	clarity.	
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Figure	76:	PCA	and	Loading	of	 a	 resistant	 clone	 control	 cells	 incubated	with	0	µM	Nilotinib	at	21%	O2	(diamonds)	and	10%	O2	(squares),	and	of	a	sensitive	clone	to	100	
µM	Nilotinib	 control	 cells	 incubated	with	 0	µM	Nilotinib	 at	 21%	O2	 (triangles)	 and	10%	O2	(crosses).	
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Figure	75:	Mean	 spectra	 of	 50	 cells	 of	 control	 sensitive	 clone	 cells	 (Blue)	 vs	mean	spectra	 of	 resistant	 clone	 cells	 (Red)	 incubated	 at	 21%	 O2.	Spectra	 are	 offset	 for	clarity.	
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Therefore,	 the	 data	 presented	 here	 indicates	 that	 oxygen	 concentration	 in	 culture	conditions	could	definitely	affect	the	Raman	spectra	of	some	leukaemia	cell	clones.	
 
Figures 74 and 75 are representative examples of the comparison between resistant clone 
cells versus sensitive clone cells incubated at both O2 levels (10% and 21%). Interestingly, 
there were no any major variations between the spectra of cells incubated at 10% O2 but 
only a slight decrease in the protein concentrations but an increase in DNA content in 
resistant clone shown by a decrease in the intensity of 1616 cm-1 peak, and an increase in 
the peaks at 1243 cm-1 and 1335 cm-1 (Figure 74). However, when comparing spectra of 
both clones’ cells incubated at 21% O2 (Figure 75), there are major changes in the 
intensities and frequencies of the peaks. These data suggest that oxygen levels do make a 
difference in the biology of cells which can be measured with Raman microspectroscopy. 
As it can be seen in Figure 75, there is a decrease in the intensity of the peaks attributed to 
nucleic acid (e.g. 1575 cm-1, 1366 cm-1, 1335 cm-1, and 782 cm-1), while there is an 
increase in 1616 cm-1 for the resistant clone, Further work is needed to better understand 
how culture conditions mimic in vivo conditions. 
 
The spectral data was analysed with PCA. As can be seen in figure 76, there was a small 
separation between cells incubated with 21% O2 and 10% O2 for the resistant clone as it 
would be expected from the spectra presented in figure 72, which did not show major 
differences. However, for the sensitive clone, there was a clear separation between cells 
incubated in 21% O2 and 10% O2. Furthermore, there was a trend in the PCA to separate 
between clones incubated in 21% O2 and 10% O2. These data stresses the importance of 
taking into account that changing cell culture conditions to those that best mimic the real 
physiological situation could also translate into changes in their Raman spectra. It also 
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stresses the need to understand in drug related studies that even within a cell line, there 
will be different clonal cells which could present different spectral characteristics not 
related to the effects of a given drug.  
 
PC1 verses PC2 loading plots for both groups shown in Figure 76 highlight the peaks that 
are important in the separation. It is clear from the loadings that the main differences reside 
at DNA signals and protein concentrations, confirming the data observed in the spectra 
(Figure 72 and 73).   
 
Loading curves indicate which variables account for the differences among the groups. 
PC1 versus PC2 loading plots for both groups shown in figure 76B highlights the peaks 
that are important in the separation. The main differences are at DNA signal (e.g. 725, 783, 
853, 1090, 1306, and 1335 cm-1) (Chan 2006; Short 2005; Akyuz 2011], as appeared in the 
spectra.  
 
So, it could be concluded that DNA could be the main difference between normal K562 
cells and the cells exposed to the Nilotinib for both groups. As we have observed that there 
is a remarkable decrease in the DNA content of the cells exposed to the Nilotinib.  
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Figure	77:	Mean	spectra	of	resistant	clone	incubated	at	21%	O2	with	Nilotinib	0	μM	(blue),	50	μM	(red),	and	100	μM	(green).	Spectra	are	offset	for	clarity.	
Figure	78:	Mean	spectra	of	resistant	clone	incubated	at	10%	O2	with	Nilotinib	0	μM	(blue),	50	μM	(red),	and	100	μM	(green).	Spectra	are	offset	for	clarity.	
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
400500600700800900100011001200130014001500160017001800
Wavenumbercm-1
In
te
ns
it
y	
(a
.u
.)
15
53
	
11
25
95
2
78
2
10
92
16
16
	
0
1
2
3
4
5
6
400500600700800900100011001200130014001500160017001800
Wavenumbercm-1
In
te
ns
it
y	
(a
.u
.)
15
53
	
66
8
11
25
95
2
78
2
72
8
16
16
		
164	
 
The next step was to obtain Raman spectra of clone cells in the presence and absence of Nilotinib	 but incubated at either 21% or 10% O2. Figures 77, 78, 79, and 81, show the 
Raman spectra of a resistant and a sensitive clone to 100 µM Nilotinib	 in the presence and 
absence of Nilotinib	 and in 2 different O2 concentrations. This study focused on distinct 
peaks that exhibit the major differences between the spectra of the cells incubated at 
different doses of Nilotinib	at both concentration of oxygen, 10% and 21%.  
 
Generally, most features of the Raman spectra from controls and cells incubated in the 
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Figure	79:	PCA	and	loading	of	a	resistant	clone	cells	incubated	at	21%	O2	(A	and	B)	and	cells	incubated	at	10%	O2	(C	and	D)	with	0	μM	(diamonds),	50	μM	(squares)	and	100	μM	(triangles)	doses	of	Nilotinib.	
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presence of Nilotinib	 for both clones are very similar, but there are some spectral changes 
in cells incubated with the drug. The data show that the biochemical changes in the spectra 
are both dose and oxygen concentration dependent.   
 
In cells incubated in 21% O2, drug exposure translated into an increase in the intensity of 
peaks 1616 cm-1, 1553 cm-1, 1125 cm-1, and 952 cm-1 for the resistant clone, and of peak 
1125 cm-1 and 748 cm-1 for the sensitive clone (figure 80) at 100 µM Nilotinib.  On the 
other hand, there was a decrease in the intensity of peaks 782 cm-1 and 1092 cm-1 for the 
resistant clone and of peaks 1575 cm-1, 1335 cm-1 and 782 cm-1 for the sensitive clone.  
 
In the case of cells incubated in the presence of 10% O2, there was an increase in intensity 
of the peaks at 1616 cm-1, 1550 cm-1, 1125 cm-1, and 952 cm-1 for the resistant clone 
(figure 78) and of peak 1335 cm-1 for the sensitive clone (figure 81). On the other hand, 
there was a remarkable decrease in the intensity of peak 782 cm-1, 728 cm-1, and 668 cm-1 
for the resistant clone and for peak 1448 cm-1, 1306 cm-1, 728 cm-1, and 668 cm-1 for the 
sensitive clone. Taken together, these results indicated that the O2 concentration will affect 
the Raman spectra of cells in the presence or absence of Nilotinib. On the other hand, O2 
concentration does not seem to affect the effects on certain peaks caused by Nilotinib. For 
the resistant clone, the peaks at 1550 cm-1 and 1616 cm-1 increase in the presence of Nilotinib	 and the peak at 782 cm-1 decreases in the presence of Nilotinib	 regardless of O2 
concentration. For the sensitive clone, there was no clear pattern with different changes 
occurring at different O2 concentrations. 
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Figure	80:	Mean	spectra	of	a	clone	sensitive	to	100	μM	Nilotinib	incubated	at	21%	O2	with	Nilotinib	0	μM	(blue)	and	50	μM	(red).	Spectra	are	offset	for	clarity.	
	
Figure	81:	Mean	spectra	of	a	clone	sensitive	to	100	μM	Nilotinib	incubated	at	10%	O2	with	Nilotinib	0	μM	(blue)	and	50	μM	(red).	Spectra	are	offset	for	clarity.	
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It is immediately clear that there is significant heterogeneity in the Raman spectra within 
each dose of drug exposure, reflecting the variability in cellular response due to the nature 
of biochemical reactions inside the cell or drug sensitivity [Niepel 2009].  
 
In general, the major changes in the Raman spectra for both clones at both oxygen 
concentrations can be attributed to a decrease of DNA signal (e.g. 668, 728, 782, 1092, 
1306, 1335 and 1575 cm-1) [Short 2005; Chan 2006; Akyuz 2011]. Interestingly a decrease 
of DNA signal at band 668 cm-1 appears in both clones but only in the spectra of the 
Figure	82:	PCA	and	Loading	of	a	clone	sensitive	to	100	μM	Nilotinib	incubated	at	21%	O2	(A	and	B)	and	cells	incubated	at	10%	O2	(C	and	D)	with	0	μM	(diamonds)	and	50	μM	(squares)	of	Nilotinib.		
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second group (10% O2). There is a decrease for 782 cm-1 peak with the addition of the 
drug in the sensitive clone incubated in 10% O2 but not when incubated in 21% O2. There 
is an increase of lipid intensity (e.g. 952 cm-1), in the resistant clone incubated at both O2 
concentrations but not in the sensitive clone.  
 
Lyng et al. (2007) reported that increased nucleic acid and protein bands are a result of the 
increased proliferation of the cancerous cells [Lyng 2007]. Thus, it could be hypothesised 
that decrease in the intensity of DNA specific peaks and increase in intensity of protein 
specific peaks in the spectrum of both groups suggests late phases of apoptosis or may be 
dead cells, as nuclear fragments are expelled from the cell leaving an empty shell of cell 
membrane and cytoplasm [Lavie 1999]. However, an increase in the intensity of DNA 
specific bands can also be associated with chromatin condensation and nuclear 
fragmentation during the apoptosis process [George 1996; Johnson 2000; Sokolovskaya 
2001]. An increase in DNA density due to chromatin condensation would lead to an 
increase in the DNA peak intensities in the Raman spectra. The increase of intensity in the 
lipid related peak at 952 cm-1 could be attributed to the presence of intracellular vesicles. 
This observation is consistent with the formation of lipid vesicles at the cell surface 
[Ferraro-Peyret 2002] that is known to occur during early stages of apoptosis of leukemic 
T-lymphocytes cells when exposed to anticancer drugs (e.g. doxorubicin) [Gamen 2000; 
Dartsch 2002]. Zoladek A et al. (2010) reported spectral changes in lipid and DNA bands 
consistent with the appearance of lipid vesicles at early stages of apoptosis and DNA 
condensation. Changes in DNA and protein associated peaks of the cells exposed to drug 
have also been observed by other groups [Owen 2006; Buckmaster 2009; Yao 2009].  
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PCA was carried out to assess possible differences between cells incubated in the presence 
or absence of Nilotinib	 and different O2 concentrations. The grouping of the samples into 
three clusters according to cells incubated in either of the 3 doses of Nilotinib	 indicates 
that differences between the Raman spectra can be revealed easily by PCA (Figures 79, 
and 82). The loadings curves reveal the scores plot of the second principal component 
(PC2) versus the first principal component (PC1) and which variables account for the 
differences among the groups. PC1 verses PC2 loading plots for both groups shown in 
figure 80B, 80D, 83B, and 83D, highlight the peaks that are important in the separation. 
So, it could be concluded that DNA could be one of the main differences between K562 
cells exposed to different doses of Nilotinib for both groups.  
 
7.4: Conclusion 
Overall, the differences I observed in both groups incubated in different oxygen levels 
pose a key challenge to investigators using these types of assays. Somehow, it has been 
assumed in some cases that results obtained when cells are cultured at atmospheric oxygen 
levels might mimic in vivo behaviour. This theory appears reasonably secure, as a lot of 
the data obtained through conventional culture systems is compatible with in vivo findings. 
But with the advanced knowledge of signalling pathways and other molecular mechanisms 
of cells’ development and function, it is necessary to use culture systems that more closely 
approximate in vivo conditions. Conventional in vitro cell culture is performed at ambient 
oxygen concentration. Lukashev 2006, reported that under changing oxygen 
concentrations, the HIF-1α pathway shows considerably different effects on the post-
translational modification of proteins and it can also influence a broad range of pathways 
by acting at the transcriptional level [Lukashev 2006]. The exact oxygen level in vivo is 
unknown yet, although recent improvements in technology, have allowed its measurement 
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ex vivo [Zhdanov 2008]. Although it was reported that the extracellular environment of 
cells rapidly equilibrated to the ambient oxygen level [Newby 2005], it would be 
appropriate to take oxygen level into account for in vitro work. 
 
Raman spectroscopy is shown to be a powerful technique for the investigation of drug-
induced alterations in cells. The most effective application of Raman spectroscopy in the 
field of oncology could be in the area of therapeutic management. Due to the complexity 
of tumours, histopathology is not able to predict tumour/ cancer’s therapeutic response or 
recurrence and the associated biochemical processes in-vivo. It can be hypothesized, that 
Raman spectroscopy could provide information on the mechanical and biochemical 
structure of cells and be able to identify changes in cells due to different levels of oxygen 
and the effects of drugs at different oxygen concentrations. I propose that careful, in vitro 
studies as close as possible to the in vivo environment will be necessary to determine the 
efficacy of the Raman approach for drug response assessment. Data from Raman 
spectroscopy along with PCA has improved the reliability and the accuracy of Raman 
spectra interpretation and classification. Importantly, this proposed approach provides a 
useful tool to assess cell behaviour in different physiological conditions. 
 
The results obtained in this work show there are changes in DNA concentration in the 
spectra of cells exposed to Nilotinib	 such as a decrease in the peak at 782 cm-1 and as one 
of the main mechanism for the induction of cell apoptosis. Decreased DNA content would 
suggest cells to be in the late apoptosis stage. Nuclear condensation occurs in early stages 
of the apoptosis process as chromatin compacts (pyknosis) being a hallmark process of 
apoptosis. However, this process is short-termed as during fragmentation DNA is cleaved 
into very short fragments that cause reduction in the intensity of DNA peaks [Yaho 2009].  
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It has been shown in this study that there are remarkable differences in the biochemical 
composition of cells incubated at different oxygen concentrations. Further studies are 
needed to confirm these difference and changes in the spectra that could be linked to 
mechanisms behind these changes.  
 
The future of Raman microspectroscopy in treatment response assessment is exciting. With 
recent and promising technological developments, cancer patients might one day benefit 
from the capability of this technology to predict tumour response to drugs. 
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Chapter	8		
Discussion	and	Future	Work		Early	detection	of	leukaemia	is	critical	for	a	successful	treatment	and	in	the	reduction	of	 morbidity	 and	 mortality.	 In	 the	 last	 few	 years,	 significant	 technological	developments	 have	 taken	 place	 that	 could	 be	 exploited	 for	 the	 detection	 and	management	 of	 the	 disease.	 However,	 the	 real	 challenge	 is	 to	 enhance	 these	technologies	 further	 to	 enable	 the	 early	 detection	 of	 the	 cancer	 and	 monitor	 its	progression	and	therapeutic	response.	Several	studies	have	determined	the	problems	and	complexities	along	with	the	risk	level	involved	in	the	diagnosis	and	management	of	leukaemia	for	each	individual	patient.	Due	to	the	complexities	of	disease	diagnosis,	high	 costs,	 its	 prognosis	 and	 management,	 there	 is	 a	 great	 prerequisite	 for	 the	development	of	new	ways	and	approaches	which	would	be	 safe,	non	 invasive,	 low-cost	 and	 could	 detect	 cancer	 at	 early	 stages.	 This	 would	 lead	 to	 better	 patient	management	and	improve	survival.	The	aim	of	this	thesis	was	to	use	3	techniques,	(SIFT-MS,	S-FTIR	Spectroscopy,	and	Raman	Spectroscopy)	to	address	some	of	the	practical	 issues	associated	with	their	potential	clinical	application,	which	should	lead	towards	better	management	of	leukaemia.			The	 first	 experimental	 chapter	 (Chapter	 3)	 is	 focused	 on	 the	 use	 of	 SIFT-MS	 to	quantify	 the	 VOCs	 released	 by	 leukaemia	 cells	 compared	 to	 PBMC	 and	 bone	marrow	cells.	As	a	novel	technique,	SIFT-MS	offers	non-destructive	and	real-time	analysis	 of	 VOCs	 released	 through	 breath.	 SIFT-MS,	 used	 in	 this	 work,	 detects	accurately	 and	 in	 real	 time	 several	 compounds	 simultaneously	 down	 to	concentrations	of	parts-per-billion	by	volume	 (ppbv).	More	 importantly,	 it	 obviates	
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sample	 preparation,	 thus	 speeding	 the	 process	 to	 obtain	 data	 when	 compared	 to	other	instruments	where	sample	processing	is	a	crucial	step.	SIFT-MS	could	be	used	to	 identify	 VOCs	 profiles	 that	 could	 differentiate	 leukaemia	 cells	 from	 healthy	cells.		One	 possible	 VOC	 identified	 for	 cancer	 diagnosis	 is	 acetaldehyde.	 It	 has	 been	shown	 to	 be	 released	 by	 lung	 cancer	 cells	 both	 in	 2D	 and	 3D	 cell	 culture	conditions	 and	 its	 concentration	 to	 correlate	 with	 cancer	 cell	 number	 [Smith	2003;	 Sulé-Suso	 2009].	 In	 the	 study	 presented	 here,	 the	 levels	 of	 acetaldehyde	released	by	both	leukaemia	cell	lines	and	PBMC	were	similar	to	the	acetaldehyde	released	 by	 culture	 medium.	 However,	 it	 is	 important	 to	 understand	 the	metabolical	pathways	of	the	different	VOCs	and	whether	and	how	modifying	them	could	lead	to	improving	the	management	of	cancer.	As	an	example,	the	inhibition	of	ALDH	with	disulfiram	translated	into	an	increase	of	the	levels	of	acetaldehyde	in	 the	 headspace	 of	 Jurkat	 and	 K562	 cells	 but	 not	 in	 the	 headspace	 of	 PBMC	(Chapter	 3).	 This	 shows	 that	 modifying	 VOCs	 metabolism	 could	 lead	 to	 a	differential	in	the	concentration	of	VOCs	which	could	have	clinical	application.		
	Another	important	point	is	to	understand	the	origin	of	the	cancer	cells	and	whether	VOCs	 could	be	used	 to	better	 identify	 the	different	 steps	 of	 cancer	progression.	On	this	basis,	the	VOCs	of	bone	marrow	cells	were	also	studied.	The	results	showed	that	the	VOCs	profile	of	leukaemia	cells	and	bone	marrow	cells	could	be	easily	separated.			The	work	presented	 in	Chapter	3	sets	up	 the	basis	 to	 further	develop	SIFT-MS	as	a	potential	technique	in	the	diagnosis	of	leukaemia.	The	data	obtained	is	now	part	of	a	
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manuscript	 in	 preparation.	 However,	 it	 is	 obvious	 that	 further	 work	 is	 needed	 to	assess	 the	 potential	 of	 SIFT-MS	 in	 the	 management	 of	 leukaemia,	 and	 more	important,	to	better	understand	the	metabolical	pathways	behind	the	release	of	VOCs	by	both	leukaemia	cells	and	blood	cells.		Chapter	3	also	set	up	the	basis	for	Chapter	4.	In	the	former,	work	was	carried	out	to	develop	the	experimental	set	up	for	VOCs	analysis.	This	was	then	used	to	study	the	effects	of	drugs	on	leukaemia	cells	as	described	in	Chapter	4.		The	first	aim	of	the	study	in	Chapter	4	was	to	find	out	whether	VOCs’	analysis	could	have	 a	 role	 to	 assess	 the	 therapeutic	 response	 of	 leukaemia	 to	 drugs.	 For	 this	purpose,	 Jurkat	 and	 K562	 leukaemia	 cells	 were	 exposed	 to	 either	 Imatinib	 or	Nilotinib	and	the	release	of	VOCs	was	measured	using	SIFT-MS	prior	to	and	after	the	 addition	of	 the	drugs.	As	 in	 the	previous	 chapter,	 the	 levels	 of	 acetaldehyde	were	measured	both	in	cells	cultured	in	the	absence	or	 in	the	presence	of	either	drug.	 The	 results	 indicated	 that	 the	 release	of	VOCs	 from	different	 cell	 lines	 varies	following	the	addition	of	drugs.	 In	 fact,	 the	 levels	of	acetaldehyde	released	by	K562	cell	 line	 increased	 following	 the	 addition	 of	 either	 Imatinib	 or	 Nilotinib	 while	 the	levels	 of	 acetaldehyde	 remained	 similar	 for	 the	 Jurkat	 cell	 line.	 Therefore,	 it	 is	obvious	 that	 the	application	of	breath	analysis	 in	 the	management	of	cancer	should	not	limit	itself	to	studying	one	or	a	few	VOCs,	but	rather	a	whole	profile	of	VOCs.	SIFT-MS	has	the	possibility	of	analysing	several	VOCs	at	the	same	time	using	the	full	scan	mode.	Therefore,	the	VOCs	profile	of	leukaemia	cells	prior	to	and	after	the	addition	of	either	 imatinib	or	Nilotinib	were	 studied	 in	order	 to	assess	whether	 they	 could	be	used	as	biomarkers	 for	 therapeutic	 response	of	 leukaemia.	PCA	of	 full	 scan	data	
		
175	
was	able	to	separate	both	cell	lines	but	more	importantly,	it	showed	a	difference	between	control	cells	and	cells	exposed	to	drugs	at	different	drug	concentrations.	These	data	 show	promise	as	 a	 tool	 to	 assess	 tumour	 response	 to	 treatment	 in	 a	non-invasive	way.			It	 is,	 however,	 important	 to	 recognise	 that	while	 the	 in	vitro	studies	 can	 help	 to	assess	the	potential	of	a	new	technique	in	clinical	practice	and	are	a	necessary	step	in	this	process,	the	results	obtained	in	a	clinical	set	up	might	not	be	so	straightforward.	Several	aspects	need	to	be	 taken	 into	account,	one	of	 them	being	sample	collection.	The	 way	 samples	 are	 collected	 and	 stored	 could	 affect	 the	 final	 results	 and	 its	potential	clinical	application.		The	work	in	Chapter	5	was	carried	out	with	this	in	mind	so	a	better	understanding	of	sample	collection	for	SIFT-MS	analysis	could	be	achieved.	This	chapter	complements	the	 previous	 findings	 towards	 the	 translation	 of	 this	 novel	 technique	 (SIFT-MS)	into	clinics.	At	 the	same	time,	 the	data	presented	 in	 this	chapter	 is	 the	 first	step	towards	in	vivo	breath	analysis.	The	chapter	was	aimed	at	establishing	a	suitable	methodology	for	the	acquisition	of	breath	samples	from	leukaemia	patients.	This	study	was	 also	 aimed	 at	 assessing	 the	 loss	 of	 VOCs	 during	 sample	 storage	 over	time.		In	 this	 chapter	 three	 different	 sampling	 methods	 direct,	 Nalophan	 bags	 and	 Glass	bottles	were	studied.	We	found	that	establishing	a	suitable	sampling	method	was	a	real	 challenge	 with	 each	 sampling	 method	 having	 its	 own	 advantages	 and	disadvantages.		
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The	presence	of	humidity	in	the	samples	is	crucial	as	it	will	affect	the	concentration	of	VOCs	 measured.	 Higher	 levels	 of	 humidity	 in	 the	 exhaled	 breath	 cause	 significant	decrease	in	concentration	for	those	VOCs	that	are	highly	soluble	in	water	[Mochalski	2013].	The	work	presented	in	this	chapter	indicated	that	loss	of	humidity	takes	place	even	within	one	hour	of	breath	acquisition	in	case	of	bags.	However,	the	humidity	of	breath	collected	 in	bottles	did	not	 change	markedly	up	 to	24	hours	storage.	On	 the	other	hand,	 it	has	 to	be	taken	 into	account	 that	depending	upon	the	material	of	 the	bag,	water	vapours	may	diffuse	in	different	proportions	[Gilchrist	2012].	Background	contamination	 and	 diffusion	 are	 the	 main	 problems	 of	 bags.	 Another	 factor	 that	affects	VOCs’	concentration	is	temperature.	As	the	temperature	of	the	breath	sample	falls	down	below	the	body	temperature	(37	°C),	water	vapour	may	condense	on	the	walls	of	the	sample	container,	which	could	result	in	lower	concentration	of	the	more	water	soluble	VOCS.	Therefore,	keeping	the	sample	at	37	°C	 is	an	 important	step	to	avoid	the	risk	of	losing	water-soluble	VOCs.				One	 way	 to	 avoid	 this	 issue	 is	 through	 direct	 sampling.	 While	 this	 is	 the	 most	convenient	method	to	obtain	breath	samples,	it	also	has	its	problems.	Some	patients,	specially	the	elderly,	might	find	difficult	to	breathe	directly	into	the	instrument	due	to	the	flow	resistance	inherent	to	the	instrument.	Also,	not	every	patient	will	be	able	or	exhale	for	a	prolonged	period	of	time.			The	data	presented	in	this	chapter	indicated	that	collecting	breath	in	either	bottles	of	bags	allowed	for	a	better	identification	of	VOCs,	especially	those	present	in	very	low	concentrations.	Furthermore,	this	allows	the	storage	and	transport	of	breath	samples,	
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an	 important	 point	 when	 carrying	 out	 studies	 involving	 different	 centres	 some	 of	which	might	not	be	able	to	have	the	SIFT-MS	instrument.			If	bottles	or	bags	are	to	be	used	in	breath	analysis,	the	next	step	is	to	assess	how	many	 exhalations	 are	 needed	 to	 get	 a	 reproducible	 sample.	 A	 single	 exhalation	may	not	necessarily	be	representative	of	the	alveolar	air	[Herbig	2008;	O’Hara	2008;	Filipiak	2012].	Multiple	breaths	are	therefore	preferable	to	reduce	this	risk.	The	work	presented	 in	 this	 chapter	 indicated	 that	 there	are	no	major	differences	 in	 the	VOCs	measured	between	3	or	5	exhalations.			There	are	other	aspects	of	 sampling	which	are	of	great	debate	among	 the	scientific	community	and	should	be	taken	into	account	when	running	large	multicentre	studies.	These	include	body	posture	of	the	subject	during	sampling,	hyperventilation,	control	of	 the	 flow	or	 volume	of	 the	 breath	during	 collection,	 sampling	 via	 nose	 or	mouth,	number	of	breaths	exhaled,	respiratory	rate,	and	heart	beat	amongst	other	[Gilchrist	2012].	Furthermore,	different	body	compartments	produce	a	large	variety	of	VOCs,	a	considerable	 part	 of	 which	 is	 found	 in	 the	 breath.	 Therefore,	 different	 diseases	 in	patients	 could	 affect	 the	VOCs	 released	 in	 breath.	 This	 is	 important	when	 studying	VOCs	 from	patients	with	 cancer	 as	 other	metabolical	 processes	 and	 diseases	 could	produce	confounding	factors.	All	these	factors	will	need	to	be	taken	into	account	if	this	technique	is	to	be	taken	into	clinical	practice.		Future	 work	 will	 need	 to	 refine	 the	 sampling	 methods,	 including	 finding	 some	other	 material	 that	 could	 hold	 the	 VOCs	 for	 long	 periods	 during	 storage	minimising	 the	 loss	 of	 trace	 gases.	 Storage	 temperature	 of	 the	 sample	 is	 also	
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another	major	point	to	be	considered,	as	reducing	the	temperature	of	the	samples	below	 -80°C,	 for	 example,	 would	 slow	 down	 the	 loss	 of	 VOCs.	 Further	 work	 is	needed	to	assess	whether	this	could	potentially	decrease	the	overall	loss	of	VOCs	from	 the	 samples	but	how	 it	might	 affect	 the	measurement	of	VOCs	by	 SIFT-MS	when	returning	the	sample	to	37	°C.			In	 Chapter	 6,	 S-FTIR	 microspectroscopy	 as	 a	 tool	 to	 study	 the	 spectral	 changes	induced	 by	 drugs	 on	 clonal	 populations	 of	 leukaemia	 was	 used.	 The	 aim	 of	 the	chapter	 was	 to	 characterize	 spectral	 biomarkers	 of	 leukaemia	 cells	sensitivity/resistance	 to	 drugs.	 Whole	 cancer	 populations	 are	 composed	 of	 a	combination	 of	 different	 cells	 sensitive	 and	 resistant	 to	 drugs	 and	 all	 the	 variation	between	 them.	 Most	 studies	 aimed	 at	 characterising	 spectral	 markers	 of	sensitivity/resistance	 to	drugs	have	used	whole	 cancer	 cell	populations.	This	might	make	 it	 more	 difficult	 to	 fully	 characterise	 these	 markers.	 This	 problem	 was	approached	 in	 this	 chapter	 by	 obtaining	 cell	 clones	 and	 identifying	 those	 clones	sensitive	to	a	drug,	those	clones	resistant	to	the	same	drug	and	those	clones	that	were	resistant	to	lower	doses	of	the	drug	but	sensitive	to	higher	doses	of	the	same	drug.		Another	 problem	 on	 the	 study	 of	 the	 effects	 of	 drugs	 on	 cells	 using	 FTIR	microspectroscopy	is	the	fact	that	drugs	cause	not	only	biochemical	changes	but	also	morphological	changes.	Therefore,	spectral	biochemical	changes	have	to	be	identified	separately	from	the	morphologically	 induced	spectral	changes.	The	ideal	alternative	in	this	work	was	to	obtain	S-FTIR	spectra	of	sensitive	and	resistant	cells	to	Imatinib	or	 Nilotinib	 prior	 to	 adding	 the	 drug	 so	 neither	 biochemical	 nor	 morphological	changes	caused	by	the	drug	itself	interfere	with	their	S-FTIR	spectra.		
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The	data	presented	in	Chapter	6	showed	clear	FTIR	spectral	changes	in	sensitive	cells	exposed	to	a	drug	when	compared	to	the	same	clonal	cells	in	the	absence	of	the	drug.	More	 important,	 those	clones	 resistant	 to	 the	higher	concentration	of	 the	drug	also	presented	 the	 same	 spectral	 changes	 albeit	 to	 a	 lower	 level.	 This	 is	 an	 important	finding	as	it	shows	that	the	spectra	of	sensitive	cells	are	obtained	from	those	cells	that	have	suffered	damage	by	the	drug	but	they	were	still	alive	(repairing	the	damage	or	not)	when	they	were	collected	for	S-FTIR	analysis.	More	important,	the	data	indicates	that	even	in	resistant	clones,	some	cells	will	have	suffered	this	damage	and	probably	trying	to	repair	it	when	they	were	collected	for	S-FTIR	analysis.		The	second	aim	of	this	chapter	was	to	assess	whether	S-FTIR	microspectroscopy	can	identify	resistant	and	sensitive	cells	prior	to	drug	exposure.	In	the	present	study,	no	major	 spectral	 differences	 between	 resistant	 and	 sensitive	 clones	 prior	 to	 the	addition	of	the	drug	were	seen.	PCA	might	have	shown	some	separation	but	it	has	to	be	taken	into	account	that	these	were	different	clones.	Therefore,	it	is	not	possible	to	say	how	much	a	difference	is	due	to	the	fact	that	these	are	different	clones	and/or	to	some	of	 them	being	 sensitive	 to	 a	 drug	while	 others	 are	 resistant.	 Further	work	 is	needed	to	better	understand	where	exactly	these	differences	lie.			The	 results	 of	 the	 present	 study	 have	 revealed	 that	 s-FTIR	microspectroscopy	 has	great	potential	 to	be	used	as	an	analytical	method	 to	assess	 tumor	cell	 response	 to	treatment.	 There	 are	 different	 mechanisms	 that	 cause	 resistance	 in	 cancer	 cells.	Therefore,	 comprehensive	 studies	 should	 be	 carried	 out	 to	 better	 understand	 the	onset	and	progression	of	cancer	resistance	to	drugs.	This	work	was	carried	out	using	a	synchrotron,	the	next	step	is	to	carry	out	this	work	using	benchtop	spectrometers.		
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In	Chapter	7	Raman	Spectroscopy	was	used	to	assess	the	sensitivity	and	resistance	of	leukaemia	cells	to	drugs	and	the	consequences	of	culture	conditions	on	the	effects	of	drugs	 on	 leukaemia	 cells.	 Raman	 spectroscopy	 is	 a	 complementary	 technique	 to	 IR	spectroscopy.	As	it	was	the	case	in	the	previous	chapter,	Raman	spectroscopy	could	also	identify	changes	in	leukaemia	cells	cultured	in	the	presence	or	absence	of	drugs.		The	oxygenation	levels	of	cancer	cells	can	play	a	role	in	the	resistance	of	these	cells	to	drugs.	 In	 the	 case	 of	 leukaemia,	 cells	 circulate	 in	 both	 arterial	 and	 venous	 blood	where	 the	 levels	 of	 oxygen	 vary.	 Furthermore,	 in	 advance	 stages,	 leukaemia	 cells	might	migrate	to	lymph	nodes	where,	again,	the	levels	of	oxygen	vary.	Conventional	cell	culture	in-vitro	is	performed	at	ambient	oxygen	concentration,	Lukashev	(2006),	reported	 that	 changing	 oxygen	 concentrations	 can	 influence	 a	 broad	 range	 of	pathways	acting	at	the	transcriptional	level	[Lukashev	2006].	Exact	oxygen	levels	in	
in	 vivo	 conditions	 is	 unknown	 yet,	 only	 recent	 improvements	 have	 allowed	 its	measurement	ex	vivo	[Zhdanov	2008].	To	assess	this,	leukaemia	cells	were	incubated	in	 21%	 or	 10%	 O2.	 PCA	 provided	 certain	 degree	 of	 separation	 between	 clones	incubated	 in	21%	O2	or	10%	O2.	Furthermore,	 for	sensitive	clones,	PCA	was	able	to	separate	between	cells	 incubated	 in	21%	O2	or	10%	O2.	The	 separation	was	not	 so	clear	for	resistant	clones.			These	 data	 stress	 the	 importance	 of	 taking	 into	 account	 not	 only	 cell	 culture	conditions	 but	 also	 the	 fact	 that	 leukaemia	 cells	 obtained	 from	 different	compartments	 could	 produce	 different	 spectral	 results.	 It	 also	 stresses	 the	 need	 to	understand	 those	 factors	 that	 even	 in	 a	 cloned	 cell	 line,	 could	 affect	 the	 spectral	characteristics	linked	to	drugs.	Further	work	is	needed	to	extend	this	knowledge.		
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8.1:	Future	work	This	 thesis	 has	 set	 up	 the	 basis	 to	 further	 develop	 SIFT-MS	 and	 vibrational	spectroscopy	into	their	potential	applications	 in	the	management	of	 leukaemia,	 i.	e.,	improving	diagnosis	 and	 assessing	 tumour	 response	 to	 treatment.	The	next	 step	 in	SIFT-MS	 research	 would	 be	 to	 obtain	 the	 breath	 of	 patients	 with	 leukaemia	 and	compare	to	age	and	sex	matched	controls	(ethical	approval	will	obviously	be	needed).	Also,	to	obtain	the	breath	of	patients	with	leukaemia	prior	to	and	after	treatment	to	assess	whether	it	could	identify	tumour	response	to	treatment	in	a	fast-non-invasive	way.	This	would	help	to	clarify	if	this	technique	can	make	it	into	the	clinics.		Vibrational	spectroscopy	has	been	used	here	to	assess	the	effects	of	drugs	on	cloned	leukaemia	cells.	The	next	step	would	be	to	obtain	blood	from	patients	with	leukaemia	and	assess,	following	the	addition	of	the	drug,	leukaemia	cell	sensitivity/resistance	to	a	given	drug	or	combination	of	drugs.	These	data	could	be	obtained	within	few	days	and	could	be	used	to	better	tailor	treatment	to	each	individual	patient.	Further	work	is,	however,	needed	to	see	whether	this	also	applies	to	different	drugs.										
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Appendix	1	
	
Stages of Leukaemia 	Leukaemia	 starts	 in	 the	bone	marrow	and	often	has	 spread	 to	 other	 organs	by	 the	time	it	is	detected,	so	traditional	staging	is	not	being	done.	Staging	is	the	process	used	to	 find	out	how	 far	 the	 cancer	has	 spread.	 It	 is	 important	 to	 know	 the	 stage	of	 the	disease	 in	order	 to	plan	 the	best	 treatment. Instead,	 cytologic	 classification	systems	to	identify	the	type	and	subtype	of	leukaemia	are	used.	 
 
Chronic Lymphocytic Leukemia:	The	following	stages	are	used	for	chronic	lymphocytic	leukemia:	1. Stage	0	2. Stage	I	3. Stage	II	4. Stage	III	5. Stage	IV	
 
Stage	0	In	stage	0	chronic	lymphocytic	leukemia,	there	are	too	many	lymphocytes	in	the	blood,	but	there	are	no	other	signs	or	symptoms	of	leukemia.	Stage	0	chronic	lymphocytic	leukemia	is	indolent	(slow-growing). 
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Stage	I	In	stage	I	chronic	lymphocytic	leukemia,	there	are	too	many	lymphocytes	in	the	blood	and	the	lymph	nodes	are	larger	than	normal.	
 
Stage	II	In	stage	II	chronic	lymphocytic	leukemia,	there	are	too	many	lymphocytes	in	the	blood,	the	liver	or	spleen	are	larger	than	normal,	and	the	lymph	nodes	may	be	larger	than	normal.	
 
Stage	III	In	stage	III	chronic	lymphocytic	leukemia,	there	are	too	many	lymphocytes	in	the	blood	and	there	are	too	few	red	blood	cells.	The	lymph	nodes,	liver,	or	spleen	may	be	larger	than	normal.	
 
Stage	IV	In	 stage	 IV	 chronic	 lymphocytic	 leukemia,	 there	 are	 too	 many	 lymphocytes	 in	 the	blood	 and	 too	 few	 platelets.	 The	 lymph	 nodes,	 liver,	 or	 spleen	may	 be	 larger	 than	normal	and	there	may	be	too	few	red	blood	cells.	
 
Chronic	Myelogenous Leukemia	
CML instead of stages have 3 phases. The	number	of	blast	cells	in	the	blood	and	bone	marrow	and	the	severity	of	signs	or	symptoms	determine	the	phase	of	the	disease. 
The phases are: 	1. Chronic	phase	
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2. Accelerated	phase	3. Blastic	phase	
	
Chronic	phase	In	chronic	phase	CML,	fewer	than	10%	of	the	cells	in	the	blood	and	bone	marrow	are	blast	cells. 	
Accelerated	phase	In	accelerated	phase	CML,	10%	to	19%	of	the	cells	in	the	blood	and	bone	marrow	are	blast	cells. 	
Blastic	phase	In	blastic	phase	CML,	20%	or	more	of	the	cells	in	the	blood	or	bone	marrow	are	blast	cells.	When	tiredness,	fever,	and	an	enlarged	spleen	occur	during	the	blastic	phase,	it	is	called	blast	crisis.	
 
Acute	Lymphocytic	Leukemia: There	is	no	standard	staging	system	for	adult	ALL.	The	disease	is	described	as	untreated,	in	remission,	or	recurrent. 
 
Acute Myelogenous Leukemia	There	is	no	standard	staging	system	for	adult	AML.	The	disease	is	described	as	untreated,	in	remission,	or	recurrent.		
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Hairy Cell Leukemia There	is	no	standard	staging	system	for	hairy	cell	leukemia.	Groups	are	used	in	place	of	stages	for	hairy	cell	leukemia.	The	disease	is	grouped	as;	 1. Untreated	2. Progressive	3. Refractory.	
 
Untreated	Hairy Cell Leukemia	The	hairy	cell	leukemia	is	newly	diagnosed	and	has	not	been	treated	except	to	relieve	signs	 or	 symptoms	 such	 as	 weight	 loss	 and	 infections.	 In	 untreated	 hairy	 cell	leukemia,	some	or	all	of	the	following	conditions	occur:	 	
Ø Hairy	(leukemia)	cells	are	found	in	the	blood	and	bone	marrow.	
Ø The	number	of	red	blood	cells,	white	blood	cells,	or	platelets	may	be	lower	than	normal.	
Ø The	spleen	may	be	larger	than	normal.	
 
Progressive	Hairy Cell Leukemia	In	progressive	hairy	cell	leukemia,	the	leukemia	has	been	treated	with	either	chemotherapy	or	splenectomy	(removal	of	the	spleen)	and	one	or	both	of	the	following	conditions	occur: 	
Ø There	is	an	increase	in	the	number	of	hairy	cells	in	the	blood	or	bone	marrow.	
Ø The	number	of	 red	blood	cells,	white	blood	cells,	 or	platelets	 in	 the	blood	 is	
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lower	than	normal.		
 
Childhood Acute	Lymphocytic Leukemia In	childhood	ALL,	risk	groups	are	used	to	plan	treatment.	There	are	two	risk	groups 
 1. Standard	 (low)	 risk:	 Includes	children	aged	1	 to	younger	 than	10	years	who	have	a	white	blood	cell	count	of	less	than	50,000/µL	at	diagnosis.	2. High	 risk:	 Includes	 children	10	 years	 and	older	 and/or	 children	who	have	 a	white	blood	cell	count	of	50,000/µL	or	more	at	diagnosis.	
 
Childhood Acute	Myelogenous Leukemia There	 is	 no	 standard	 staging	 system	 for	 childhood	 AML,	 childhood	 chronic	myelogenous	 leukemia	 (CML),	 juvenile	 myelomonocytic	 leukemia	 (JMML),	 or	myelodysplastic	syndromes	(MDS).	
 Instead	of	stages,	treatment	of	childhood	AML,	childhood	CML,	JMML,	and	MDS	is	based	on	one	or	more	of	the	following: 	 1. The	type	of	disease	or	the	subtype	of	AML.	2. Whether	leukemia	has	spread	outside	the	blood	and	bone	marrow.	3. Whether	the	disease	is	newly	diagnosed,	in	remission,	or	recurrent.	
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Newly	Diagnosed Childhood AML	Newly	 diagnosed	 childhood	 AML	 has	 not	 been	 treated	 except	 to	 relieve	 signs	 and	symptoms	such	as	fever,	bleeding,	or	pain,	and	one	of	the	following	is	true: 	 1. More	than	20%	of	the	cells	in	the	bone	marrow	are	blasts	(leukemia	cells).or	2. Less	than	20%	of	the	cells	in	the	bone	marrow	are	blasts	and	there	is	a	specific	change	in	the	chromosome.										
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Appendix	2:		Typical	Operating	Conditions	of	the	SIFT-MS		
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Appendix	3	Schematic	mechanism	of	Philadelphia	chromosome	production.	
	
	
	
	
 
